# Patent

## Title
Pyrimidine derivatives as kinase inhibitors

## Abstract

The invention provides novel pyrimidine derivatives of formula I and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-IR) or analplastic lymphoma kinase (ALK).

## Background
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a 371 U.S. national phase application of international application number PCT/US2009/048428 filed 24 Jun. 2009, which application claims priority to U.S. provisional patent application No. 61/075,583 filed 25 Jun. 2008 and U.S. provisional patent application No. 61/155,434 filed 25 Feb. 2009, each of which is incorporated herein by reference in its entirety and for all purposes.
TECHNICAL FIELD
The invention relates to protein kinase inhibitors, more particularly novel pyrimidine derivatives and pharmaceutical compositions thereof, and their use as pharmaceuticals.
BACKGROUND ART
Insulin-like growth factor (IGF-1) signaling is highly implicated in cancer, with the IGF-1 receptor (IGF-1R) as the predominating factor. IGR-1R is important for tumor transformation and survival of malignant cells, but is only partially involved in normal cell growth. Targeting of IGF-1R has been suggested to be a promising option for cancer therapy. (Larsson et al., Br. J. Cancer 92:2097-2101 (2005)).
Anaplastic lymphoma kinase (ALK), a member of the insulin receptor superfamily of receptor tyrosine kinases, has been implicated in oncogenesis in hematopoietic and non-hematopoietic tumors. The aberrant expression of full-length ALK receptor proteins has been reported in neuroblastomas and glioblastomas; and ALK fusion proteins have occurred in anaplastic large cell lymphoma. The study of ALK fusion proteins has also raised the possibility of new therapeutic treatments for patients with ALK-positive malignancies. (Pulford et al., Cell. Mol. Life. Sci. 61:2939-2953 (2004)).
Because of the emerging disease-related roles of IGF-1R and ALK, there is a continuing need for compounds which may be useful for treating and preventing a disease which responds to inhibition of IGF-1R and ALK.
DISCLOSURE OF THE INVENTION
The invention relates to novel pyrimidine derivatives and pharmaceutical compositions thereof, and their use as pharmaceuticals.
In one aspect, the invention provides a compound of Formula (1):




or a physiologically acceptable salt thereof;
wherein ring E may optionally contain a double bond;
one of Z1, Z2 and Z3 is NR6, N(R6)+—O− or S(O)1-2 and the others are CR2;
R1 is halo or an optionally halogenated C1-6 alkyl;
R2 is pyridine-2-onyl, azepan-2-onyl or a monocyclic 5-6 membered heteroaryl having 1-3 heteroatoms selected from N, O and S; each of which is optionally substituted with R9 wherein R9 is C1-6 alkyl, C1-6 haloalkyl or C3-7 cycloalkyl;
R3 and R4 are each H;
R5 is halo, hydroxyl, C1-6 alkyl, C1-6 alkoxy, halo-substituted C1-6 alkyl, halo-substituted C1-6 alkoxy, cyano or C(O)O0-1R8;
R6 is H; C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, each of which may be optionally substituted with halo and/or hydroxyl groups; —(CR2)p—OR7, —(CR2)p—CH(OH)CtF2t+1 wherein t is 1-3, (CR2)p—CN; (CR2)p—NR(R7), —(CR2)p—C(O)OR7, (CR2)pNR(CR2)pOR7,
(CR2)pNR-L-C(O)R8, C(O)(CR2)qOR8, —C(O)O—(CR2)p—NRR7, —C(O)—(CR2)p—OR7, L-Y, -L-C(O)R7, -L-C(O)—NRR7, -L-C(O)—NR—(CR2)p—NRR7, -L-C(O)NR(CR2)pOR7,
-L-C(O)—(CR2)q—NR—C(O)—R8, -L-C(O)NR(CR2)pSR7, -L-C(O)NR(CR2)pS(O)1-2R8, -L-S(O)2R8, -L-S(O)2—(CR2)q—NRR7, -L-S(O)2NR(CR2)pNR(R7) or -L-S(O)2NR(CR2)pOR7;
alternatively, R6 is a radical selected from formula (a), (b), (c) or (d):




R10 is O, S, NR17 wherein R17 is H, C1-6 alkyl, SO2R8a or CO2R8a;
R11, R12, R13, R14, R15 and R16 are independently selected from H; C1-6 alkoxy; C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, each of which may be optionally substituted with halo, amino or hydroxyl groups; or R11 and R12, R12 and R15, R15 and R16, R13 and R14, or R13 and R15 together with the atoms to which they are attached may form a 3-7 membered saturated, unsaturated or partially unsaturated ring containing 1-3 heteroatoms selected from N, O and S, and optionally substituted with oxo and 1-3 R5 groups;
L is (CR2)1-4 or a bond;
Y is C3-7 carbocyclic ring, C6-10 aryl, or a 5-10 membered heteroaryl or 4-10 membered heterocyclic ring, each of which is optionally substituted with 1-3 R5 groups;
R7, R8 and R8a are independently C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, each of which may be optionally substituted with halo, amino, hydroxyl or cyano; (CR2)qY or C1-6 alkoxy; or R7 is H;
each R is independently H or C1-6 alkyl;
R and R7 together with N in each NRR7 may form a 5-6 membered ring containing 1-3 heteroatoms selected from N, O and S, and optionally substituted with oxo and 1-3 R5 groups;
m is 2-4;
n is 1-3;
p is 1-4; and
q is 0-4.
In one embodiment, the invention provides a compound is of Formula (2):




wherein one of R5a, R5b and R5c is H and the others are independently halo, C1-6 alkyl, C1-6 alkoxy, halo-substituted C1-6 alkyl, cyano or C(O)O0-1R8 wherein R8 is C1-6 alkyl; and
R1, R2, R3, R4, E, Z1, Z2 and Z3 are as defined in Formula (1).
In some examples, Z3 in the above Formula (2) is NR6 or N(R6)+—O−; and Z1 and Z2 are CH2. In other examples, R6 is H, C1-6 alkyl optionally substituted with halo and/or hydroxyl groups; —(CR2)p—OR7, —(CR2)p—CH(OH)CtF2t+1 wherein t is 1-3, L-Y,
(CR2)p—CN; (CR2)p—NR(R7), —(CR2)p—C(O)OR7, C(O)(CR2)qOR8, —C(O)O—(CR2)p—NRR7,
-L-C(O)R7, -L-C(O)—NRR7, -L-C(O)—NR—(CR2)p—NRR7, -L-C(O)—(CR2)q—NR—C(O)—R8 
-L-S(O)2R8, -L-S(O)2—(CR2)q—NRR7, or a radical selected from formula (a), (b), (c) or (d):




R10 is O, S, NR17 wherein R17 is H, C1-6 alkyl, SO2R8a or CO2R8a;
R8a is C1-6 alkyl; and
R7, R8, R10, R11, R12, R13, R14, R15, R16, R, L, Y, p and q are as defined in Formula (1).
In the above Formula (1) and (2), R2 may be pyrazolyl, isoxazolyl, pyridine-2-onyl or azepan-2-onyl, each of which is substituted with C1-6 alkyl, C1-6 haloalkyl or C3-7 cycloalkyl.
In another embodiment, the invention provides a compound of Formula (3):




or a tautomer thereof;
wherein R5b is H; and R5a and R5c are independently halo, C1-6 alkyl, C1-6 alkoxy, halo-substituted C1-6 alkyl, cyano or C(O)O0-1R8 wherein R8 is C1-6 alkyl;
Z1 and Z2 are CH2;
Z3 is NR6 or N(R6)+—O−;
R6 is H, C1-6 alkyl optionally substituted with halo and/or hydroxyl groups; —(CR2)p—OR7, —(CR2)p—CH(OH)CtF2t+1 wherein t is 1-3, (CR2)p—CN; (CR2)p—NR(R7), —(CR2)p—C(O)OR7, C(O)(CR2)qOR8, —C(O)O—(CR2)p—NRR7, L-Y, -L-C(O)R7, -L-C(O)—NRR7, -L-C(O)—NR—(CR2)p—NRR7, -L-C(O)—(CR2)q—NR—C(O)—R8, -L-S(O)2R8,
-L-S(O)2—(CR2)q—NRR7, or a radical selected from formula (a), (b), (c) or (d):




R10 is O, S, NR17 wherein R17 is H, C1-6 alkyl, SO2R8a or CO2R8a;
R8a is C1-6 alkyl; and
R1, R3, R4, R7, R8, R10, R11, R12, R13, R14, R15, R16, R, L, Y, p, q and E are as defined in Formula (1).
In the above Formula (3), R5a may be halo and R5c is C1-6 alkyl. In some examples, R6 is C1-6 alkyl or a radical of formula (a) or (c); and R10 is O.
In the above Formula (1), (2) and (3), R1 may be halo. In particular examples, R1 is chloro. In other examples, R3 and R4 are H.
In another aspect, the present invention provides a compound of Formula (4).




or a physiologically acceptable salt thereof;
wherein X is a monocyclic 5-6 membered heterocyclic ring containing 1-3 heteroatoms selected from N, O and S, and optionally substituted on a substitutable ring carbon with oxo and at any substitutable ring nitrogen by R6;
R1 is halo;
R3 and R4 are each H;
R5 is halo, hydroxyl, C1-6 alkyl, C1-6 alkoxy, halo-substituted C1-6 alkyl, halo-substituted C1-6 alkoxy, cyano or C(O)O0-1R8;
R6 is H; C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, each of which may be optionally substituted with halo and/or hydroxyl groups; —(CR2)p—OR7, —(CR2)p—CH(OH)CtF2t+1 wherein t is 1-3, (CR2)p—CN; (CR2)p—NR(R7), —(CR2)p—C(O)OR7, (CR2)pNR(CR2)pOR7,
(CR2)pNR-L-C(O)R8, C(O)(CR2)qOR8, —C(O)O—(CR2)p—NRR7, —C(O)—(CR2)p—OR7, L-Y,
-L-C(O)R7, -L-C(O)—NRR7, -L-C(O)—NR—(CR2)p—NRR7, -L-C(O)NR(CR2)pOR7, -L-C(O)—(CR2)q—NR—C(O)—R8, -L-C(O)NR(CR2)pSR7, -L-C(O)NR(CR2)pS(O)1-2R8, -L-S(O)2R8, -L-S(O)2—(CR2)q—NRR7, -L-S(O)2NR(CR2)pNR(R7) or -L-S(O)2NR(CR2)pOR7;
alternatively, R6 is a radical selected from formula (a), (b), (c) or (d):




R10 is O, S, NR17 wherein R17 is H, C1-6 alkyl, SO2R8a or CO2R8a;
R11, R12, R13, R14, R15 and R16 are independently selected from H; C1-6 alkoxy; C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, each of which may be optionally substituted with halo, amino or hydroxyl groups; or R11 and R12, R12 and R15, R15 and R16, R13 and R14, or R13 and R15 together with the atoms to which they are attached may form a 3-7 membered saturated, unsaturated or partially unsaturated ring containing 1-3 heteroatoms selected from N, O and S, and optionally substituted with oxo and 1-3 R5 groups;
L is (CR2)14 or a bond;
Y is C3-7 carbocyclic ring, C6-10 aryl, or a 5-10 membered heteroaryl or 4-10 membered heterocyclic ring, each of which is optionally substituted with 1-3 R5 groups;
R7, R8 and R8a are independently C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, each of which may be optionally substituted with halo, amino, hydroxyl or cyano; (CR2)qY or C1-6 alkoxy; or R7 is H;
each R is independently H or C1-6 alkyl;
R and R7 together with N in each NRR7 may form a 5-6 membered ring containing 1-3 heteroatoms selected from N, O and S, and optionally substituted with oxo and 1-3 R5 groups;
m is 2-4;
n is 1-3;
p is 1-4; and
q is 0-4.
In the above Formula (4), X may be morpholinyl, piperazinyl, piperazin-2-onyl, oxazolidin-2-onyl or piperidin-2-onyl each of which is substituted at any substitutable ring nitrogen by C1-6 alkyl; or X is tetrahydro-2H-pyran-2-onyl; and R1 is chloro.
In another aspect, the present invention provides pharmaceutical compositions comprising a compound having Formula (1), (2), (3) and (4), and a physiologically acceptable excipient.
In yet another aspect, the invention provides methods for inhibiting IGF-1R in a cell, comprising contacting the cell with an effective amount of a compound having Formula (1), (2), (3) and (4) or a pharmaceutical composition thereof.
The invention also provides methods to treat, ameliorate or prevent a condition which responds to inhibition of IGF-1R or anaplastic lymphoma kinase (ALK) in a mammal suffering from said condition, comprising administering to the mammal a therapeutically effective amount of a compound having Formula (1), (2), (3) and (4) or a pharmaceutical composition thereof, and optionally in combination with a second therapeutic agent. Alternatively, the present invention provides for the use of a compound having Formula (1), (2), (3) and (4), and optionally in combination with a second therapeutic agent, in the manufacture of a medicament for treating a condition mediated by IGF-1R or ALK. The compounds of the invention may be administered, for example, to a mammal suffering from an autoimmune disease, a transplantation disease, an infectious disease or a cell proliferative disorder. In particular examples, the compounds of the invention may be used alone or in combination with a chemotherapeutic agent to treat a cell proliferative disorder, including but not limited to, multiple myeloma, neuroblastoma, synovial, hepatocellular, Ewing's Sarcoma or a solid tumor selected from a osteosarcoma, melanoma, and tumor of breast, renal, prostate, colorectal, thyroid, ovarian, pancreatic, lung, uterine or gastrointestinal tumor.
DEFINITIONS
“Alkyl” refers to a moiety and as a structural element of other groups, for example halo-substituted-alkyl and alkoxy, and may be straight-chained or branched. An optionally substituted alkyl, alkenyl or alkynyl as used herein may be optionally halogenated (e.g., CF3), or may have one or more carbons that is substituted or replaced with a heteroatom, such as NR, O or S (e.g., —OCH2CH2O—, alkylthiols, thioalkoxy, alkylamines, etc).
“Aryl” refers to a monocyclic or fused bicyclic aromatic ring containing carbon atoms. “Arylene” means a divalent radical derived from an aryl group. For example, an aryl group may be phenyl, indenyl, indanyl, naphthyl, or 1,2,3,4-tetrahydronaphthalenyl, which may be optionally substituted in the ortho, meta or para position.
“Heteroaryl” as used herein is as defined for aryl above, where one or more of the ring members is a heteroatom. For example, a heteroaryl substituent for use in the compounds of the invention may be a monocyclic or bicyclic 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S. Examples of heteroaryls include but are not limited to pyridyl, pyrazinyl, indolyl, indazolyl, quinoxalinyl, quinolinyl, benzofuranyl, benzopyranyl, benzothiopyranyl, benzo[1,3]dioxole, imidazolyl, benzo-imidazolyl, pyrimidinyl, furanyl, oxazolyl, isoxazolyl, triazolyl, benzotriazolyl, tetrazolyl, pyrazolyl, thienyl, pyrrolyl, isoquinolinyl, purinyl, thiazolyl, tetrazinyl, benzothiazolyl, oxadiazolyl, benzoxadiazolyl, etc.
A “carbocyclic ring” as used herein refers to a saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring containing carbon atoms, which may optionally be substituted, for example, with ═O. Examples of carbocyclic rings include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylene, cyclohexanone, etc.
A “heterocyclic ring” as used herein is as defined for a carbocyclic ring above, wherein one or more ring carbons is a heteroatom. For example, a heterocyclic ring for use in the compounds of the invention may be a 4-7 membered heterocyclic ring containing 1-3 heteroatoms selected from N, O and S, or a combination thereof such as —S(O) or —S(O)2—. Examples of heterocyclic rings include but are not limited to azetidinyl, morpholino, pyrrolidinyl, pyrrolidinyl-2-one, piperazinyl, piperidinyl, piperidinylone, 1,4-dioxa-8-aza-spiro[4.5]dec-8-yl, 1,2,3,4-tetrahydroquinolinyl, etc. Heterocyclic rings as used herein may encompass bicyclic amines and bicyclic diamines.
As used herein, an H atom in any substituent groups (e.g., CH2) encompasses all suitable isotopic variations, e.g., H, 2H and 3H.
The term “pharmaceutical combination” as used herein refers to a product obtained from mixing or combining active ingredients, and includes both fixed and non-fixed combinations of the active ingredients. The term “fixed combination” means that the active ingredients, e.g. a compound of Formula (1) and a co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage. The term “non-fixed combination” means that the active ingredients, e.g. a compound of Formula (1) and a co-agent, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the active ingredients in the body of the patient. The latter also applies to cocktail therapy, e.g. the administration of three or more active ingredients.
“Mammal” refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, etc. In particular examples, the mammal is human.
The term “administration” or “administering” of the subject compound means providing a compound of the invention and prodrugs thereof to a subject in need of treatment. Administration “in combination with” one or more further therapeutic agents includes simultaneous (concurrent) and consecutive administration in any order, and in any route of administration.
An “effective amount” of a compound is an amount sufficient to carry out a specifically stated purpose. An “effective amount” may be determined empirically and in a routine manner, in relation to the stated purpose.
The term “therapeutically effective amount” refers to an amount of a compound (e.g., an IGF-1R antagonist) effective to “treat” an IGF-1R-mediated disorder in a subject or mammal. In the case of cancer, the therapeutically effective amount of the drug may reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer. See the definition herein of “treating”. To the extent the drug may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic.
The term “cancer” refers to the physiological condition in mammals that is typically characterized by unregulated cell growth/proliferation. Examples of cancer include, but are not limited to: carcinoma, lymphoma, blastoma, and leukemia. More particular examples of cancers include, but are not limited to: chronic lymphocytic leukemia (CLL), lung, including non small cell (NSCLC), breast, ovarian, cervical, endometrial, prostate, colorectal, intestinal carcinoid, bladder, gastric, pancreatic, hepatic (hepatocellular), hepatoblastoma, esophageal, pulmonary adenocarcinoma, mesothelioma, synovial sarcoma, osteosarcoma, head and neck squamous cell carcinoma, juvenile nasopharyngeal angiofibromas, liposarcoma, thyroid, melanoma, basal cell carcinoma (BCC), medulloblastoma and desmoid.
“Treating” or “treatment” or “alleviation” refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic disease or condition or disorder. Those in need of treatment include those already with the disorder as well as those prone to having the disorder or those in whom the disorder is to be prevented (prophylaxis). When the IGF-1R-mediated disorder is cancer, a subject or mammal is successfully “treated” or shows a reduced tumor burden if, after receiving a therapeutic amount of an IGF-1R antagonist according to the methods of the present invention, the patient shows observable and/or measurable reduction in or absence of one or more of the following: reduction in the number of cancer cells or absence of the cancer cells; reduction in the tumor size; inhibition (i.e., slow to some extent and preferably stop) of cancer cell infiltration into peripheral organs including the spread of cancer into soft tissue and bone; inhibition (i.e., slow to some extent and preferably stop) of tumor metastasis; inhibition, to some extent, of tumor growth; and/or relief to some extent, one or more of the symptoms associated with the specific cancer; reduced morbidity and mortality, and improvement in quality of life issues. To the extent the IGF-1R antagonist may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic. Reduction of these signs or symptoms may also be felt by the patient.
“Carriers” as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution. Examples of physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEEN®, polyethylene glycol (PEG), and PLURONICS®.
A “chemotherapeutic agent” is a chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include alkylating agents such as thiotepa and CYTOXAN® cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethiylenethiophosphoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); delta-9-tetrahydrocannabinol (dronabinol, MARINOL®); beta-lapachone; lapachol; colchicines; betulinic acid; a camptothecin (including the synthetic analogue topotecan (HYCAMTIN®), CPT-11 (irinotecan, CAMPTOSAR®), acetylcamptothecin, scopolectin, and 9-aminocamptothecin); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); podophyllotoxin; podophyllinic acid; teniposide; cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics such as the enediyne antibiotics (e.g., calicheamicin, especially calicheamicin gamma1I and calicheamicin omegaI1 (see, e.g., Agnew, Chem. Intl. Ed. Engl., 33: 183-186 (1994)); dynemicin, including dynemicin A; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, ADRIAMYCIN® doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfomithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; 2-ethylhydrazide; procarbazine; PSK® polysaccharide complex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin; sizofuran; spirogermanium; tenuazonic acid; triaziquone; 2,2′,2′′-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine (ELDISINE®, FILDESIN®); dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside (“Ara-C”); thiotepa; taxoids, e.g., TAXOL® paclitaxel (Bristol-Myers Squibb Oncology, Princeton, N.J.), ABRAXANETM Cremophor-free, albumin-engineered nanoparticle formulation of paclitaxel (American Pharmaceutical Partners, Schaumberg, Ill.), and TAXOTERE® doxetaxel (Rhône-Poulenc Rorer, Antony, France); chloranbucil; gemcitabine (GEMZAR®); 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine (VELBAN®); platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine (ONCOVIN®); oxaliplatin; leucovovin; vinorelbine (NAVELBINE®); novantrone; edatrexate; daunomycin; aminopterin; ibandronate; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; capecitabine (XELODA®); pharmaceutically acceptable salts, acids or derivatives of any of the above; as well as combinations of two or more of the above such as CHOP, an abbreviation for a combined therapy of cyclophosphamide, doxorubicin, vincristine, and prednisolone, and FOLFOX, an abbreviation for a treatment regimen with oxaliplatin (ELOXATINTM) combined with 5-FU and leucovovin.
Furthermore, a “chemotherapeutic agent” may include anti-hormonal agents that act to regulate, reduce, block, or inhibit the effects of hormones that can promote the growth of cancer, and are often in the form of systemic, or whole-body treatment. They may be hormones themselves. Examples include anti-estrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including NOLVADEX® tamoxifen), EVISTA® raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and FARESTON® toremifene; anti-progesterones; estrogen receptor down-regulators (ERDs); agents that function to suppress or shut down the ovaries, for example, leutinizing hormone-releasing hormone (LHRH) agonists such as LUPRON® and ELIGARD® leuprolide acetate, goserelin acetate, buserelin acetate and tripterelin; other anti-androgens such as flutamide, nilutamide and bicalutamide; and aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazoles, aminoglutethimide, MEGASE® megestrol acetate, AROMASIN® exemestane, formestanie, fadrozole, RIVISOR® vorozole, FEMARA® letrozole, and ARIMIDEX® anastrozole. In addition, such definition of chemotherapeutic agents includes bisphosphonates such as clodronate (for example, BONEFOS® or OSTAC®), DIDROCAL® etidronate, NE-58095, ZOMETA® zoledronic acid/zoledronate, FOSAMAX® alendronate, AREDIA® pamidronate, SKELID® tiludronate, or ACTONEL® risedronate; as well as troxacitabine (a 1,3-dioxolane nucleoside cytosine analog); antisense oligonucleotides, particularly those that inhibit expression of genes in signaling pathways implicated in abherant cell proliferation, such as, for example, PKC-alpha, Raf, H-Ras, and epidermal growth factor receptor (EGF-R); vaccines such as THERATOPE® vaccine and gene therapy vaccines, for example, ALLOVECTIN® vaccine, LEUVECTIN® vaccine, and VAXID® vaccine; LURTOTECAN® topoisomerase 1 inhibitor; ABARELIX® rmRH; lapatinib ditosylate (an ErbB-2 and EGFR dual tyrosine kinase small-molecule inhibitor also known as GW572016); and pharmaceutically acceptable salts, acids or derivatives of any of the above.
MODES OF CARRYING OUT THE INVENTION
The invention provides novel pyrimidine derivatives and pharmaceutical compositions thereof, and methods for using such compounds.
In one aspect, the invention provides a compound of Formula (1):




or a physiologically acceptable salt thereof;
wherein ring E may optionally contain a double bond; one of Z1, Z2 and Z3 is NR6, N(R6)+—O− or S(O)1-2 and the others are CR2;
R1 is halo or an optionally halogenated C1-6 alkyl;
R2 is pyridine-2-onyl, azepan-2-onyl or a monocyclic 5-6 membered heteroaryl having 1-3 heteroatoms selected from N, O and S; each of which is optionally substituted with R9 wherein R9 is C1-6 alkyl, C1-6haloalkyl or C1-7 cycloalkyl;
R3 and R4 are each H;
R5 is halo, hydroxyl, C1-6 alkyl, C1-6 alkoxy, halo-substituted C1-6 alkyl, halo-substituted C1-6 alkoxy, cyano or C(O)O0-1R8;
R6 is H; C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, each of which may be optionally substituted with halo and/or hydroxyl groups; —(CR2)p—OR7, —(CR2)p—CH(OH)CtF2t+1 wherein t is 1-3, (CR2)p—CN; (CR2)p—NR(R7), —(CR2)p—C(O)OR7, (CR2)pNR(CR2)pOR7,
(CR2)pNR-L-C(O)R8, C(O)(CR2)qOR8, —C(O)O—(CR2)p—NRR7, —C(O)—(CR2)p—OR7, L-Y,
-L-C(O)R7, -L-C(O)—NRR7, -L-C(O)—NR—(CR2)p—NRR7, -L-C(O)NR(CR2)pOR7, -L-C(O)—(CR2)q—NR—C(O)—R8, -L-C(O)NR(CR2)pSR7, -L-C(O)NR(CR2)pS(O)1-2R8, -L-S(O)2R8, -L-S(O)2—(CR2)q—NRR7, -L-S(O)2NR(CR2)pNR(R7) or -L-S(O)2NR(CR2)pOR7;
alternatively, R6 is a radical selected from formula (a), (b), (c) or (d):




R10 is O, S, NR17 wherein R17 is H, C1-6 alkyl, SO2R8a or CO2R8a;
R11, R12, R13, R14, R15 and R16 are independently selected from H; C1-6 alkoxy; C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, each of which may be optionally substituted with halo, amino or hydroxyl groups; or R11 and R12, R12 and R15, R15 and R16, R13 and R14, or R13 and R15 together with the atoms to which they are attached may form a 3-7 membered saturated, unsaturated or partially unsaturated ring containing 1-3 heteroatoms selected from N, O and S, and optionally substituted with oxo and 1-3 R5 groups;
L is (CR2)1-4 or a bond;
Y is C3-7 carbocyclic ring, C6-10 aryl, or a 5-10 membered heteroaryl or 4-10 membered heterocyclic ring, each of which is optionally substituted with 1-3 R5 groups;
R7, R8 and R8a are independently C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, each of which may be optionally substituted with halo, amino, hydroxyl or cyano; (CR2)qY or C1-6 alkoxy; or R7 is H;
each R is independently H or C1-6 alkyl;
R and R7 together with N in each NRR7 may form a 5-6 membered ring containing 1-3 heteroatoms selected from N, O and S, and optionally substituted with oxo and 1-3 R5 groups;
m is 2-4;
n is 1-3;
p is 1-4; and
q is 0-4.
In one embodiment, the invention provides a compound is of Formula (2):




wherein one of R5a, R5b and R5c is H and the others are independently halo, C1-6 alkyl, C1-6 alkoxy, halo-substituted C1-6 alkyl, cyano or C(O)O0-1R8 wherein R8 is C1-6 alkyl; and
R1, R2, R3, R4, E, Z1, Z2 and Z3 are as defined in Formula (1).
In another embodiment, the invention provides a compound of Formula (3):




or a tautomer thereof;
wherein R5b is H; and R5a and R5c are independently halo, C1-6 alkyl, C1-6 alkoxy, halo-substituted C1-6 alkyl, cyano or C(O)O0-1R8 wherein R8 is C1-6 alkyl;
Z1 and Z2 are CH2;
Z3 is NR6 or N(R6)+—O−;
R6 is H, C1-6 alkyl optionally substituted with halo and/or hydroxyl groups; —(CR2)p—OR7, —(CR2)p—CH(OH)CtF2t+1 wherein t is 1-3, (CR2)p—CN; (CR2)p—NR(R7), —(CR2)p—C(O)OR7, C(O)(CR2)qOR8, —C(O)O—(CR2)p—NRR7, L-Y, -L-C(O)R7,
-L-C(O)—NRR7, -L-C(O)—NR—(CR2)p—NRR7, -L-C(O)—(CR2)q—NR—C(O)—R8, -L-S(O)2R8,
-L-S(O)2—(CR2)q—NRR7, or a radical selected from formula (a), (b), (c) or (d):




R10 is O, S, NR17 wherein R17 is H, C1-6 alkyl, SO2R8a or CO2R8a;
R8a is C1-6 alkyl; and
R1, R3, R4, R7, R8, R10, R11, R12, R13, R14, R15, R16, R, L, Y, p, q and E are as defined in Formula (1).
In another aspect, the present invention provides a compound of Formula (4).




or a physiologically acceptable salt thereof;
wherein X is a monocyclic 5-6 membered heterocyclic ring containing 1-3 heteroatoms selected from N, O and S, and optionally substituted on a substitutable ring carbon with oxo and at any substitutable ring nitrogen by R6;
R1 is halo;
R3 and R4 are each H;
R5 is halo, hydroxyl, C1-6 alkyl, C1-6 alkoxy, halo-substituted C1-6 alkyl, halo-substituted C1-6 alkoxy, cyano or C(O)O0-1R8;
R6 is H; C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, each of which may be optionally substituted with halo and/or hydroxyl groups; —(CR2)p—OR7, —(CR2)p—CH(OH)CtF2t+1 wherein t is 1-3, (CR2)p—CN; (CR2)p—NR(R7), —(CR2)p—C(O)OR7, (CR2)pNR(CR2)pOR7,
(CR2)pNR-L-C(O)R8, C(O)(CR2)qOR8, —C(O)O—(CR2)p—NRR7, —C(O)—(CR2)p—OR7, L-Y,
-L-C(O)R7, -L-C(O)—NRR7, -L-C(O)—NR—(CR2)p—NRR7, -L-C(O)NR(CR2)pOR7, -L-C(O)—(CR2)q—NR—C(O)—R8, -L-C(O)NR(CR2)pSR7, -L-C(O)NR(CR2)pS(O)1-2R8, -L-S(O)2R8, -L-S(O)2—(CR2)q—NRR7, -L-S(O)2NR(CR2)pNR(R7) or -L-S(O)2NR(CR2)pOR7;
alternatively, R6 is a radical selected from formula (a), (b), (c) or (d):




R10 is O, S, NR17 wherein R17 is H, C1-6 alkyl, SO2R8a or CO2R8a;
R11, R12, R13, R14, R15 and R16 are independently selected from H; C1-6 alkoxy; C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, each of which may be optionally substituted with halo, amino or hydroxyl groups; or R11 and R12, R12 and R15, R15 and R16, R13 and R14, or R13 and R15 together with the atoms to which they are attached may form a 3-7 membered saturated, unsaturated or partially unsaturated ring containing 1-3 heteroatoms selected from N, O and S, and optionally substituted with oxo and 1-3 R5 groups;
L is (CR2)1-4 or a bond;
Y is C3-7 carbocyclic ring, C6-10 aryl, or a 5-10 membered heteroaryl or 4-10 membered heterocyclic ring, each of which is optionally substituted with 1-3 R5 groups;
R7, R8 and R8a are independently C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, each of which may be optionally substituted with halo, amino, hydroxyl or cyano; (CR2)qY or C1-6 alkoxy; or R7 is H;
each R is independently H or C1-6 alkyl;
R and R7 together with N in each NRR7 may form a 5-6 membered ring containing 1-3 heteroatoms selected from N, O and S, and optionally substituted with oxo and 1-3 R5 groups;
m is 2-4;
n is 1-3;
p is 1-4; and
q is 0-4.
In yet another aspect, the invention provides compounds of Formula (5):




or physiologically acceptable salts thereof;
wherein X is a 4-7 membered heterocyclic ring containing NR6,




O or S, and optionally substituted with 1-3 R5 groups;

wherein R1 is halo, C1-6 alkyl, or a halo-substituted C1-6 alkyl;
R2 is an optionally substituted 5-6 membered heteroaryl or 5-7 membered heterocyclic ring, each having 1-3 heteroatoms selected from N, O and S and optionally substituted with 1-3 R9 groups;
R3 and R4 are independently H, C(O)R8, C1-6 alkyl or halo-substituted C1-6 alkyl;
R5 and R9 are independently C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, each of which may be optionally substituted with halo, amino or hydroxyl groups; or R5 and R9 are independently C1-6 alkoxy, halo-substituted C1-6 alkoxy, halo, nitro, cyano, CR(OR7)R7, OR7, O(CR2)p—OR7, NR(R7), CR(R7)NRR7, (CR2)1-6NR(CR2)pOR7, (CR2)1-6NR(CR2)qC(O)R8, —C(O)— (CR2)q—NR—C(O)—R8, (CR2)qY, C(O)O0-1R7, C(O)NR(R7), C(O)CRR7—NR(R7), C(O)NR(CR2)pNR(R7), C(O)NR(CR2)pOR7, C(O)NR(CR2)pSR7, C(O)NR(CR2)pS(O)1-2R8, S(O)0-2R8, S(O)2NRR7, S(O)2NR(CR2)pNR(R7), or S(O)2NR(CR2)pOR7;
R6 is H; C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, each of which may be optionally substituted with halo, amino, hydroxyl or alkoxy; —(CR2)p—CN; C(O)H, CR(OR7)R7, (CR2)p—OR7, (CR2)p—NR(R7), CR(R7)NRR7, -L-Y, -L-C(O)O0-1—(CR2)q—R8, —(CR2)p—C(O)O0-1—R7, -L-C(O)—NRR7, -L-C(O)O0-1—CR(R7)—NRR7, -L-C(O)—NR—(CR2)p—NRR7, -L-C(O)NR(CR2)pOR7, -L-C(O)—(CR2)q—NR—C(O)—R8, -L-C(O)NR(CR2)pSR7, -L-C(O)NR(CR2)pS(O)1-2R8, -L-S(O)2R8, (CR2)pNR(CR2)pOR7, (CR2)pNR-L-C(O)R8, -L-S(O)2NRR7, -L-S(O)2NR(CR2)pNR(R7) or -L-S(O)2NR(CR2)pOR7;
alternatively, R6 is a radical selected from formula (a), (b), (c) or (d):




wherein R11, R12, R13, R14, R15 and R16 are independently selected from H or C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl or C2-6 alkynyl, each of which may be optionally substituted with halo, amino or hydroxyl groups; or R11 and R12, R12 and R15, R15 and R16, R13 and R14, or R13 and R15 together with the carbon and/or nitrogen atoms to which they are attached may form a 3-7 membered saturated, unsaturated or partially unsaturated ring optionally containing up to 3 atoms or groups selected from C(O), N, O and S(O)0-2;
R17 is O or SO2R8;
L is (CR2)1-4 or a bond;
Y is C3-7 carbocyclic ring, C6-10 aryl, or a 5-10 membered heteroaryl or 4-10 membered heterocyclic ring, each of which is optionally substituted with 1-3 R5 groups;
R7 and R8 are independently C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, each of which may be optionally substituted with halo, amino, hydroxyl or cyano; (CR2)qY or C1-6 alkoxy; or R7 is H;
each R is H or C1-6 alkyl;
m is 2-4;
n is 1-3;
p is 1-4; and
q is 0-4.
In the above Formula (5), examples of 5-6 membered heteroaryl or 5-7 membered heterocyclic ring R2 groups include but are not limited to pyrazolyl, pyrrolyl, thiophenyl, pyrimidinyl, isoxazolyl, pyridyl, azepan-2-onyl, 2H-thipyran, 3H-thipyran, 4H-thipyran, tetrahydrothiopyran, 2H-pyran, 4H-pyran, tetrahydropyran, piperidine, 1,2-dithiin, 1,2-dithiane, 1,3-dithiin, 1,3-dithiane, 1,4-dithiin, 1,4-dithiane, 1,2-dioxin, 1,2-dioxane, 1,3-dioxin, 1,3-dioxane, 1,4-dioxin, 1,4-dioxane, piperazine, 1,2-oxathiin, 1,2-oxathiane, 4H-1,3-oxathiin, 1,3-oxathiane, 1,4-oxathiin, 1,4-oxathiane, 2H-1,2-thiazine, tetrahydro-1,2-thiazine, 2H-1,3-thiazine, 4H-1,3-thiazine, 5,6-dihydro-4H-thiazine, 4H-1,4-thiazine, tetrahydro-1,4-thiazine, 2H-1,2-oxazine, 4H-1,2-oxazine, 6H-1,2-oxazine, 2H-1,3-oxazine, 4H-1,3-oxazine, 4H-1,4-oxazine, morpholine, trioxane, 4H-1,2,3-trithiin, 1,2,3-trithiane, 1,3,5-trithiane, hexahydro-1,3,5-triazine, tetrahydrothiophene, tetrahydrofuran, pyrroline, pyrrolidine, pyrrolidone, pyrrolidione, pyrazoline, pyrazolidine, imidazoline, imidazolidine, 1,2-dioxole, 1,2-dioxolane, 1,3-dioxole, 1,3-dioxolane, 3H-1,2-dithiole, 1,2-dithiolane, 1,3-dithiole, 1,3-dithiolane, isoxazoline, isoxazolidine, oxazoline, oxazolidine, thiazoline, thiozolidine, 3H-1,2-oxathiole, 1,2-oxathiolane, 5H-1,2-oxathiole, 1,3-oxathiole, 1,3-oxathiolane, 1,2,3-trithiole, 1,2,3-trithiolane, 1,2,4-trithiolane, 1,2,3-trioxole, 1,2,3-trioxolane. 1,2,4-trioxolane, 1,2,3-triazoline and 1,2,3-triazolidine.
In each of the above formula, any asymmetric carbon atoms may be present in the (R)-, (S)- or (R,S)-configuration. The compounds may thus be present as mixtures of isomers or as pure isomers, for example, as pure enantiomers or diastereomers. The invention further encompasses possible tautomers of the inventive compounds.
Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2H, 3H, 11C, 13C, 14C, 15N, 18F 31P, 32P, 35S, 36Cl, 125I respectively.
The invention includes various isotopically labeled compounds as defined herein, for example, those into which radioactive isotopes such as 3H, 13C, and 14C, are present. Such isotopically labelled compounds are useful in metabolic studies (with, for example, 14C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In other examples, an 18F or labeled compound may be used for PET or SPECT studies. Isotopic variations of the compounds have the potential to change a compound's metabolic fate and/or create small changes in physical properties such as hydrophobicity, and the like. Isotopic variations also have the potential to enhance efficacy and safety, enhance bioavailability and half-life, alter protein binding, change biodistribution, increase the proportion of active metabolites and/or decrease the formation of reactive or toxic metabolites. Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
In each of the above formula, each optionally substituted moiety may be substituted with C1-6 alkyl, C2-6 alkenyl or C3-6 alkynyl, each of which may be optionally halogenated or optionally having a carbon that may be replaced or substituted with N, S, O, or a combination thereof (for example, hydroxylC1-C8alkyl, C1-C8alkoxyC1-C8alkyl); halo, amino, amidino, C1-6 alkoxy; hydroxyl, methylenedioxy, carboxy; C1-8 alkylcarbonyl, C1-8 alkoxycarbonyl, carbamoyl, C1-8 alkylcarbamoyl, sulfamoyl, cyano, oxo, nitro, or an optionally substituted carbocyclic ring, heterocyclic ring, aryl or heteroaryl as previously described.
Pharmacology and Utility
The compounds of the invention and their pharmaceutically acceptable salts exhibit valuable pharmacological properties when tested in vitro in cell-free kinase assays and in cellular assays, and are therefore useful as pharmaceuticals.
In one aspect, the compounds of the invention may inhibit insulin like growth-factor receptor 1 (IGF-1R), and may be useful in the treatment of IGF-1 R mediated diseases. Examples of IGF-1R mediated diseases include but are not limited to proliferative diseases, such as tumors, for example breast, renal, prostate, colorectal, thyroid, ovarian, pancreas, neuronal, lung, uterine and gastro intestinal tumors, as well as osteosarcomas and melanomas. The efficacy of the compounds of the invention as inhibitors of IGF-1R tyrosine kinase activity may be demonstrated using a cellular capture ELISA. In this assay, the activity of the compounds of the invention against (IGF-1)-induced autophosphorylation of the IGF-1R is determined.
In another aspect, the compounds of the invention may inhibit the tyrosine kinase activity of anaplastic lymphoma kinase (ALK) and the fusion protein of NPM-ALK. This protein tyrosine kinase results from a gene fusion of nucleophosmin (NPM) and ALK, rendering the protein tyrosine kinase activity of ALK ligand independent. NPM-ALK plays a key role in signal transmission in a number of hematopoetic and other human cells leading to hematological and neoplastic diseases, for example in anaplastic large-cell lymphoma (ALCL) and non-Hodgkin's lymphomas (NHL), specifically in ALK+NHL or Alkomas, in inflammatory myofibroblastic tumors (IMT) and neuroblastomas. (Duyster et al. 2001 Oncogene 20, 5623-5637). In addition to NPM-ALK, other gene fusions have been identified in human hematological and neoplastic diseases; for example, TPM3-ALK (a fusion of nonmuscle tropomyosin with ALK).
The inhibition of ALK tyrosine kinase activity may be demonstrated using known methods, for example using the recombinant kinase domain of the ALK in analogy to the VEGF-R kinase assay described in J. Wood et al. Cancer Res. 60, 2178-2189 (2000). In general, in vitro enzyme assays using GST-ALK protein tyrosine kinase are performed in 96-well plates as a filter binding assay in 20 mM Tris HCl, pH=7.5, 3 mM MgCl2, 10 mM MnCl2, 1 mM DTT, 0.1 μCi/assay (=30 μl) [γ-33P]-ATP, 2 μM ATP, 3 μg/mL poly (Glu, Tyr 4:1) Poly-EY (Sigma P-0275), 1% DMSO, 25 ng ALK enzyme. Assays are incubated for 10 min at ambient temperature. Reactions are terminated by adding 50 μl of 125 mM EDTA, and the reaction mixture is transferred onto a MAIP Multiscreen plate (Millipore, Bedford, Mass., USA), previously wet with methanol, and rehydrated for 5 min with H2O. Following washing (0.5% H3PO4), plates are counted in a liquid scintillation counter. IC50 values are calculated by linear regression analysis of the percentage inhibition.
The compounds of the invention may potently inhibit the growth of human NPM-ALK overexpressing murine BaF3 cells (DSMZ Deutsche Sammiung von Mikroorganismen and Zelikulturen GmbH, Germany). The expression of NPM-ALK may be achieved by transfecting the BaF3 cell line with an expression vector pClneoTM (Promega Corp., Madison Wis., USA) coding for NPM-ALK and subsequent selection of G418 resistant cells. Non-transfected BaF3 cells depend on IL-3 for cell survival. In contrast, NPM-ALK expressing BaF3 cells (named BaF3-NPM-ALK hereinafter) can proliferate in the absence of IL-3 because they obtain proliferative signal through NPM-ALK kinase. Putative inhibitors of the NPM-ALK kinase therefore abolish the growth signal and may result in antiproliferative activity. The antiproliferative activity of putative inhibitors of the NPM-ALK kinase can however be overcome by addition of IL-3, which provides growth signals through an NPM-ALK independent mechanism. An analogous cell system using FLT3 kinase has also been described (see, E Weisberg et al. Cancer Cell; 1, 433-443 (2002)).
The inhibitory activity of the compounds of the invention may be determined as follows. In general, BaF3-NPM-ALK cells (15,000/microtitre plate well) are transferred to 96-well microtitre plates. Test compounds dissolved in dimethyl sulfoxide (DMSO) are added in a series of concentrations (dilution series) in such a manner that the final concentration of DMSO is not greater than 1% (v/v). After the addition, the plates are incubated for two days during which the control cultures without test compound are able to undergo two cell-division cycles. The growth of the BaF3-NPM-ALK cells is measured by means of YOPROTM staining [T Idziorek et al. J. Immunol. Methods; 185: 249-258 (1995)]: 25 μl of lysis buffer comprising 20 mM sodium citrate, pH 4.0, 26.8 mM sodium chloride, 0.4% NP40 and 20 mM EDTA is added to each well. Cell lysis is completed within 60 min at room temperature and total amount of YOPROTM bound to DNA is determined by measurement using the Cytofluor II 96-well reader (PerSeptive Biosystems) with the following settings: Excitation (nm) 485/20 and Emission (nm) 530/25.
The compounds of the invention may also be useful in the treatment and/or prevention of acute or chronic inflammatory diseases or disorders or autoimmune diseases e.g. rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, diabetes (type I and II) and the disorders associated therewith, respiratory diseases such as asthma or inflammatory liver injury, inflammatory glomerular injury, cutaneous manifestations of immunologically-mediated disorders or illnesses, inflammatory and hyperproliferative skin diseases (such as psoriasis, atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis and further eczematous dermatitis, seborrhoeic dermatitis), inflammatory eye diseases, e.g. Sjoegren's syndrome, keratoconjunctivitis or uveitis, inflammatory bowel disease, Crohn's disease or ulcerative colitis.
In accordance with the foregoing, the present invention provides:
(1) a compound of the invention for use as a pharmaceutical;
(2) a compound of the invention for use as an IGF-1R inhibitor, for example for use in any of the particular indications hereinbefore set forth;
(3) a pharmaceutical composition, e.g. for use in any of the indications herein before set forth, comprising a compound of the invention as active ingredient together with one or more pharmaceutically acceptable diluents or carriers;
(4) a method for the treatment of any particular indication set forth hereinbefore in a subject in need thereof which comprises administering an effective amount of a compound of the invention or a pharmaceutical composition comprising same;
(5) the use of a compound of the invention for the manufacture of a medicament for the treatment or prevention of a disease or condition in which IGF-1R activation plays a role or is implicated;
(6) the method as defined above under (4) comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of a compound of the invention and one or more further drug substances, said further drug substance being useful in any of the particular indications set forth hereinbefore;
(7) a combination comprising a therapeutically effective amount of a compound of the invention and one or more further drug substances, said further drug substance being useful in any of the particular indications set forth hereinbefore;
(8) use of a compound of the invention for the manufacture of a medicament for the treatment or prevention of a disease which responds to inhibition of the anaplastic lymphoma kinase;
(9) the use according to (8), wherein the disease to be treated is selected from anaplastic large cell lymphoma, non-Hodgkin's lymphomas, inflammatory myofibroblastic tumors, neuroblastomas and neoplastic diseases;
(10) the use according to (8) or (9), wherein the compound is any one of the examples, or a pharmaceutically acceptable salt thereof;
(11) a method for the treatment of a disease which responds to inhibition of the anaplastic lymphoma kinase, especially a disease selected from anaplastic large-cell lymphoma, non Hodgkin's lymphomas, inflammatory myofibroblastic tumors, neuroblastomas and neoplastic diseases, comprising administering an effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof.
Administration and Pharmaceutical Compositions
In general, compounds of the invention will be administered in therapeutically effective amounts via any of the usual and acceptable modes known in the art, either singly or in combination with one or more therapeutic agents. A therapeutically effective amount may vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors known to those of ordinary skill in the art. For example, for the treatment of neoplastic diseases and immune system disorders, the required dosage will also vary depending on the mode of administration, the particular condition to be treated and the effect desired.
In general, satisfactory results are indicated to be obtained systemically at daily dosages of from about 0.01 to about 100 mg/kg per body weight, or particularly, from about 0.03 to 2.5 mg/kg per body weight. An indicated daily dosage in the larger mammal, e.g. humans, may be in the range from about 0.5 mg to about 2000 mg, or more particularly, from about 0.5 mg to about 100 mg, conveniently administered, for example, in divided doses up to four times a day or in retard form. Suitable unit dosage forms for oral administration comprise from ca. 1 to 50 mg active ingredient.
Compounds of the invention may be administered as pharmaceutical compositions by any conventional route; for example, enterally, e.g., orally, e.g., in the form of tablets or capsules; parenterally, e.g., in the form of injectable solutions or suspensions; or topically, e.g., in the form of lotions, gels, ointments or creams, or in a nasal or suppository form.
Pharmaceutical compositions comprising a compound of the present invention in free form or in a pharmaceutically acceptable salt form in association with at least one pharmaceutically acceptable carrier or diluent may be manufactured in a conventional manner by mixing, granulating, coating, dissolving or lyophilizing processes. For example, pharmaceutical compositions comprising a compound of the invention in association with at least one pharmaceutical acceptable carrier or diluent may be manufactured in conventional manner by mixing with a pharmaceutically acceptable carrier or diluent. Unit dosage forms for oral administration contain, for example, from about 0.1 mg to about 500 mg of active substance.
In one embodiment, the pharmaceutical compositions are solutions of the active ingredient, including suspensions or dispersions, such as isotonic aqueous solutions. In the case of lyophilized compositions comprising the active ingredient alone or together with a carrier such as mannitol, dispersions or suspensions can be made up before use. The pharmaceutical compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. Suitable preservatives include but are not limited to antioxidants such as ascorbic acid, or microbicides, such as sorbic acid or benzoic acid. The solutions or suspensions may further comprise viscosity-increasing agents, including but not limited to, sodium carboxymethylcellulose, carboxymethylcellulose, dextran, polyvinylpyrrolidone, gelatins, or solubilizers, e.g. Tween 80 (polyoxyethylene(20)sorbitan mono-oleate).
Suspensions in oil may comprise as the oil component the vegetable, synthetic, or semi-synthetic oils customary for injection purposes. Examples include liquid fatty acid esters that contain as the acid component a long-chained fatty acid having from 8 to 22 carbon atoms, or in some embodiments, from 12 to 22 carbon atoms. Suitable liquid fatty acid esters include but are not limited to lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, arachidic acid, behenic acid or corresponding unsaturated acids, for example oleic acid, elaidic acid, erucic acid, brassidic acid and linoleic acid, and if desired, may contain antioxidants, for example vitamin E, 3-carotene or 3,5-di-tert-butyl-hydroxytoluene. The alcohol component of these fatty acid esters may have six carbon atoms and may be monovalent or polyvalent, for example a mono-, di- or trivalent, alcohol. Suitable alcohol components include but are not limited to methanol, ethanol, propanol, butanol or pentanol or isomers thereof; glycol and glycerol.
Other suitable fatty acid esters include but are not limited ethyl-oleate, isopropyl myristate, isopropyl palmitate, LABRAFIL® M 2375, (polyoxyethylene glycerol), LABRAFIL® M 1944 CS (unsaturated polyglycolized glycerides prepared by alcoholysis of apricot kernel oil and comprising glycerides and polyethylene glycol ester), LABRASOLTM (saturated polyglycolized glycerides prepared by alcoholysis of TCM and comprising glycerides and polyethylene glycol ester; all available from GaKefosse, France), and/or MIGLYOL® 812 (triglyceride of saturated fatty acids of chain length C8 to C12 from Hills AG, Germany), and vegetable oils such as cottonseed oil, almond oil, olive oil, castor oil, sesame oil, soybean oil, or groundnut oil.
Pharmaceutical compositions for oral administration may be obtained, for example, by combining the active ingredient with one or more solid carriers, and if desired, granulating a resulting mixture, and processing the mixture or granules by the inclusion of additional excipients, to form tablets or tablet cores.
Suitable carriers include but are not limited to fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations, and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, and also binders, such as starches, for example corn, wheat, rice or potato starch, methylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, such as the above-mentioned starches, carboxymethyl starch, crosslinked polyvinylpyrrolidone, alginic acid or a salt thereof, such as sodium alginate. Additional excipients include flow conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol, or derivatives thereof.
Tablet cores may be provided with suitable, optionally enteric, coatings through the use of, inter alia, concentrated sugar solutions which may comprise gum arable, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents or solvent mixtures, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate. Dyes or pigments may be added to the tablets or tablet coatings, for example for identification purposes or to indicate different doses of active ingredient.
Pharmaceutical compositions for oral administration may also include hard capsules comprising gelatin or soft-sealed capsules comprising gelatin and a plasticizer, such as glycerol or sorbitol. The hard capsules may contain the active ingredient in the form of granules, for example in admixture with fillers, such as corn starch, binders, and/or glidants, such as talc or magnesium stearate, and optionally stabilizers. In soft capsules, the active ingredient may be dissolved or suspended in suitable liquid excipients, such as fatty oils, paraffin oil or liquid polyethylene glycols or fatty acid esters of ethylene or propylene glycol, to which stabilizers and detergents, for example of the polyoxyethylene sorbitan fatty acid ester type, may also be added.
Pharmaceutical compositions suitable for rectal administration are, for example, suppositories comprising a combination of the active ingredient and a suppository base. Suitable suppository bases are, for example, natural or synthetic triglycerides, paraffin hydrocarbons, polyethylene glycols or higher alkanols.
Pharmaceutical compositions suitable for parenteral administration may comprise aqueous solutions of an active ingredient in water-soluble form, for example of a water-soluble salt, or aqueous injection suspensions that contain viscosity-increasing substances, for example sodium carboxymethylcellulose, sorbitol and/or dextran, and, if desired, stabilizers. The active ingredient, optionally together with excipients, can also be in the form of a lyophilizate and can be made into a solution before parenteral administration by the addition of suitable solvents. Solutions such as are used, for example, for parenteral administration can also be employed as infusion solutions. The manufacture of injectable preparations is usually carried out under sterile conditions, as is the filling, for example, into ampoules or vials, and the sealing of the containers.
The compounds of the invention may be administered as the sole active ingredient, or together with other drugs useful against neoplastic diseases or useful in immunomodulating regimens. For example, the compounds of the invention may be used in accordance with the invention in combination with pharmaceutical compositions effective in various diseases as described above, e.g. with cyclophosphamide, 5-fluorouracil, fludarabine, gemcitabine, cisplatinum, carboplatin, vincristine, vinblastine, etoposide, irinotecan, paclitaxel, docetaxel, rituxan, doxorubicine, gefitinib, or imatinib; or also with cyclosporins, rapamycins, ascomycins or their immunosuppressive analogs, e.g. cyclosporin A, cyclosporin G, FK-506, sirolimus or everolimus, corticosteroids, e.g. prednisone, cyclophosphamide, azathioprene, methotrexate, gold salts, sulfasalazine, antimalarials, brequinar, leflunomide, mizoribine, mycophenolic acid, mycophenolate, mofetil, 15-deoxyspergualine, immuno-suppressive monoclonal antibodies, e.g. monoclonal antibodies to leukocyte receptors, e.g. MHC, CD2, CD3, CD4, CD7, CD25, CD28, I CD40, CD45, CD58, CD80, CD86, CD152, CD137, CD154, ICOS, LFA-1, VLA-4 or their ligands, or other immunomodulatory compounds, e.g. CTLA41g.
The invention also provides for a pharmaceutical combinations, e.g. a kit, comprising a) a first agent which is a compound of the invention as disclosed herein, in free form or in pharmaceutically acceptable salt form, and b) at least one co-agent. The kit can comprise instructions for its administration.
Processes for Making Compounds of the Invention
General procedures for preparing compounds of the invention are described in the Examples, infra. In the reactions described, reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, may be protected to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice (see e.g., T. W. Greene and P. G. M. Wuts in “Protective Groups in Organic Chemistry”, John Wiley and Sons, 1991).
The compounds of the invention, including their salts, are also obtainable in the form of hydrates, or their crystals may include for example the solvent used for crystallization (present as solvates). Salts can usually be converted to compounds in free form, e.g., by treating with suitable basic agents, for example with alkali metal carbonates, alkali metal hydrogen carbonates, or alkali metal hydroxides, such as potassium carbonate or sodium hydroxide. A compound of the invention in a base addition salt form may be converted to the corresponding free acid by treating with a suitable acid (e.g., hydrochloric acid, etc.). In view of the close relationship between the novel compounds in free form and those in the form of their salts, including those salts that may be used as intermediates, for example in the purification or identification of the novel compounds, any reference to the free compounds is to be understood as referring also to the corresponding salts, as appropriate.
Salts of the inventive compounds with a salt-forming group may be prepared in a manner known per se. Acid addition salts of compounds of Formula (1), (2), (3) and (4), may thus be obtained by treatment with an acid or with a suitable anion exchange reagent. Pharmaceutically acceptable salts of the compounds of the invention may be formed, for example, as acid addition salts, with organic or inorganic acids, from compounds of Formula (1), (2), (3) and (4), with a basic nitrogen atom.
Suitable inorganic acids include, but are not limited to, halogen acids, such as hydrochloric acid, sulfuric acid, or phosphoric acid. Suitable organic acids include, but are not limited to, carboxylic, phosphoric, sulfonic or sulfamic acids, for example acetic acid, propionic acid, octanoic acid, decanoic acid, dodecanoic acid, glycolic acid, lactic acid, fumaric acid, succinic acid, adipic acid, pimelic acid, suberic acid, azelaic acid, -malic acid, tartaric acid, citric acid, amino acids, such as glutamic acid or aspartic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, cyclohexanecarboxylic acid, adamantanecarboxylic acid, benzoic acid, salicylic acid, 4 aminosalicylic acid, phthalic acid, phenylacetic acid, mandelic acid, cinnamic acid, methane- or ethane-sulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 1,5-naphthalene-disulfonic acid, 2-, 3- or 4 methylbenzenesulfonic acid, methylsulfuric acid, ethylsulfuric acid, dodecylsulfuric acid, N cyclohexylsulfamic acid, N-methyl-, N-ethyl- or N-propyl-sulfamic acid, or other organic protonic acids, such as ascorbic acid. For isolation or purification purposes, it is also possible to use pharmaceutically unacceptable salts, for example picrates or perchlorates. For therapeutic use, only pharmaceutically acceptable salts or free compounds are employed (where applicable in the form of pharmaceutical preparations).
Compounds of the invention in unoxidized form may be prepared from N-oxides of compounds of the invention by treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like) in a suitable inert organic solvent (e.g. acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to 80° C.
Prodrug derivatives of the compounds of the invention may be prepared by methods known to those of ordinary skill in the art (e.g., for further details see Saulnier et al., (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985). For example, appropriate prodrugs may be prepared by reacting a non-derivatized compound of the invention with a suitable carbamylating agent (e.g., 1,1-acyloxyalkylcarbanochloridate, para-nitrophenyl carbonate, or the like).
Protected derivatives of the compounds of the invention may be made by means known to those of ordinary skill in the art. A detailed description of techniques applicable to the creation of protecting groups and their removal may be found in T. W. Greene, “Protecting Groups in Organic Chemistry”, 3rd edition, John Wiley and Sons, Inc., 1999.
Compounds of the invention may be prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomers. Resolution of enantiomers may be carried out using covalent diastereomeric derivatives of the compounds of the invention, or by using dissociable complexes (e.g., crystalline diastereomeric salts). Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and may be readily separated by taking advantage of these dissimilarities. The diastereomers may be separated by fractionated crystallization, chromatography, or by separation/resolution techniques based upon differences in solubility. The optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization. A more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from their racemic mixture may be found in Jean Jacques, Andre Collet, Samuel H. Wilen, “Enantiomers, Racemates and Resolutions”, John Wiley And Sons, Inc., 1981.
In summary, the compounds of the invention may be made by a process as described in the Examples; and
(a) optionally converting a compound of the invention into a pharmaceutically acceptable salt;
(b) optionally converting a salt form of a compound of the invention to a non-salt form;
(c) optionally converting an unoxidized form of a compound of the invention into a pharmaceutically acceptable N-oxide;
(d) optionally converting an N-oxide form of a compound of the invention to its unoxidized form;
(e) optionally resolving an individual isomer of a compound of the invention from a mixture of isomers;
(f) optionally converting a non-derivatized compound of the invention into a pharmaceutically acceptable prodrug derivative; and
(g) optionally converting a prodrug derivative of a compound of the invention to its non-derivatized form.
Insofar as the production of the starting materials is not particularly described, the compounds are known or can be prepared analogously to methods known in the art or as disclosed in the Examples hereinafter. One of skill in the art will appreciate that the above transformations are only representative of methods for preparation of the compounds of the present invention, and that other well known methods can similarly be used. The present invention is further exemplified, but not limited, by the following and Examples that illustrate the preparation of the compounds of the invention.
Intermediate 1
2,5-dichloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine




A mixture of 5-methyl-1H-pyrazol-3-amine (3.00 g, 30.9 mmol), 2,4,5-trichloropyrimidine (5.67 g, 30.9 mmol, 1 equiv.) and Na2CO3 (3.60 g, 34.0 mmol, 1.1 equiv.) in EtOH (100 mL) was heated at 40° C. for 24 h. The solvent was removed in vacuo. The resulting residue was partitioned between EtOAc (350 mL) and water (100 mL). The EtOAc layer was washed with water (3×), saturated aqueous NaCl (1×) and dried over Na2SO4. The resulting EtOAc solution was concentrated in vacuo, providing the product 2,5-dichloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine; SMS m/z 244.0 (M+H+).
Intermediate 2
2-chloro-N-(5-methyl-1H-pyrazol-3-yl)-5-(trifluoromethyl)pyrimidin-4-amine




A mixture of 2,4-dichloro-5-(trifluoromethyl)pyrimidine (1.06 g, 4.86 mmol), 5-methyl-1H-pyrazol-3-amine (472.2 mg, 4.86 mmol) and sodium carbonate (2.06 g, 19.4 mmol) in 100 mL of EtOH was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo. The crude solid was partitioned between EtOAc and water. The combined organic extracts were dried (Na2SO4), concentrated in vacuo, and purified by silica chromatography (EtOAc/hexanes: 1/1) to afford 2-chloro-N-(5-methyl-1H-pyrazol-3-yl)-5-(trifluoromethyl)pyrimidin-4-amine; ESMS m/z 278.0 (M+H+).
Intermediate 3
2-chloro-5-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine




A mixture of 5-methyl-1H-pyrazol-3-amine (3.00 g, 30.9 mmol), 2,4-dichloro-5-methylpyrimidine (5.03 g, 30.9 mmol, 1 equiv.) and Na2CO3 (3.60 g, 34.0 mmol, 1.1 equiv.) in EtOH (100 mL) was heated at 40° C. for 24 h. The solvent was removed in vacuo. The resulting residue was partitioned between EtOAc (350 mL) and water (100 mL). The EtOAc layer was washed with water (3×), saturated aqueous NaCl (1×), dried over Na2SO4, and concentrated in vacuo. The resulting crude product was sonicated in Et2O (200 mL) and the resulting precipitate collected by filtration. This powder was further washed with Et2O, providing the product 2-chloro-5-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine; ESMS m/z 224.1 (M+H+).
Intermediate 4
N-(2,5-dichloropyrimidin-4-yl)-5-methylisoxazol-3-amine




The mixture 5-methylisoxazol-3-amine (98 mg, 1.0 mmol), 2,4,5-trichloropyrimidine (344 μL, 3.0 mmol), and sodium carbonate (106 mg, 1.0 mmol) in 3 mL of EtOH was heated at 60° C. overnight. The reaction mixture was concentrated and then partitioned between EtOAc and brine. The collected organic extracts were dried (Na2SO4), concentrated in vacuo, and purified with silica gel chromatography (MeOH/DCM: 1/9) to afford N-(2,5-dichloropyrimidin-4-yl)-5-methylisoxazol-3-amine; ESMS m/z 245.0 (M+H+).
Intermediate 5
2,5-dichloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidin-4-amine




A mixture of 5-cyclopropyl-1H-pyrazol-3-amine (246 mg, 2.00 mmol), 2,4,5-trichloropyrimidine (367 mg, 2.00 mmol, 1 equiv.) and Na2CO3 (233 mg, 2.20 mmol, 1.1 equiv.) in EtOH (10 mL) was heated at 40° C. for 16 h. The crude reaction mixture was diluted with EtOAc and sequentially washed with: water (3×) and saturated aqueous NaCl (1×). The resulting EtOAc layer was dried over Na2SO4 and then concentrated in vacuo, providing 2,5-dichloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidin-4-amine; ESMS m/z 270.0 (M+H+).
Intermediate 6
3-(2,5-dichloropyrimidin-4-ylamino)azepan-2-one




A mixture of (±)-α-amino-ε-caprolactam (256 mg, 2.0 mmol), 2,4,5-trichloropyrimidine (366 mg, 2.0 mmol, 1 equiv.) and NaHCO3 (168 mg, 2 mmol, 1 equiv.) in a mixture of MeOH (12 mL) and H2O (6 mL) was stirred at room temperature for 15 h. The resulting precipitate was collected by vacuum filtration and washed with small amounts of MeOH and water, providing the product 3-(2,5-dichloropyrimidin-4-ylamino)azepan-2-one; ESMS m/z 275.0 (M+H+).
Intermediate 7
3-(2,5-dichloropyrimidin-4-ylamino)pyridin-2(1H)-one




A mixture of 3-aminopyridin-2(1H)-one (99 mg, 0.90 mmol), 2,4,5-trichloropyrimidine (165 mg, 0.90 mmol, 1 equiv.) and NaHCO3 (76 mg, 0.90 mmol, 1 equiv.) in a mixture of MeOH (6 mL) and H2O (3 mL) was stirred at room temperature for 24 h. The resulting precipitate was collected by vacuum filtration and washed with small amounts of MeOH and water, providing the product 3-(2,5-dichloropyrimidin-4-ylamino)pyridin-2(1H)-one; ESMS m/z 257.0 (M+H+).
Intermediate 8
2,5-Dichloro-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidin-4-amine




To a mixture of 2,5-dichloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine (2.44 g, 10 mmol) and 4-toluenesulfonic acid monohydrate (1.9 g, 10 mmol) in THF (200 mL), was added DHP (4.25 g, 50 mmol). After stirring overnight, the reaction turned clear. After concentration, the residue was dissolved in ethyl acetate and washed with Na2CO3 saturated aqueous solution. The organic layer was then washed with brine, dried over sodium sulfate and concentrated in vacuo to afford 2,5-Dichloro-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidin-4-amine as light yellow solid, which was used in subsequent reactions without further purification; ESMS m/z 244 (M−THP+H+); TLC Rf=0.6 (Silica; 1:1 ethyl acetate/hexanes; starting material Rf=0.2).
Intermediate 9
2,5-Dichloro-N-(5-(trifluoromethyl)-1H-pyrazol-3-yl)pyrimidin-4-amine




Step 1: 5-(Trifluoromethyl)-1H-pyrazol-3-amine
A mixture of (E)-4-amino-4-ethoxy-1,1,1-trifluorobut-3-en-2-one (5.00 g, 27 mmol) and hydrazine (1.05 g) in anhydrous EtOH (20 mL) was stirred at 80° C. in a sealed vial overnight. The reaction was quenched with water (50 mL), and extracted with EtOAc (100 ml, then 2×50 mL). The EtOAc layers were combined and sequentially washed with water (25 mL), brine (25 mL), dried over Na2SO4 and evaporated to give a light brown oily residue. The crude product was purified by silica chromatography (30-100% EtOAc in hexanes gradient) to give 5-(trifluoromethyl)-1H-pyrazol-3-amine as an off white solid; ESMS m/z 152.0 (MAI).
Step 2: 2,5-Dichloro-N-(5-(trifluoromethyl)-1H-pyrazol-3-yl)pyrimidin-4-amine
A mixture of 5-(trifluoromethyl)-1H-pyrazol-3-amine (500 mg, 3.3 mmol), 2,4,5-trichloropyrimidine (607 mg, 3.3 mmol) and sodium carbonate (525 mg, 5 mmol) in anhydrous EtOH (10 mL) was stirred at rt. After one day, LCMS showed the reaction was not complete. Additional 2,4,5-trichloropyrimidine (0.15 mL) and sodium carbonate (525 mg) were added and the reaction continued for two more days. The solvent was evaporated, and the residue was extracted with DCM (3×20 mL). The combined DCM layers were washed with brine (10 mL), dried over Na2SO4 and evaporated. The crude product was purified by silica chromatography (0-50% EtOAc in hexanes gradient) to give 2,5-Dichloro-N-(5-(trifluoromethyl)-1H-pyrazol-3-yl)pyrimidin-4-amine as a light tan colored solid; ESMS m/z 297.9 (MAI).
Intermediate 10
2,5-Dichloro-N-(5-ethyl-1H-pyrazol-3-yl)pyrimidin-4-amine




A mixture of 5-ethyl-1H-pyrazol-3-amine (1.00 g, 6.77 mmol), 2,4,5-trichloropyrimidine (1.24 g, 6.77 mmol) and Na2CO3 (1.79 g, 16.9 mmol) in iso-propanol (15 mL) was stirred in a sealed vial at rt for two days. Water (10 mL) was added. The solid was collected by filtration, washed with water (10 mL) and dried to give 2,5-Dichloro-N-(5-ethyl-1H-pyrazol-3-yl)pyrimidin-4-amine as a light yellow solid; ESMS m/z 258.0 (M+H+).
Intermediate 11
1-chloro-5-methyl-4-nitro-2-(trifluoromethyl)benzene




To a solution of 2-chloro-4-methyl-1-(trifluoromethyl)benzene (6.65 g, 34.1 mmol) in conc. sulfuric acid (25 mL) at 0° C. was added potassium nitrate (3.46 g, 34.1 mmol) in sulfuric acid (15 mL). After stirring at 0° C. for 1.5 h, the reaction mixture was poured into 500 mL of ice water. The precipitate was collected by filtration and washed with copious amounts of water, yielding 1-chloro-5-fluoro-4-nitro-2-(trifluoromethyl)benzene as an orange solid; 1H NMR (400 MHz, chloroform-d) δ 8.356 (s, 1H), 7.543 (s, 1H), 2.660 (s, 3H).
Intermediate 12
2-Bromo-4-methyl-5-nitrobenzonitrile




Following the same procedure as described in Intermediate 11 starting with 2-bromo-4-methylbenzonitrile, 2-bromo-4-methyl-5-nitrobenzonitrile was obtained as a yellow solid; 1H NMR (400 MHz, chloroform-d) δ 8.290 (s, 1H), 7.742 (s, 1H), 2.683 (s, 3H).
Intermediate 13
5-Amino-2-bromo-4-methylbenzonitrile




To a solution of 2-bromo-4-methyl-5-nitrobenzonitrile (500 mg, 2.07 mmol) in ethanol (20 mL) was added tin chloride (785 mg, 4.14 mmol). The mixture was refluxed for 5 h. After cooling to room temperature, triethylamine (1.01 g, 10 mmol) was added. The mixture was concentrated and purified by silica chromatography (30-50% ethyl acetate in hexanes gradient) to afford 5-Amino-2-bromo-4-methylbenzonitrile a as beige solid; ESMS m/z 211 (M+H+).
Intermediate 14
Methyl 2-bromo-4-methyl-5-nitrobenzoate




Following the same procedure as described in Intermediate 11 starting with methyl 2-bromo-4-methylbenzoate, the title compound was obtained as a white solid; 1H NMR (400 MHz, chloroform-d) 68.505 (s, 1H), 7.711 (s, 1H), 3.967 (s, 3H), 2.640 (s, 3H).
Intermediate 15
Methyl 5-amino-2-bromo-4-methylbenzoate




Following the same procedure as described in Intermediate 13, the title compound was obtained as a beige solid; ESMS m/z 244 (M+H+).
Intermediate 16
4-Bromo-5-methoxy-2-methylaniline




Step 1: N-(5-methoxy-2-methylphenyl)acetamide
To a solution of triethylamine (2.9 g, 14.4 mmol) and 5-methoxy-2-methylaniline (1.0 g, 7.2 mmol) in DCM (30 mL) at 0° C., was added acetyl chloride (0.57 g, 7.2 mmol) dropwise. The mixture was stirred at room temperature for 1 hour. The reaction was quenched with saturated ammonium chloride aqueous solution, and extracted with DCM. The organic layer was dried over Na2SO4 and concentrated to give N-(5-methoxy-2-methylphenyl)acetamide as needle-shaped crystals. The crude product was used in the next step without further purification.
Step 2: N-(4-bromo-5-methoxy-2-methylphenyl)acetamide
To a solution of N-(5-methoxy-2-methylphenyl)acetamide in acetic acid (40 mL) was added Br2 (3 g, 19 mmol) slowly. The mixture was capped and stirred at 50° C. for 5 hours. The reaction was cooled to room temperature, then quenched with sodium sulfite aqueous solution, and extracted with ethyl acetate (3×50 mL). The combined organic layer was dried over Na2SO4 and concentrated to give crude N-(4-bromo-5-methoxy-2-methylphenyl)acetamide as a brown oil, which was used in the next step without further purification.
Step 3: 4-bromo-5-methoxy-2-methylaniline
N-(4-bromo-5-methoxy-2-methylphenyl)acetamide was dissolved in methanol (15 mL) and concentrated HCl (30 mL). The mixture was refluxed at 95° C. overnight. After cooling to room temperature, the mixture was poured into ice water, and basified to pH=12 with conc. NaOH aqueous solution. The mixture was then extracted with ethyl acetate (3×50 mL). The combined organic layer was dried over Na2SO4 and concentrated. The crude product was purified by silica chromatography (15% ethyl acetate in hexanes) to give 4-bromo-5-methoxy-2-methylaniline as a beige solid; 1H NMR (400 mHz, CDCl3) 7.20 (s, 1H), 6.37 (s, 1H), 4.6 (br, 2H), 3.82 (s, 3H), 2.12 (s, 3H).
Intermediate 17
2-Fluoro-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline




A mixture of 4-bromo-2-fluoro-5-methylaniline (2.0 g, 9.8 mmol), bis(pinacolato)diboron (2.74 g, 10.8 mmol), tricyclohexylphosphine (274.8 mg, 0.98 mmol), Pd2(dba)3 (448.9 mg, 0.49 mmol), and potassium acetate (1.92 g, 19.6 mmol) in 60 mL of 1,4-dioxane was degassed and purged with nitrogen. The reaction mixture was heated at 80° C. overnight and then cooled to room temperature. The mixture was partitioned between EtOAc and water and the collected organic extracts were dried (Na2SO4), concentrated in vacuo, and purified by silica chromatography (EtOAc/Hexanes: 20/80) to afford 2-fluoro-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline; ESMS m/z 252.2 (M+H+).
Intermediate 18
2-Isopropoxy-5-methyl-4-(1-methyl-piperidin-4-yl)-phenylamine




Step 1: 1-bromo-5-fluoro-2-methyl-4-nitrobenzene
To a solution of 2-bromo-4-fluoro-1-methylbenzene (5 g, 26.4 mmol) dissolved in conc. sulfuric acid (20 mL) was added potassium nitrate (2.67 g, 26.4 mmol) in sulfuric acid (5 mL) at 0° C. After stirring at 0° C. for 1 hr, the reaction was diluted with water, extracted with ethyl acetate (3×40 mL). The combined organic phases were washed with saturated sodium bicarbonate solution and brine sequentially, and then dried over Na2SO4. The crude product obtained after concentration was purified by silica gel column chromatography with mixed solvent hexanes/EtOAc (95/5) to afford 1-bromo-5-fluoro-2-methyl-4-nitrobenzene as an orange solid. 1H NMR (400 MHz, chloroform-d) δ 7.93 (d, 1H, J=7.6 Hz), 7.50 (d, 1H, J=10 Hz), 2.43 (s, 3H).
Step 2: 1-bromo-5-isopropoxy-2-methyl-4-nitrobenzene
To a solution of 1-bromo-5-fluoro-2-methyl-4-nitrobenzene (Step 1, 1.5 g, 6.4 mmol) in 2-propanol (30 mL) was added cesium carbonate (5.3 g, 16 mmol). The mixture was heated at 50° C. overnight. The mixture was concentrated and partitioned between ethyl acetate and water. The organic layer was concentrated and the residue was purified with silica gel column chromatography with 5% ethyl acetate in hexanes to afford 1-bromo-5-isopropoxy-2-methyl-4-nitrobenzene as a yellow solid.
Step 3: 4-(5-Isopropoxy-2-methyl-4-nitrophenyl)pyridine
To a mixture of 1-bromo-5-isopropoxy-2-methyl-4-nitrobenzene (Step 2, 1 g, 3.65 mmol), pyridine-4-boronic acid (490 mg, 4 mmol), 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (300 mg, 0.73 mmol) and potassium phosphate (1.55 g, 7.3 mmol) in mixed solvent of dioxane (15 mL) and water (7.5 mL) was added tris(dibenzylidene-acetone)dipalladium (0) (334 mg, 0.36 mmol). This mixture was sealed and purged with nitrogen for 3 minutes and then heated at 120° C. for 5 hours. The mixture was cooled to room temperature, filtered, and the filtrate was concentrated. After concentration, the crude product was purified with silica gel flash column chromatography (60% ethyl acetate in hexanes) to afford 4-(5-isopropoxy-2-methyl-4-nitrophenyl)pyridine a as yellow solid: ESMS m/z 273.2 (M+H+).
Step 4: 4-(5-Isopropoxy-2-methyl-4-nitro-phenyl)-1-methyl-pyridinium iodide
4-(5-Isopropoxy-2-methyl-4-nitro-phenyl)-pyridine (Step 3, 217 mg, 0.797 mmol) was dissolved in anhydrous THF (9 mL). Iodomethane (0.10 mL, 1.61 mmol, 2 equiv.) was added, and the reaction was stirred at 40° C. in a sealed tube for 2 days. The volatiles were removed under vacuum, generating 4-(5-Isopropoxy-2-methyl-4-nitro-phenyl)-1-methyl-pyridinium iodide as a brown solid: ESMS m/z 287.1 (M+).
Steps 5 and 6: 2-Isopropoxy-5-methyl-4-(1-methyl-piperidin-4-yl)-phenylamine
4-(5-Isopropoxy-2-methyl-4-nitro-phenyl)-1-methyl-pyridinium iodide (Step 4, 0.697 mmol) was dissolved in CH3OH (20 mL) and cooled to 0° C. NaBH4 (264 mg, 6.97 mmol, 10 equiv.) was slowly added. After this addition was complete, the cooling bath was removed and the reaction was stirred at room temperature for 1 h. The reaction was quenched by the slow addition of 1N aqueous HCl (14 mL). The CH3OH was partially removed by vacuum. The resulting residue was partitioned between EtOAc and 1 N aqueous NaOH. Additional 50% aqueous NaOH was added until the aqueous layer had a pH>12. The EtOAc layer was washed with 1 N aqueous NaOH (2×), the organic layer was then dried over sodium sulfate, filtered, and concentrated under vacuum. After concentration, the crude product (175 mg) was dissolved in acetic acid (10 mL). TFA (0.15 mL, 3 equiv.) and PtO2 (53 mg, 30% w/w) were added and the reaction was placed under 50 psi H2 gas in a Parr Shaker for 14 h. The reaction mixture was filtered and the filtrate was concentrated under vacuum. The resulting residue was partitioned between EtOAc and 1 N aqueous NaOH. Additional 50% aqueous NaOH was added until the aqueous layer has a pH>12. The EtOAc layer was washed with 1 N aqueous NaOH (2×), the organic layer was then dried over sodium sulfate, filtered, and concentrated under vacuum to give 2-isopropoxy-5-methyl-4-(1-methyl-piperidin-4-yl)-phenylamine, which was used in subsequent steps without further purification: ESMS m/z 263.2 (M+H+).
Intermediate 19
tert-butyl 4-(4-amino-5-fluoro-2-methylphenyl)piperidine-1-carboxylate




Step 1: 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester
A solution of N-tert-Butoxycarbonyl-4-piperidone (10.17 g, 0.05 mol) in THF (100 mL) was added dropwise into a cooled (−78° C.), vigorously stirring solution of LDA (40 mL of 1.5 M solution in cyclohexanes, 0.06 mol) in THF (100 mL), under N2. The reaction mixture was left at −78° C. for 30 min before adding a solution of phenyl trifluorosulfonimide (19.85 g, 0.055 mol) in THF (50 mL). Then the reaction mixture was warmed to room temperature and stirred for 3 h. The reaction was quenched at 0° C. with 100 mL of saturated aqueous NH4Cl and filtered through Celite. The filtrate was added to 100 mL of EtOAc, and the layers were separated. The organic layer was washed with H2O, dried over MgSO4 and concentrated. The crude product was purified by silica gel chromatography (0-30% EtOAc in Hexanes as eluent and checked by TLC stained with 2% of KMnO4 in EtOH) to afford 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester as a yellow oil.
Step 2: Tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate
A solution of tert-butyl 4-(trifluoromethylsulfonyloxy)-5,6-dihydropyridine-1(2H)-carboxylate (16.0 g, 48.2 mmol) in DMSO (200 mL) was treated with bis(pinacolato)diboron (12.6 g, 49.6 mmol), potassium acetate (14.65 g, 149 mmol) and Pd(dppf)Cl2 (790 mg, 0.96 mmol). The solution was purged with N2 (g) for 5 minutes, and then sealed and heated at 80° C. for 15 h. The reaction was cooled to room temperature and poured into ice water. The mixture was extracted with ethyl acetate (3×100 mL). The combined organic phase was washed with brine, dried over sodium sulfate, and concentrated in vacuo. The crude product was purified with silica gel chromatography (15% ethyl acetate in hexanes) to afford tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate as a white solid.
Steps 3 and 4: Tert-butyl 4-(4-amino-5-fluoro-2-methylphenyl)piperidine-1-carboxylate
To a mixture of 5′-chloro-N,2′-dimethyl-4′-nitrobiphenyl-4-carboxamide (204 mg, 1 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (370 mg, 1.2 mmol) and sodium carbonate (742 mg, 7 mmol) in DMF/H2O (12/3 mL) was added tetrakis(triphenylphosphine) palladium (0) (58 mg, 5% mmol). The reaction tube was sealed, the mixture was purged with N2 for 3 min and then heated at 90° C. under N2 for overnight. The reaction was cooled to room temperature, and poured into saturated aqueous ammonia chloride solution. The crude reaction mixture was extracted with ethyl acetate (3×15 mL). The organic extracts were combined, washed with brine and concentrated. The crude product was purified with silica gel chromatography (20% ethyl acetate in hexanes) to afford tert-butyl 4-(4-amino-5-fluoro-2-methylphenyl)-5,6-dihydropyridine-1(2H)-carboxylate as a yellow oil. The obtained oil was dissolved in methanol (20 mL). To the solution was added Pd/C (10%). The reaction mixture was degassed and purged with H2 for several times and stirred under H2 (1 atm) overnight. The mixture was filtered and concentrated to afford the tert-butyl 4-(4-amino-5-fluoro-2-methylphenyl)piperidine-1-carboxylate as a white solid. ESMS m/z 207 (M−Boc+H+)
Intermediate 20
2,5-Dimethyl-4-(piperidin-2-yl)aniline




To a mixture of 1-bromo-2,5-dimethyl-4-nitrobenzene (185 mg, 1 mmol) and 2-(tributylstannyl)pyridine (202 mg, 1.1 mmol) in DMF (4 mL) was added tetrakis(triphenylphosphine) palladium (0) (58 mg, 5% mmol). The reaction tube was sealed, the mixture was purged with N2 for 3 min and then heated at 120° C. under N2 for overnight. The reaction was cooled to room temperature and poured into saturated aqueous ammonia chloride solution. The crude reaction mixture was extracted with ethyl acetate (3×15 mL). The organic extracts were combined, washed with brine and concentrated. The crude product was purified with silica gel column chromatography (60% ethyl acetate in hexanes) to afford 2-(2,5-dimethyl-4-nitrophenyl)pyridine as a white solid. The obtained solid was dissolved in acetic acid/TFA (15 mL/200 uL). To this solution was added PtO2 (10% w/w). The reaction mixture was degassed and purged with H2 for several times and stirred under 1 atm. hydrogen gas overnight. The mixture was filtered and concentrated to afford 2,5-Dimethyl-4-(piperidin-2-yl)aniline as a yellow oil. ESMS m/z 205 (M+H+).
Intermediate 21
tert-butyl 3-(4-amino-2,5-dimethylphenyl)azetidine-1-carboxylate




Step 1: tert-Butyl 3-(2,5-dimethyl-4-nitrophenyl)azetidine-1-carboxylate
Prepared from tert-butyl 3-iodoazetidine-1-carboxylate and 1-bromo-2,5-dimethyl-4-nitrobenzene by following the general protocol as described in Billotte, S. Synlett 1998, 379.
Step 2: tert-butyl 3-(4-amino-2,5-dimethylphenyl)azetidine-1-carboxylate
tert-Butyl 3-(2,5-dimethyl-4-nitrophenyl)azetidine-1-carboxylate was reduced to tert-butyl 3-(4-amino-2,5-dimethylphenyl)azetidine-1-carboxylate by standard Raney Ni hydrogenation at room temperature using MeOH as the solvent.
Intermediate 22
5-Ethyl-2-methyl-4-(piperidin-4-yl)aniline




Step 1: tert-butyl 4-(4-amino-5-methyl-2-vinylphenyl)-5,6-dihydropyridine-1(2H)-carboxylate
To a mixture of 4-bromo-5-chloro-2-methylaniline (500 mg, 2.27 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (840 mg, 3.73 mmol) and sodium carbonate (2.52 g, 15.9 mmol) in DMF/H2O (20/5 mL) was added tetrakis(triphenylphosphine) palladium (0) (131 mg, 5 mol %). The reaction tube was sealed, the mixture was purged with N2 for 3 min and then heated at 100° C. under N2 for overnight. The reaction was cooled to room temperature and poured into saturated aqueous ammonia chloride solution. The crude reaction mixture was extracted with ethyl acetate (3×15 mL). The organic extracts were combined, washed with brine and concentrated. The crude product was purified with silica chromatography (80% ethyl acetate in hexanes) to afford tert-butyl 4-(4-amino-2-chloro-5-methylphenyl)-5,6-dihydropyridine-1(2H)-carboxylate as a yellow solid. This obtained product (322 mg, 1 mmol) was dissolved in dioxane/NMP (anhydrous, 4 mL, 3/1). To this solution was added tributyl(vinyl)stannane (380 mg, 1.2 mmol), cesium fluoride (304 mg, 2 mmol) and palladium bis(tri-tert-butyl-phosphine) (51 mg, 10 mol %). This mixture was purged with N2 for 3 minutes and then heated in a sealed tube at 120° C. for overnight. The mixture was cooled to room temperature and diluted with ethyl acetate. The resulting mixture was sequentially washed with saturated aqueous ammonium chloride and brine, and finally dried over sodium sulfate. After concentration, the crude product was purified via silica chromatography (10% ethyl acetate in hexanes) to afford tert-butyl 4-(4-amino-5-methyl-2-vinylphenyl)-5,6-dihydropyridine-1(2H)-carboxylate as a light yellow oil; ESMS m/z 215.2 (M−Boc+H+).
Step 2: 5-Ethyl-2-methyl-4-(piperidin-4-yl)aniline
The product obtained from the previous step was dissolved in methanol (20 mL). To this solution was added conc. aqueous HCl (200 uL) and platinum oxide (23 mg, 0.1 mmol). The reaction mixture was degassed and purged with H2 for several times and vigorously stirred under 1 atm. H2 for 3 h. The mixture was filtered and concentrated to afford 5-Ethyl-2-methyl-4-(piperidin-4-yl)aniline as a yellow solid. ESMS m/z 219.2 (M+H+).
Intermediate 23
2,5-Dimethyl-4-(piperidin-3-yl)aniline




Step 1: 2,5-Dimethyl-4-(pyridin-3-yl)aniline
A suspension of 4-bromo-2,5-dimethylaniline (4.00 g, 20 mmol), pyridin-3-ylboronic acid (2.70 g, 11 mmol), Pd2(dba)3 (0.55 g, 0.6 mmol), 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (0.98 g, 1.2 mmol) and Na2CO3 (10.6 g, 100 mmol) in n-BuOH (50 mL) was degassed by a stream of argon gas for 15 min. The reaction flask was sealed and placed in a pre-heated oil bath (115° C.). After stirring overnight, the reaction was cooled and filtered. The filter cake was washed with DCM and the filtrate was concentrated in vacuo. The resulting residue was dissolved in EtOAc (150 mL). EtOAC was sequentially washed with water (20 mL), brine (20 mL), dried over Na2SO4 and evaporated. The crude product was purified by silica chromatography (0-50% EtOAC in hexanes gradient) to give 2,5-dimethyl-4-(pyridin-3-yl)aniline as a yellow solid; ESMS m/z 199.1 (MAI).
Step 2: 2,5-Dimethyl-4-(piperidin-3-yl)aniline
2,5-Dimethyl-4-(pyridin-3-yl)aniline (403 mg, 2.03 mmol) was dissolved in MeOH (5 mL) and conc. aqueous HCl (1 mL), followed by addition of PtO2 (40 mg). The flask was purged with H2 and the reaction was vigorously stirred at rt under H2 (1 atm). After two days, LCMS shows the completion of the reaction. The catalyst was removed by filtration and the remaining solution was concentrated in vacuo to give 2,5-Dimethyl-4-(piperidin-3-yl)aniline as a white solid, which can be used in subsequent reactions without further purification; ESMS m/z 205.2 (MAI).
Intermediate 24
1-(tert-butoxycarbonyl(methyl)amino)cyclopropanecarboxylic acid




To a solution of 1-(tert-butoxycarbonylamino)cyclopropanecarboxylic acid (201 mg, 1.0 mmol) in DMF (2 mL) was added NaH (120 mg, 3.0 mmol) at 0° C. The resulting mixture was stirred at 0° C. for 10 min. before the addition of MeI (568 mg, 4.0 mmol). The mixture was then warmed up to room temperature and stirred for 2 hr. Saturated NH4Cl aqueous solution (20 mL) was added into the mixture, and the solution was extracted with EtOAc (3×10 mL). The combined organic layers were concentrated and the residue was dissolved in MeOH (3 ml) with NaOH (3 N, 1 mL). This mixture was stirred at 80° C. for 1 hr and cooled down to room temperature. The clear solution was purified directly on preparative RP-HPLC to provide 1-(tert-butoxycarbonyl(methyl)amino)cyclopropanecarboxylic acid. ESMS m/z 238.2 (M+Na+).
Intermediate 25
(R)-2-bromopropanamide




Step 1: (R)-2-bromopropanoyl chloride
Under nitrogen, to the solution of (R)-2-bromopropanoic acid (5.0 g, 32.68 mmol) in 100 mL of DCM was added thionyl chloride (7.1 mL, 98.04 mmol) and 1 mL of DMF sequentially at 0° C. The reaction was stirred at room temperature overnight, and concentrated in vacuo. The resulting crude product was directly used in next step without further purification.
Step 2: (R)-2-bromopropanamide
(R)-2-bromopropanoyl chloride was slowly added to a 37% ammonia hydroxide water solution cooled to 0° C. The reaction was allowed to warm to room temperature and was stirred for 2 h. The product was extracted with EtOAc and the collected organic extracts were dried (Na2SO4) and concentrated in vacuo to afford (R)-2-bromopropanamide.
Intermediate 26
(R)-2-bromo-N-methylpropanamide




(R)-2-bromopropanoyl chloride was slowly added to a methylamine water solution cooled to 0° C. The reaction was allowed to warm to room temperature and was stirred for 2 h. The product was extracted with EtOAc and the collected organic extracts were dried (Na2SO4) and concentrated in vacuo to afford (R)-2-bromo-N-methylpropanamide.
Intermediate 27
1-(tert-butoxycarbonyl(ethyl)amino)cyclopropanecarboxylic acid




Step 1: Ethyl 1-(tert butoxycarbonyl(ethyl)amino)cyclopropanecarboxylate
Under nitrogen, to the solution of 1-(tert-butoxycarbonylamino)cyclopropanecarboxylic acid (201.2 mg, 1.0 mmol) in 4 mL of DMF was added NaH (120.0 mg, 3.0 mmol) at 0° C. After 30 min stirring, iodoethane (0.4 mL, 5.0 mmol) was added to the reaction. The reaction was warmed gradually to room temperature and stirred overnight. The reaction mixture was partitioned between EtOAc and water. The combined organic extracts were dried (Na2SO4), and concentrated in vacuo to afford crude ethyl 1-(tert butoxycarbonyl(ethyl)amino) cyclopropanecarboxylate, which was used in the next step without further purification.
Step 2: 1-(tert-butoxycarbonyl(ethyl)amino)cyclopropanecarboxylic acid
The crude product from Step 1 was dissolved in a mixture of EtOH (4.0 mL) and water (1.0 mL). LiOH (82.0 mg, 2.0 mmol) was added to the reaction. The reaction was heated at 120° C. in a microwave reactor for 10 min. The reaction was concentrated in vacuo, and the crude product was partitioned between EtOAc and water. The water layer was neutralized with 4N aq. HCl to pH 4 and then extracted with EtOAc. The combined organic extracts were dried (Na2SO4), and concentrated in vacuo to afford 1-(tert butoxycarbonyl(ethyl)amino)cyclopropanecarboxylic acid.
Intermediate 28
1-(tert-butoxycarbonyl(ethyl)amino)cyclobutanecarboxylic acid




Step 1: Ethyl 1-(tert-butoxycarbonyl(ethyl)amino)cyclobutanecarboxylate
Under nitrogen, to the solution of 1-(tert-butoxycarbonylamino)cyclobutanecarboxylic acid (430.0 mg, 2.0 mmol) in 4 mL of DMF was added NaH (240.0 mg, 6.0 mmol) at 0° C. After stirring for 30 min., iodoethane (0.8 mL, 10.0 mmol) was added to the reaction. The reaction was warmed to room temperature gradually and stirred overnight. The reaction mixture was partitioned between EtOAc and water. The combined organic extracts were dried (Na2SO4), and concentrated in vacuo to afford crude ethyl 1-(tert-butoxycarbonyl(ethyl)amino) cyclobutanecarboxylate.
Step 2: 1-(tert-butoxycarbonyl(ethyl)amino)cyclobutanecarboxylic acid
The crude product from Step 1 was dissolved in EtOH (4.0 mL) and water (1.0 mL). LiOH (164.0 mg, 4.0 mmol) was added to the reaction. The reaction was heated at 120° C. in a microwave reactor for 10 min. The reaction was concentrated in vacuo, and the crude was partitioned between EtOAc and water. The water layer was neutralized with 4N aq. HCl to pH 4 and then extracted with EtOAc. The combined organic extracts were dried (Na2SO4), and concentrated in vacuo to afford 1-(tert-butoxycarbonyl(ethyl)amino) cyclobutanecarboxylic acid.
Intermediate 29
1-(tert-butoxycarbonyl(methyl)amino)cyclobutanecarboxylic acid




Step 1: Methyl 1-(tert-butoxycarbonyl(ethyl)amino)cyclobutanecarboxylate
Under nitrogen, to the solution of 1-(tert-butoxycarbonylamino) cyclobutanecarboxylic acid (430.0 mg, 2.0 mmol) in 4 mL of DMF was added NaH (240.0 mg, 6.0 mmol) at 0° C. After stirring for 30 min., iodomethane (0.62 mL, 10.0 mmol) was added to the reaction. The reaction was warmed to room temperature gradually and stirred overnight. The reaction mixture was partitioned between EtOAc and water. The combined organic extracts were dried (Na2SO4), and concentrated in vacuo to afford crude methyl 1-(tert-butoxycarbonyl(ethyl)amino) cyclobutanecarboxylate.
Step 2: 1-(tert-butoxycarbonyl(methyl)amino)cyclobutanecarboxylic acid
The crude product from Step 1 was dissolved in MeOH (4.0 mL) and water (1.0 mL). LiOH (164.0 mg, 4.0 mmol) was added to the reaction. The reaction was heated at 120° C. in a microwave reactor for 10 min. The reaction was concentrated in vacuo, and the crude was partitioned between EtOAc and water. The water layer was neutralized with 4N aq. HCl to pH 4, and then extracted with EtOAc. The combined organic extracts were dried (Na2SO4), and concentrated in vacuo to afford 1-(tert-butoxycarbonyl(methyl)amino) cyclobutanecarboxylic acid.
Intermediate 30
2-bromobutanamide




Under nitrogen, to a solution of 2-bromobutanoic acid (2.0 g, 12.0 mmol) in DCM (50 mL) at 0° C. were sequentially added thionyl chloride (2.6 mL, 35.9 mmol) and 0.5 mL of DMF. The reaction was allowed to warm to room temperature and was stirred overnight. The reaction mixture was concentrated in vacuo and then cooled to 0° C. Thirty (30) mL of 37% aqueous ammonia hydroxide was added slowly. The reaction was allowed to warm to room temperature and was stirred for 2 h followed by extraction with EtOAc. The combined organic extracts were dried (Na2SO4), and concentrated in vacuo to afford 2-bromobutanamide.
Intermediate 31
2-bromo-N-methylbutanamide




Under nitrogen, to a solution of 2-bromobutanoic acid (2.0 g, 12.0 mmol) in DCM (50 mL) at 0° C. were sequentially added thionyl chloride (2.6 mL, 35.9 mmol) and 0.5 mL of DMF. The reaction was allowed to warm to room temperature and was stirred overnight. The reaction mixture was concentrated in vacuo and then cooled to 0° C. Thirty (30) mL of 40% methylamine water solution was added slowly. The reaction was allowed to warm to room temperature and was stirred for 2 h followed by extraction with EtOAc. The combined organic extracts were dried (Na2SO4), and concentrated in vacuo to afford 2-bromo-N-methylbutanamide.
Intermediate 32
2-bromo-N-ethylbutanamide




Under nitrogen, to a solution of 2-bromobutanoic acid (2.0 g, 12.0 mmol) in DCM (50 mL) at 0° C. were sequentially added thionyl chloride (2.6 mL, 35.9 mmol) and 0.5 mL of DMF. The reaction was allowed to warm to room temperature and was stirred overnight. The reaction mixture was concentrated in vacuo and then cooled to 0° C. Thirty (30) mL of 40% ethylamine water solution was added slowly. The reaction was allowed to warm to room temperature and was stirred for 2 h, followed by extraction with EtOAc. The combined organic extracts were dried (Na2SO4), and concentrated in vacuo to afford 2-bromo-N-ethylbutanamide.
Intermediate 33
1-(Methylsulfonyl)azetidin-3-one




To a mixture of 3-azetidinone hydrochloride (471 mg, 3.28 mmol) and K2CO3 (1.50 g, 11 mmol) in CHCl3/H2O (5/5 mL) was added methanesulfonic anhydride (1.14 g, 6.57 mmol) in one portion at 0° C. After stirring for 2 h, the reaction was diluted with saturated aqueous NaHCO3 (5 mL) and extracted with DCM (3×25 mL). The combined DCM layers were washed with brine (5 mL), dried over Na2SO4 and evaporated to afford 1-(Methylsulfonyl)azetidin-3-one as an off white solid, which was used without further purification; 1H NMR (400 MHz, CDCl3) δ 4.82 (s, 4H), 3.05 (s, 3H).


EXAMPLE 1
5-Chloro-N2-(2-fluoro-5-methyl-4-(1-methylpiperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (1)




Step 1:
A mixture of 2,5-dichloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine (Intermediate 1, 132 mg, 0.54 mmol) and tert-butyl 4-(4-amino-5-fluoro-2-methylphenyl)piperidine-1-carboxylate (Intermediate 19, 166 mg, 0.54 mmol) in 2-propanol (15 mL) was treated with conc. aqueous HCl (14 drops). The mixture was sealed and heated in a microwave at 130° C. for 60 min. The mixture was concentrated to afford 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine as a yellow solid. A portion of the crude product was purified with preparative RP-HPLC to afford 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine as a white solid; ESMS m/z 416.1 (M+H+). The remainder of the crude product was used directly for the next step without further purification.
Step 2:
To a solution of the crude product from previous step in THF (5 mL) and methanol (5 mL) was added formaldehyde (100 uL, 1.3 mmol) and 10 drops of AcOH sequentially. The reaction mixture was stirred at room temperature for 1 h, then sodium cyanoborohydride (175 mg, 2.78 mmol) was added in one portion, and the reaction was stirred for an additional 30 min. The reaction was quenched by saturated aqueous NH4Cl and concentrated in vacuo to give an oily residue. The residue was purified with preparative RP-HPLC to afford 5-Chloro-N2-(2-fluoro-5-methyl-4-(1-methylpiperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.33 (br, 1H), 9.90 (br, 1H0, 9.60 (br, 1H), 8.22 (s, 1H), 7.56 (d, 1H), 7.00 (d, 1H), 6.20 (s, 1H), 3.53-3.50 (m, 2H), 3.16-3.10 (m, 2H), 2.97-2.92 (m, 1H), 2.81 (d, 3H), 2.26 (s, 3H), 2.16 (s, 3H), 1.94-1.91 (m, 2H), 1.83-1.73 (m, 2H); ESMS m/z 430.1 (M+H+).
EXAMPLE 2
5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (2)




A mixture of 2,5-dichloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine (Intermediate 1, 132 mg, 0.54 mmol) and tert-butyl 4-(4-amino-5-fluoro-2-methylphenyl)piperidine-1-carboxylate (Intermediate 19, 166 mg, 0.54 mmol) in 2-propanol (15 mL) was treated with conc. aqueous HCl (14 drops). The mixture was sealed and heated in a microwave at 130° C. for 60 min. The mixture was concentrated to afford 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine as yellow solid. A portion of the crude product was purified with preparative RP-HPLC to afford 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine as a white solid; ESMS m/z 416.1 (M+H+).
EXAMPLES 3 AND 4
(S)-3-(5-chloro-2-(2-fluoro-5-methyl-4-(1-methylpiperidin-4-yl)phenylamino) pyrimidin-4-ylamino)azepan-2-one (10)




(R)-3-(5-chloro-2-(2-fluoro-5-methyl-4-(1-methylpiperidin-4-yl)phenylamino) pyrimidin-4-ylamino)azepan-2-one (11)




(±)-3-(5-chloro-2-(2-fluoro-5-methyl-4-(1-methylpiperidin-4-yl)phenylamino)pyrimidin-4-ylamino)azepan-2-one was synthesized by the same series of procedures as described in Example 1, utilizing Intermediate 6 and Intermediate 19. Chiral separation of the racemic mixture was conducted with normal phase HPLC using ChiralPaK AD column using the following solvent system: hexanes (80%) and iPrOH (20%) modified with 0.1% Diethylamine. The two purified enantiomer peaks were collected separately: (S)-3-(5-chloro-2-(2-fluoro-5-methyl-4-(1-methylpiperidin-4-yl)phenylamino)pyrimidin-4-ylamino)azepan-2-one and (R)-3-(5-chloro-2-(2-fluoro-5-methyl-4-(1-methylpiperidin-4-yl)phenylamino)pyrimidin-4-ylamino)azepan-2-one; both peaks: ESMS m/z 461.2 (M+H+). The earlier eluting peak (RT=7.26 min.) and the later eluting peak (RT=10.17 min.) were arbitrarily assigned as the (S) and (R) enantiomer, respectively.
EXAMPLE 5
5-Chloro-N2-(4-(14(3,5-dimethylisoxazol-4-yl)methyl)piperidin-4-yl)-2-fluoro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (19)




To a mixture of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (0.12 mmol) and triethylamine (83 uL, 0.6 mmol) in DMF (1.5 mL), was added 4-(chloromethyl)-3,5-dimethylisoxazole (35 mg, 0.24 mmol). The mixture was stirred at room temperature for 3 hours. The reaction was filtered and the filtrate was purified by preparative RP-HPLC to afford 5-Chloro-N2-(4-(1-((3,5-dimethylisoxazol-4-yl)methyl)piperidin-4-yl)-2-fluoro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine as a white solid. 1H NMR (400 MHz, MeOD-d4) 8.12 (s, 1H), 7.75 (d, 1H), 7.03 (s, 1H), 6.27 (s, 1H), 4.25 (s, 2H), 3.69-3.67 (m, 2H), 3.27-3.20 (m, 3H), 2.54 (s, 3H), 2.37 (s, 3H), 2.34 (s, 3H), 2.30 (s, 3H), 2.10-1.95 (m, 4H); ESMS m/z 525.1 (M+H+).
EXAMPLE 6
2-(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)ethanol (22)




5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (0.12 mmol) was dissolved in anhydrous DMF (1 mL). TEA (50 uL, 0.36 mmol, 3 equiv.) was added followed by 2-bromo-ethanol (0.018 mL, 0.24 mmol, 2 equiv.) dissolved in anhydrous DMF (0.7 mL). The reaction vessel was sealed and heated in a microwave at 100° C. for 20 min. After cooling to room temperature, the reaction was concentrated and the crude product was purified using preparative RP-HPLC to give 2-(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)ethanol as a white solid: ESMS m/z 460.2 (M+H+).
EXAMPLE 7
5-chloro-N2-(2-fluoro-5-methyl-4-(1-(3,3,3-trifluoropropyl)piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (24)




The mixture of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (0.12 mmol), 3-bromo-1,1,1-trifluoropropane (85.0 uL, 0.60 mmol) and triethylamine (102.0 uL, 0.60 mmol) in 2 mL of DMF was stirred overnight. The reaction mixture was purified by preparative RP-HPLC to afford 5-chloro-N2-(2-fluoro-5-methyl-4-(1-(3,3,3-trifluoropropyl)piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine. ESMS m/z 512.2 (M+H+).
EXAMPLE 8
3-(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)-1,1,1-trifluoropropan-2-ol (30)




The mixture of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (50.0 mg, 0.12 mmol) and 2-(trifluoromethyl)oxirane (67.8 mg, 0.60 mmol) in 2 mL of DMF was stirred overnight. The reaction mixture was purified by preparative RP-HPLC to afford 3-(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)-1,1,1-trifluoropropan-2-ol. ESMS m/z 528.2 (M+H+).
EXAMPLE 9
2-(4-(4-(5-Chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)acetamide (39)




To a mixture of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (0.12 mmol) and triethylamine (50 uL, 0.36 mmol) in DMF (1.5 mL), was added 2-bromo-acetamide (33 mg, 0.24 mmol). The mixture was stirred at room temperature for 2 hours. The reaction was filtered and the filtrate was purified by preparative RP-HPLC to give 2-(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)acetamide as a white solid: 1H NMR (400 MHz, MeOD-d4) δ 8.11 (s, 1H), 7.76 (d 1H), 7.09 (d, 1H), 6.27 (s, 1H), 4.0 (s, 2H), 3.75-3.73 (m, 2H), 3.22-3.13 (m, 3H), 2.34 (s, 3H), 2.30 (s, 3H), 2.04-2.00 (m, 4H); ESMS m/z 473.2 (M+H+).
EXAMPLE 10
5-Chloro-N2-(2-fluoro-5-methyl-4-(1-(2-(methylsulfonyflethyl)piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (55)




To a mixture of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (0.12 mmol) and triethylamine (83 uL, 0.6 mmol) in DMF (1.5 mL), was added methyl vinyl sulfone (38 mg, 0.36 mmol). The mixture was stirred at room temperature for 1 hour. The reaction was filtered and the filtrate was purified by preparative RP-HPLC to afford 5-Chloro-N2-(2-fluoro-5-methyl-4-(1-(2-(methylsulfonyl)ethyl)piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine as a white solid. ESMS m/z 522.1 (M+H+).
EXAMPLE 11
5-Chloro-N2-(2-fluoro-5-methyl-4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (62)




To a mixture of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (0.12 mmol) and triethylamine (50 uL, 0.36 mmol) in DMF (1.5 mL) was added methanesulfonyl chloride (18 uL, 0.24 mmol). The mixture was stirred at room temperature for 2 hours. The reaction was filtered and the filtrate was purified by preparative RP-HPLC to give 5-Chloro-N2-(2-fluoro-5-methyl-4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine as a white solid: ESMS m/z 494.2 (M+H+).
EXAMPLE 12
Ethyl 4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidine-1-carboxylate (66)




To a mixture of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (0.12 mmol) and triethylamine (50 uL, 0.36 mmol) in DMF (1.5 mL) was added ethyl chloroformate (26 mg, 0.24 mmol). The mixture was stirred at room temperature for 2 hours. The reaction was filtered and the filtrate was purified by preparative RP-HPLC to give Ethyl 4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidine-1-carboxylate as a white solid: 1H NMR (400 MHz, MeOD-d4) δ 8.13 (s, 1H), 7.54 (d, 1H), 7.10 (d, 1H), 6.28 (s, 1H), 4.30-4.26 (m, 2H), 4.14 (q, 2H), 2.99-2.96 (m, 3H), 2.33 (s, 3H), 2.29 (s, 3H), 1.8-1.77 (m, 2H), 1.64-1.55 (m, 2H), 1.28 (t, 3H); ESMS m/z 488.2 (M+H+).
EXAMPLE 13
4-(4-(5-Chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)-N,N-dimethylpiperidine-1-carboxamide (69)




To a mixture of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (0.12 mmol) and triethylamine (83 uL, 0.6 mmol) in DMF (1.5 mL) was added dimethylcarbamic chloride (39 mg, 0.36 mmol). The mixture was stirred at room temperature for 1 hour. The reaction was filtered and the filtrate was purified by preparative RP-HPLC to afford 4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)-N,N-dimethylpiperidine-1-carboxamide as a white solid. ESMS m/z 487.2 (M+H+).
EXAMPLE 14
1-(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)-2-(dimethylamino)ethanone (73)




To a mixture of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (0.12 mmol) and triethylamine (50 uL, 0.36 mmol) in DMF (1.5 mL) was added 2-(dimethylamino)acetyl chloride (38 mg, 0.24 mmol). The mixture was stirred at room temperature for 1 hour. The reaction was filtered and the filtrate was purified by preparative RP-HPLC to give 1-(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)-2-(dimethylamino)ethanone as a white solid: 1H NMR (400 MHz, MeOD-d4) δ 8.08 (s, 1H), 7.71 (d, 1H), 7.03 (d, 1H), 6.26 (s, 1H), 4.71-4.67 (m, 2H), 3.81-3.77 (m, 2H), 3.14-3.12 (m, 2H), 2.98 (s, 3H), 2.96 (s, 3H), 2.90-2.83 (m, 1H), 2.34 (s, 3H), 2.28 (s, 3H), 1.87 (d, 2H), 1.76-1.55 (m, 2H); ESMS m/z 501.2 (M+H+).
EXAMPLE 15
1-(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)-2-(4-methylpiperazin-1-yl)ethanone (105)




To the solution of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (100.0 mg, 0.24 mmol) in 4 mL of DCM was added 2-chloroacetylchloride (23.0 uL, 0.29 mmol) and triethylamine (67.0 uL, 0.48 mmol) sequentially. The reaction was stirred at room temperature for 1 h then washed by brine. The organic extract was dried over Na2SO4, followed by concentration in vacuo to afford a crude product. The crude product was mixed with 1-methylpiperazine (116.0 mg, 1.16 mmol) in 3 mL of DMF and the reaction was stirred overnight at room temperature. The reaction mixture was purified by preparative HPLC to afford 1-(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)-2-(4-methylpiperazin-1-yl)ethanone. ESMS m/z 556.3 (M+H+).
EXAMPLE 16
Azetidin-3-yl(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)methanone (131)




To a mixture of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (0.12 mmol), di-isopropylethylamine (50 uL, 0.36 mmol) and HATU (55 mg, 0.14 mmol) in DMF (1.5 mL) was added 1-(tert-butoxycarbonyl)azetidine-3-carboxylic acid (29 mg, 0.14 mmol). After stirring at room temperature for 4 hours, the mixture was diluted with methanol (1 mL) and conc. aqueous HCl (1 mL). The mixture was stirred at 50° C. for 30 min. The mixture was filtered and purified by preparative RP-HPLC to give azetidin-3-yl(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)methanone as white solid. 1H NMR (400 MHz, MeOD-d4) δ 8.08 (s, 1H), 7.68 (d, 2H), 7.04 (d, 2H), 6.26 (s, 1H), 4.74-4.68 (m, 2H), 4.39-4.35 (m, 1H), 4.29-4.24 (m, 2H), 4.11-4.07 (m, 1H), 3.74-3.71 (m, 1H), 3.25-3.24 (m, 1H), 3.07-3.04 (m, 1H), 2.87-2.80 (m, 1H), 2.33 (s, 3H), 2.28 (s, 3H), 1.87-1.84 (m, 2H), 1.66-1.56 (m, 2H); ESMS m/z 499.2 (M+H+).
EXAMPLE 17
5-chloro-N2-(2-fluoro-5-methyl-4-(1-(tetrahydro-1,1-dioxido-3-thienyl)piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (145)




To 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (30 mg, 0.072 mml) in EtOH (0.5 mL) was added thiophene-2,3-dihydro-,1,1-dioxide (17 mg, 0.144 mmol). The resulting mixture was then heated to 130° C. for 2 hr. After cooling down to room temperature, the mixture was concentrated and purified by preparative RP-HPLC to provide 5-chloro-N2-(2-fluoro-5-methyl-4-(1-(tetrahydro-1,1-dioxido-3-thienyl)piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine. ESMS m/z 534.2 (M+H+).
EXAMPLE 18
5-chloro-N2-(2,5-dimethyl-4-(1-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (146)




Step 1:
To a solution of 5-chloro-N2-(2,5-dimethyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (30 mg, 0.073 mmol) in acetonitrile (1 mL) was added Cs2CO3 (47 mg, 0.15 mmol) and 4-iodotetrahydro-2H-thiopyran (48 mg, 0.22 mmol). This mixture was then stirred at 80° C. for 16 hr. After cooling down to room temperature, the mixture was treated with saturated aqueous NH4Cl solution (3 mL) and extracted with EtOAc (3×3 mL). The organic layers were combined and concentrated. The residue was purified by silica gel chromatography (Gradient 0 ̃8% MeOH/CH2Cl2 with NH3) to provide 5-chloro-N2-(2,5-dimethyl-4-(1-(tetrahydro-2H-thiopyran-4-yl)piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine as a white solid. ESMS m/z 512.2 (M+H+).
Step 2:
To 5-chloro-N2-(2,5-dimethyl-4-(1-(tetrahydro-2H-thiopyran-4-yl)piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (18 mg, 0.035 mmol) in CH2Cl2 (1 mL) was added m-CPBA (16 mg, 0.71 mmol) at 0° C. The mixture was then warmed up to room temperature and stirred for 30 min; saturated aqueous NaHCO3 solution (3 mL) was then added and the crude product extracted with CH2Cl2 (3×3 mL). The combined organic layers were concentrated and purified by preparative thin layer chromatography (silica gel, 12% MeOH/CH2Cl2 with NH3) to provide 5-chloro-N2-(2,5-dimethyl-4-(1-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl))piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine. ESMS m/z 544.2 (M+H+).
EXAMPLE 19
5-chloro-N2-(2-fluoro-5-methyl-4-(1-(1,1-dioxido-3-thietanyl)piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (148)




To 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (30 mg, 0.072 mmol) in MeOH (1 mL) was added 3-bromothietane 1,1-dioxide (15 mg, 0.079 mmol) followed by TEA (15 mg). The resulting mixture was stirred at room temperature for 5 hr and then concentrated. The resulting residue was purified by preparative RP-HPLC to provide 5-chloro-N2-(2-fluoro-5-methyl-4-(1-(1,1-dioxido-3-thietanyl)piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine. 1H NMR (400 MHz, DMSO-d6+1 drop D2O) δ 8.02 (s, 1H), 7.37 (s, 1H), 7.02 (s, 1H), 6.23 (s, 1H), 4.28-4.22 (m, 2H), 4.12-4.07 (m, 2H), 3.22-3.18 (m, 1H), 2.95-2.92 (m, 2H), 2.68-2.62 (m, 1H), 2.22 (s, 3H), 2.13 (s, 3H), 2.07-2.01 (m, 2H), 1.71-1.55 (m, 4H). ESMS m/z 520.2 (M+H+).
EXAMPLE 20
5-Chloro-N2-(4-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yl)-2-fluoro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (149)




To a mixture of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (0.10 mmol) and triethylamine (83 uL, 0.6 mmol) in DMF (1.5 mL), was added 2-chloro-5-ethylpyrimidine (27 mg, 0.20 mmol). The mixture was heated in a microwave at 120° C. for 10 min. The reaction was filtered and the filtrate was purified by preparative RP-HPLC to afford 5-chloro-N2-(4-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yl)-2-fluoro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine as a white solid. ESMS m/z 522.2 (M+H+).
EXAMPLE 21
4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)piperidin-2-one (151)




Step 1:
In a 5 mL microwave reaction tube was added 2-(2,5-dimethyl-4-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (143 mg, 0.516 mmol, prepared from 1-bromo-2,5-dimethyl-4-nitrobenzene by standard protocol), 1-(4-methoxybenzyl)-5,6-dihydropyridin-2(1H)-one (56 mg, 0.26 mmol, prepared by following a similar procedure as reported by Lerchner etc. in Chem. Eur. J. 2006, 12, 8208), chloro(1,5-cyclooctadiene)rhodium (I) dimer (13 mg, 0.026 mmol), KOH (0.13 mL 1N aqueous solution) and dioxane (1.2 mL). The tube was degassed, filled with N2 and sealed. The reaction tube was then heated to 100° C. in a microwave reactor for 10 min. After the reaction tube was opened, the mixture was treated with saturated NH4Cl aqueous solution (3 mL) and extracted with EtOAc (3×4 mL). The organic layers were combined and concentrated. The residue was purified by flash column chromatography (silica gel, gradient 0%-70% EtOAc/hexane), to provide 4-(2,5-dimethyl-4-nitrophenyl)-1-(4-methoxybenzyl)piperidin-2-one. ESMS m/z 369.2 (M+H+).
Step 2:
To 4-(2,5-dimethyl-4-nitrophenyl)-1-(4-methoxybenzyl)piperidin-2-one (63 mg, 0.17 mmol) in MeOH (10 mL) was added 10% w/w Pd/C (6 mg), the mixture was degassed and stirred under H2 at room temperature for 14 hr. After removing the catalyst by filtration, the filtrate was concentrated to provide 4-(4-amino-2,5-dimethylphenyl)-1-(4-methoxybenzyl)piperidin-2-one as a pale yellowish oil. ESMS m/z 339.2 (M+H+).
Step 3:
To a mixture of 4-(4-amino-2,5-dimethylphenyl)-1-(4-methoxybenzyl)piperidin-2-one (23 mg, 0.094 mmol) and 2,5-dichloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine (29 mg, 0.086 mmol) in iPrOH (1 mL) was added HCl (60 uL, 4N in dioxane). The reaction vessel was then sealed and heated to 130° C. for 4 hr. After cooling to room temperature, the mixture was treated with saturated NaHCO3 aqueous solution (3 mL) and extracted with EtOAc (3×4 mL). The organic layers were combined and concentrated. The residue was purified by flash column chromatography (silica gel, gradient 0 ̃10% MeOH/CH2Cl2) to provide 4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)-1-(4-methoxybenzyl)piperidin-2-one. ESMS m/z 546.2 (M+H+).
Step 4:
A solution of 4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)-1-(4-methoxybenzyl)piperidin-2-one (45 mg) in TFA (0.5 mL) was heated to 100° C. for 24 hr. After cooling down to room temperature, the mixture was concentrated and purified by preparative RP-HPLC to provide 4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)piperidin-2-one. ESMS m/z 426.2 (M+H+).
EXAMPLE 22
5-chloro-N2-(2-fluoro-4-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (157)




Step 1:
To a microwave reaction tube was added 4-bromo-2-fluoro-5-(trifluoromethyl)aniline (256 mg, 1.0 mmol), 1-methylpiperazine (300 mg, 3 mmol) Pd2(dba)3 (91.5 mg, 0.1 mmol), di-tert-butyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine (60 mg, 0.2 mmol), NaOtBu (144 mg, 1.5 mmol) and THF (3 mL). After the reaction tube was degassed and filled with N2, the tube was heated to 120° C. in a microwave reactor for 40 min. The mixture was then poured into saturated NH4Cl aqueous solution (10 mL) and extracted with EtOAc (3×10 mL). The organic layers were combined and concentrated. The residue was purified by flash column chromatography (silica gel, gradient MeOH/CH2Cl2, 0 ̃10%) to provide 2-fluoro-4-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)aniline as a white solid. ESMS m/z 278.1 (M+H+).
Step 2:
To a mixture of 2-fluoro-4-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)aniline (37 mg, 0.133 mmol) and 2,5-dichloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine (36 mg, 0.147 mmol) in iPrOH (1 mL) was added HCl (100 uL, 4N in dioxane). The reaction vessel was then sealed and heated to 130° C. for 4 hr. After cooling to room temperature, the mixture was treated with saturated NaHCO3 aqueous solution (5 mL) and extracted with EtOAc (3×5 mL). The organic layers were combined and concentrated. The residue was purified by preparative thin layer chromatography (silica gel, 8% MeOH/CH2Cl2), to provide 5-chloro-N2-(2-fluoro-4-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine. ESMS m/z 485.2 (M+H+).
EXAMPLE 23
(S)-2-(4-(4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)propanamide (163)




A mixture of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (50.0 mg, 0.12 mmol), (R)-2-bromopropanamide (90.6 mg, 0.60 mmol), and triethylamine (102.0 μL, 0.60 mmol) in 2 mL of DMF was heated at 150° C. in a microwave reactor for 30 min. The reaction mixture was directly purified by preparative RP-HPLC to afford (S)-2-(4-(4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)propanamide; ESMS m/z 487.2 (M+H+).
EXAMPLE 24
(S)-2-(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)-N-methylpropanamide (164)




A mixture of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (50.0 mg, 0.12 mmol), (R)-2-bromo-N-methylpropanamide (100.0 mg, 0.60 mmol), and triethylamine (102.0 μL, 0.60 mmol) in 2 mL of DMF was heated at 150° C. in a microwave reactor for 30 min. The reaction mixture was directly purified by preparative RP-HPLC to afford (S)-2-(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)-N-methylpropanamide; ESMS m/z 501.2 (M+H+).
EXAMPLE 25
(S)-2-(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)piperidin-1-yl)propanamide (166)




A mixture of 5-chloro-N2-(2,5-dimethyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (50.0 mg, 0.12 mmol), (R)-2-bromopropanamide (90.6 mg, 0.60 mmol), and triethylamine (102.0 μL, 0.60 mmol) in 2 mL of DMF was heated at 150° C. in a microwave reactor for 30 min. The reaction mixture was directly purified by preparative RP-HPLC to afford (S)-2-(4-(4-(5-chloro-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)piperidin-1-yl)propanamide; ESMS m/z 483.2 (M+H+).
EXAMPLE 26
(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)(1-(ethylamino)cyclopropyl)methanone (169)




A mixture of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (67.3 mg, 0.17 mmol), 1-(tert-butoxycarbonyl(ethyl)amino)cyclopropanecarboxylic acid (38.0 mg, 0.17 mmol), HATU (63.0 mg, 0.17 mmol) and diisopropylethylamine (57 μL, 0.34 mmol) in 1 mL of DMF was stirred at room temperature overnight. The reaction mixture was partitioned between EtOAc and water, the combined organic extracts were dried (Na2SO4) and then concentrated in vacuo. The resulting crude mixture was dissolved in 5 mL of DCM and 4 mL of TFA and was then stirred for 2 h followed by concentration in vacuo. The crude product was purified by RP-HPLC to afford (4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)(1-(ethylamino)cyclopropyl)methanone; ESMS m/z 527.2 (M+H+).
EXAMPLE 27
1-(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)piperidin-1-yl)-2-(ethylamino)-2-methylpropan-1-one (175)




To a solution of 2-amino-1-(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)piperidin-1-yl)-2-methylpropan-1-one (6 mg, 0.012 mmol) in acetone (0.5 mL) was added K2CO3 (11 mg, 0.079 mmol). The mixture was stirred at room temperature for 10 min. before the addition of EtI (6 mg, 0.038 mmol). The resulting mixture was then stirred at room temperature for 14 h before it was treated with saturated aqueous NH4Cl (1 mL) and extracted with EtOAc (3×2 mL). The organic layers were combined, concentrated, and the residue was purified by preparative thin layer chromatography (silica gel, 8% MeOH/DCM/NH3) followed by further purification with preparative RP-HPLC to provide 1-(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)piperidin-1-yl)-2-(ethylamino)-2-methylpropan-1-one; ESMS m/z 525.3 (M+H+).
EXAMPLE 28
(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)(1-(ethylamino)cyclobutyl)methanone (176)




A mixture of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (50.0 mg, 0.12 mmol), 1-(tert-butoxycarbonyl(ethyl)amino)cyclobutanecarboxylic acid (29.2 mg, 0.12 mmol), HATU (45.8 mg, 0.12 mmol) and di-isopropylethylamine (20 μL, 0.12 mmol) in 1 mL of DMF was stirred at room temperature overnight. The reaction mixture was partitioned between EtOAc and water. The combined organic extracts were dried (Na2SO4), and concentrated in vacuo. The resulting crude mixture was dissolved in 5 mL of DCM and 4 mL of TFA and was then stirred for 2 h followed by concentration in vacuo. The crude product was purified by RP-HPLC to afford (4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)(1-(ethylamino)cyclobutyl)methanone; ESMS m/z 541.3 (M+H+).
EXAMPLE 29
(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)(1-(methylamino)cyclobutyl)methanone (177)




A mixture of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (50.0 mg, 0.12 mmol), 1-(tert-butoxycarbonyl(methyl)amino)cyclobutanecarboxylic acid (27.5 0.12 mmol), HATU (45.8 mg, 0.12 mmol) and di-isopropylethylamine (20 μL, 0.12 mmol) in 1 mL of DMF was stirred at room temperature overnight. The reaction mixture was partitioned between EtOAc and water. The combined organic extracts were dried (Na2SO4), and concentrated in vacuo. The resulting crude mixture was dissolved in 5 mL of DCM and 4 mL of TFA, and was stirred for 2 h followed by concentration in vacuo. The crude product was purified by RP-HPLC to afford (4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)(1-(mthylamino)cyclobutyl)methanone; ESMS m/z 527.2 (M+H+).
EXAMPLE 30
(S)-3-(4-(2,5-dimethyl-4-(5-methyl-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)phenyl)piperidin-1-yl)-1,1,1-trifluoropropan-2-ol (179)




To a solution of N2-(2,5-dimethyl-4-(piperidin-4-yl)phenyl)-5-methyl-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine hydrochloride (36.0 mg, 0.084 mmol) in DMF (0.5 mL) were added TEA (23.4 μL, 0.168 mmol) and (S)-2-(trifluoromethyl) oxirane (72.8 μL, 0.84 mmol). The reaction mixture was stirred at room temperature overnight, and purified by preparative RP-HPLC to provide (S)-3-(4-(2,5-dimethyl-4-(5-methyl-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)phenyl)piperidin-1-yl)-1,1,1-trifluoropropan-2-ol; ESMS m/z 504.3 (M+H+).
EXAMPLE 31
2-(2-(4-(5-Chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)piperidin-1-yl)acetamide (181)




To a mixture of 5-Chloro-N2-(2,5-dimethyl-4-(piperidin-2-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (0.12 mmol) and triethylamine (83 uL, 0.6 mmol) in DMF (1.5 mL), was added 2-bromoacetamide (35 mg, 0.24 mmol). The mixture was stirred at room temperature for 3 h. The reaction was filtered and the filtrate was purified by RP-HPLC to afford 2-(2-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)piperidin-1-yl)acetamide as a white solid; 1H NMR (400 MHz, MeOD-d4) 8.09 (s, 1H), 7.65 (d, 1H), 7.43 (s, 1H), 6.41 (s, 1H), 4.79-4.74 (m, 2H), 3.83-3.48 (m, 2H), 2.71 (s, 3H), 2.42 (s, 3H), 2.34 (s, 6H), 2.15-1.84 (m, 7H); ESMS m/z 469.2 (M+H+).
EXAMPLES 32 AND 33
(S) 5-Chloro-N2-(2,5-dimethyl-4-(1-methylpiperidin-2-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (183)




(R) 5-Chloro-N2-(2,5-dimethyl-4-(1-methylpiperidin-2-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (184)




Step 1:
To a mixture of 1-bromo-2,5-dimethyl-4-nitrobenzene (185 mg, 1 mmol) and 2-(tributylstannyl)pyridine (202 mg, 1.1 mmol) in DMF (4 mL) was added tetrakis(triphenylphosphine) palladium (0) (58 mg, 0.05 mmol). The reaction tube was sealed, the mixture was purged with N2 for 3 min and then heated at 120° C. under N2 for overnight. The reaction was cooled to room temperature and poured into saturated aqueous ammonia chloride solution. The crude reaction mixture was extracted with ethyl acetate (3×15 mL). The organic extracts were combined, washed with brine and concentrated. The crude product was purified with silica chromatography (60% ethyl acetate in hexanes) to afford 2-(2,5-dimethyl-4-nitrophenyl)pyridine as a white solid. The obtained solid was dissolved in acetic acid/TFA (15 mL/200 uL). To this solution was added PtO2 (10% w/w). The reaction mixture was degassed and purged with H2 for several times and then vigorously stirred under 1 atm. H2 overnight. The mixture was filtered and the filtrate concentrated to afford 2,5-Dimethyl-4-(piperidin-2-yl)aniline as a yellow oil; ESMS m/z 205 (M+H+).
Step 2:
A mixture of 2,5-dichloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine (120 mg, 0.49 mmol) and 2,5-dimethyl-4-(piperidin-2-yl)aniline (100 mg, 0.49 mmol) in 2-propanol (10 mL) was treated with conc. aqueous HCl (7 drops). The mixture was sealed and heated in a microwave at 130° C. for 45 min. The mixture was concentrated to afford 5-Chloro-N2-(2,5-dimethyl-4-(piperidin-2-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine; ESMS m/z 412.1 (M+H+). The crude product was used directly for the next step without further purification.
Step 3:
To a solution of the crude product from the previous step in THF (1 mL) and methanol (1 mL) was sequentially added formaldehyde (100 uL, 1.3 mmol) and 5 drops of AcOH. The reaction mixture was stirred at room temperature for 1 h, then sodium cyanoborohydride (160 mg, 2.45 mmol) was added in one portion, and the reaction was stirred for an additional 30 min. The reaction was quenched by saturated aqueous NH4Cl and concentrated in vacuo to give an oily residue. The residue was purified with RP-HPLC to afford (±)-5-Chloro-N2-(2,5-dimethyl-4-(1-methylpiperidin-2-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine as a white solid; ESMS m/z 426.2 (M+H+).
Step 4:
Chiral separation of the racemic mixture was conducted with normal phase HPLC using ChiralPaK AD-H column using the following solvent system: hexanes (95%), EtOH (2.5%), MeOH (2.5%). The two purified enantiomer peaks were collected separately: (R)-5-Chloro-N2-(2,5-dimethyl-4-(1-methylpiperidin-2-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine and (S)-5-Chloro-N2-(2,5-dimethyl-4-(1-methylpiperidin-2-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine; both peaks: ESMS m/z 426.2 (M+H+). The earlier eluting peak has been arbitrarily assigned as the (R) enantiomer.
EXAMPLE 34
5-Chloro-N2— (2,5-dimethyl-4-(1-(3-morpholinopropylsulfonyl)piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (194)




Step 1:
To a solution of 5-chloro-N2-(2,5-dimethyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (78 mg, 0.19 mmol) and TEA (0.52 mL, 3.78 mmol) in DCM (10 mL) was added 3-chloropropane-1-sulfonyl chloride (63 mg, 0.36 mmol, in 1 mL DCM). After stirring at rt for one hour, EtOAc (100 mL) was added. The mixture was sequentially washed with water (10 mL), brine (10 mL), dried over Na2SO4 and concentrated in vacuo. The crude product was purified by silica chromatography (0-100% EtOAc in hexanes gradient) to give 5-chloro-N2-(4-(1-(3-chloropropylsulfonyl)piperidin-4-yl)-2,5-dimethylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine as an off white solid; ESMS m/z 552.2 (M+H+).
Step 2:
The product from Step 1 was stirred in neat morpholine (0.5 mL) at 100° C. in a sealed vial for one hour. The reaction was purified by RP-HPLC to give 5-Chloro-N2-(2,5-dimethyl-4-(1-(3-morpholinopropylsulfonyl)piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine as a white powder; ESMS m/z 603.2 (M+H+).
EXAMPLE 35
1-((4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)piperidin-1-yl)methyl)cyclopropanecarbonitrile (198)




To a solution of 5-chloro-N2-(2,5-dimethyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (30 mg, 0.078 mmol) in acetonitrile (1.0 mL) was added (1-cyanocyclopropyl)methyl 4-methylbenzenesulfonate (16 mg, 0.10 mmol, prepared according to the procedure described in patent WO2005063247) followed by DIEA (30 mg, 0.23 mmol) and KI (catalytic amount). The resulting mixture was heated to 70° C. for 14 h and then cooled down to room temperature. The resulting mixture was directly purified by preparative RP-HPLC to provide 1-((4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)-piperidin-1-yl)methyl)cyclopropanecarbonitrile; ESMS m/z 491.2 (M+H+).
EXAMPLE 36
2-(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)acetonitrile (199)




To a solution of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (20 mg, 0.048 mmol) in acetonitrile (0.5 mL) was added Cs2CO3 (31 mg, 0.096 mmol) and chloroacetonitrile (7 mg, 0.096 mmol). The resulting mixture was stirred at room temperature for 14 h before it was treated with saturated aqueous NH4Cl (1 mL) and extracted with EtOAc (3×2 mL). The organic layers were combined, concentrated, and the residue was purified by preparative RP-HPLC to provide 2-(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)acetonitrile; ESMS m/z 455.2 (M+H+).
EXAMPLE 37
3-(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)propanenitrile (200)




To a solution of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (20 mg, 0.048 mmol) in MeOH (0.5 mL) was added acrylonitrile (5 mg, 0.096 mmol). The resulting mixture was stirred at room temperature for 14 h and then purified directly by preparative RP-HPLC to provide 3-(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)propanenitrile; ESMS m/z 469.2 (M+H+).
EXAMPLES 38 AND 39
(R)-2-(3-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)piperidin-1-yl)-N-methylacetamide (207)




(S)-2-(3-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)piperidin-1-yl)-N-methylacetamide (208)




A solution of 5-chloro-N2-(2,5-dimethyl-4-(piperidin-3-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (700 mg, 1.70 mmol), 2-bromo-N-methylacetamide (258 mg, 1.70 mmol) and TEA (1.2 mL, 8.5 mmol) in DMF (4 mL) was stirred at rt for 30 min. The reaction was purified by RP-HPLC to give the product as a racemate; ESMS m/z 483.2 (M+1). Chiral separation of the racemic mixture was conducted with chiral HPLC (ChiralCel OD-H, Hex:EtOH:MeOH/80:10:10, 15 min run time, 1 mL/min). The two purified enantiomer peaks were collected separately, both as white solids: (R)-2-(3-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)piperidin-1-yl)-N-methylacetamide and (S)-2-(3-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)piperidin-1-yl)-N-methylacetamide; both peaks: ESMS m/z 483.2 (M+H+). The earlier eluting peak (rt=5.63 min. vs. rt=7.62 min.) was arbitrarily assigned as the (R) enantiomer.
EXAMPLE 40
5-chloro-N2-(2-fluoro-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (209)




To a suspension of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (2.50 g, 6.0 mmol) in a mixed solvent of MeOH (42 mL) and DCM (10 mL) was added dihydro-2H-pyran-4(3H)-one (3.33 mL, 36.0 mmol) and TEA (8.36 mL, 60.0 mmol). The reaction mixture was heated at 60° C. for 1 h before NaCNBH3 (1.66 g, 26.4 mmol) was added. The mixture was heated at 60° C. for another 2 h, cooled down to room temperature, diluted with DCM (60 mL), dry loaded onto silica gel (12.5 g), and purified by silica gel chromatography (DCM with 1% NH3 to 10% MeOH in DCM with 1% NH3 gradient) to provide 5-chloro-N2-(2-fluoro-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine as a white solid; 1H NMR (DMSO-d6, 400 MHz) δ 12.08 (br, 1H), 9.58 (br, 1H), 8.65 (d, J=28.4 Hz, 1H), 8.02 (s, 1H), 7.36 (d, J=8.4 Hz, 1H), 7.03 (d, J=12.4 Hz, 1H), 6.08 (br, 1H), 3.89 (dd, J=10.8, 3.6 Hz, 2H), 3.28 (t, J=10.4 Hz, 2H), 2.99 (d, J=10.8 Hz, 2H), 2.64-2.43 (m, 2H), 2.24-2.15 (m, 8H), 1.71-1.40 (m, 8H); ESMS m/z 500.2 (M+H+).
EXAMPLE 41
5-chloro-N2-(4-(1-cyclopropylpiperidin-4-yl)-2-fluoro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (210)




To a solution of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (30 mg, 0.072 mmol) in MeOH (0.7 mL) was added AcOH (35 mg, 0.58 mmol), (1-ethoxycyclopropoxy)trimethylsilane (37 mg, 0.216 mmol) and a small amount of 4 Å molecular sieves. The mixture was stirred at room temperature for 1 h before the addition of Na(CN)BH3 (14 mg, 0.216 mmol). The resulting mixture was then stirred at 60° C. for 14 h and cooled to room temperature. Saturated aqueous NH4Cl (2 mL) was added and the mixture was extracted with EtOAc (3×3 mL). The combined organic layers were concentrated and purified by preparative RP-HPLC to provide 5-chloro-N2-(4-(1-cyclopropylpiperidin-4-yl)-2-fluoro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine; 1H NMR (400 MHz, MeOD-d4) δ 7.97 (s, 1H), 7.84 (d, 1H), 7.50 (s, 1H), 6.93 (d, 1H), 6.29 (s, 1H), 5.33 (s, 1H), 2.80 (m, 1H), 2.58 (s, 2H), 2.28 (s, 3H), 2.24 (s, 3H), 1.96 (m, 1H), 1.80-1.85 (m, 2H), 1.65-1.75 (m, 2H), 0.2-0.7 (m, 6H); ESMS m/z 456.2 (M+H+).
EXAMPLE 42
N2-(4-(1-(3-(azetidin-1-ylsulfonyl)prop yl)piperidin-4-yl)-2,5-dimethylphenyl)-5-chloro-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (214)




Step 1:
To a solution of azetidine (12 mg, 0.21 mmol) and TEA (0.1 mL, 0.71 mmol) in DCM (5 mL) was slowly added a solution of 3-chloropropane-1-sulfonyl chloride (34 mg, 0.19 mmol) in DCM (1 mL). After stirring at rt overnight, the solvent was removed in vacuo. The resulting 1-(3-chloropropylsulfonyl)azetidine crude product was dissolved in NMP (1.9 mL, 0.1 mmol/mL) and used in the next step without further purification; ESMS m/z 198.0 (M+H+).
Step 2:
A mixture of 5-chloro-N2-(2,5-dimethyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (42 mg, 0.1 mmol), 1-(3-chloropropylsulfonyl) azetidine (Step 1, 0.1 mmol), TEA (70 μL) and sodium iodide (150 mg) in NMP (1 mL) was placed in a sealed vial which was heated in a microwave for 30 min at 150° C. The reaction was purified by RP-HPLC to give N2-(4-(1-(3-(azetidin-1-ylsulfonyl)propyl)piperidin-4-yl)-2,5-dimethylphenyl)-5-chloro-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine as a white powder; ESMS m/z 573.3 (M+H+).
EXAMPLE 43
1-(4-(4-(5-Chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)piperidin-1-yl)-4-morpholinobutan-1-one (224)




Step 1:
To a solution of HATU (95 mg, 0.255 mmol) and 4-chlorobutanoic acid (36 mg, 0.25 mmol) in DMF (1 mL) was added DIEA (0.1 mL). After stirring at rt for 3 min, 5-chloro-N2-(2,5-dimethyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (100 mg, 0.24 mmol) in DMF (2 mL) was added. The reaction was stirred at rt for 90 min. at which point LCMS indicates the reaction was complete and that 4-chloro-1-(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)piperidin-1-yl)butan-1-one has been generated; ESMS m/z 516.1 (M+H+).
Step 2:
Morpholine (0.5 mL) was added directly to the crude reaction mixture from Step 1 (1 mL). The resulting solution was stirred at 100° C. in a sealed vial for 1.5 h. The crude product was purified by RP-HPLC to give 1-(4-(4-(5-Chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)piperidin-1-yl)-4-morpholinobutan-1-one as a white powder; ESMS m/z 567.3 (M+H+).
EXAMPLE 44
1-(4-(4-(5-Chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)piperidin-1-yl)-3-morpholinopropan-1-one (225)




Step 1:
A solution of HATU (108 mg, 0.28 mmol), 3-chloropropanoic acid (30 mg, 0.28 mmol) and DIEA (0.1 mL) in DMF (1 mL) was stirred at rt. After 3 min, this solution was transferred to a solution of 5-chloro-N2-(2,5-dimethyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine solution (111 mg, 0.27 mmol) in DMF (10 mL). The resulting mixture was stirred at rt overnight. The reaction was quenched with water (20 mL) and extracted with EtOAc (3×30 mL). The combined EtOAc layers were washed with brine (10 mL), dried over Na2SO4 and concentrated in vacuo. The crude product was purified by silica chromatography (0-10% MeOH in DCM gradient with 1% NH3 additive) to give 1-(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)piperidin-1-yl)prop-2-en-1-one as a light brown oil; ESMS m/z 466.1 (M+H+).
Step 2:
A solution of 1-(4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)piperidin-1-yl)prop-2-en-1-one (41 mg, 0.88 mmol) and morpholine (0.1 mL) in DMF (1 mL) was stirred at rt overnight. The crude product was purified by RP-HPLC to give 1-(4-(4-(5-Chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)piperidin-1-yl)-3-morpholinopropan-1-one as a white powder; ESMS m/z 553.2 (M+H+).
EXAMPLE 45
(S)-4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)oxazolidin-2-one (230)




Step 1:
To a microwave reaction vessel was added a mixture of 1-bromo-2,5-dimethyl-4-nitrobenzene (1.15 g, 5.0 mmol), dibutyl vinylboronate (1.16 g, 6.3 mmol), Pd(PPh3)4 (289 mg, 0.25 mmol), CsF (2.28 g, 15 mmol) and a mixed solvent (1,2-dimethoxyethane/MeOH=2:1, 15 mL). The mixture was degassed and sealed with N2. The reaction vessel was then heated to 130° C. in a microwave reactor for 15 min. After opening the reaction vessel, the mixture was poured into saturated NH4Cl aqueous solution (30 mL) and extracted with EtOAc (3×50 mL). The combined organic layers were washed with brine and dried (MgSO4). After removing the drying agent by filtration, the filtrate was concentrated and purified by flash column chromatography (silica gel, 0-30% EtOAc in hexanes gradient) to provide 1,4-dimethyl-2-nitro-5-vinylbenzene as needlelike crystals; ESMS m/z 178.1 (M+H+).
Step 2:
1,4-dimethyl-2-nitro-5-vinylbenzene was reacted via the asymmetric synthetic method reported by N. Barta et al. (Org. Lett. 2000, 2, 2821) followed by purification with preparative RP-HPLC to provide (S)-4-(2,5-dimethyl-4-nitrophenyl)oxazolidin-2-one; ESMS m/z 237.1 (M+H+).
Step 3:
To a solution of (S)-4-(2,5-dimethyl-4-nitrophenyl)oxazolidin-2-one (55 mg, 0.23 mmol) in MeOH (5 mL) was added Pd/C (5 mg, 10% w/w). The mixture was degassed and stirred at room temperature under 1 atm. H2 for 14 h. The Pd/C was removed by filtering through Celite. The filtrate was concentrated to provide (S)-4-(4-amino-2,5-dimethylphenyl)-oxazolidin-2-one which was used in the next step without further purification; ESMS m/z 207.1 (M+H+).
Step 4:
To a reaction tube was added (S)-4-(4-amino-2,5-dimethylphenyl)oxazolidin-2-one (48 mg, 0.23 mmol), 2,5-dichloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine (77 mg, 0.32 mmol), iPrOH (2 mL) and HCl (0.13 mL, 0.52 mmol, 4N in dioxane). The tube was then sealed and heated at 130° C. for 6 h. After cooling down to room temperature, the mixture was concentrated and purified by preparative RP-HPLC to provide (S)-4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethyl-phenyl)oxazolidin-2-one; ESMS m/z 414.1 (M+H+).
EXAMPLE 46
5-chloro-N2-(4-(1-ethylpiperidin-4-yl)-2-fluoro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (232)




A mixture of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (400 mg, 0.96 mmol), iodoethane (92.5 μL, 1.2 mmol) and triethylamine (201.5 μL, 1.4 mmol) in 4 mL of DMF was heated at 60° C. for 2 h. The reaction mixture was partitioned between EtOAc and water. The combined organic extracts were dried (Na2 SO4) and concentrated in vacuo. The crude product was purified by silica gel chromatography (MeOH/DCM: 1/9) to afford 5-chloro-N2-(4-(1-ethylpiperidin-4-yl)-2-fluoro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine; 1HNMR (DMSO-d6) δ 8.01 (s, 1H), 7.35 (m, 1H), 7.02 (d, 1H), 6.22 (s, 1H), 2.97 (d, 2H), 2.62 (m, 1H), 2.34 (q, 2H), 2.21 (s, 3H), 2.13 (s, 3H), 1.98 (t, 2H), 1.64 (m, 4H), 1.01 (t, 3H); ESMS m/z 444.2 (M+H+).
EXAMPLE 47
5-chloro-N2-(4-(14(2,2-difluorocyclopropyl)methyl)piperidin-4-yl)-2-fluoro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (235)




A mixture of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (40 mg, 0.096 mmol), 2-(bromomethyl)-1,1-difluorocyclopropane (32.8 mg, 0.19 mmol) and triethylamine (20.2 μL, 0.14 mmol) in 1 mL of DMF was heated at 150° C. in a microwave reactor for 30 min. The crude product was purified by RP-HPLC to afford 5-chloro-N2-(4-(1-((2,2-difluorocyclopropyl)methyl)piperidin-4-yl)-2-fluoro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine; ESMS m/z 506.2 (M+H+).
EXAMPLE 48
3-(4-(4-(5-Chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)piperidin-1-yl)propanamide (236)




A solution of 5-chloro-N2-(2,5-dimethyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (41 mg, 0.1 mmol), acrylamide (24 mg, 0.33 mmol) and DIEA (87 μL, 0.5 mmol) in NMP (1 mL) was stirred at 80° C. for 10 h. LCMS at this point shows the reaction was not complete, so additional acrylamide (2×36 mg) was added and the reaction continued until LCMS shows the reaction was complete. The crude product was purified by RP-HPLC to give 3-(4-(4-(5-Chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)piperidin-1-yl)propanamide as a white powder; ESMS m/z 483.2 (M+1).
EXAMPLE 49
4-(4-(4-(5-Chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)-1-morpholinobutan-1-one (246)




A mixture of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (41 mg, 0.1 mmol), 4-chloro-1-morpholinobutan-1-one (29 mg, 0.15 mmol) and DIEA (0.1 mL, 0.58 mmol) in NMP (1 mL) was stirred at 80° C. After 10 h, additional 4-chloro-1-morpholinobutan-1-one (51 mg) was added, and the reaction continued overnight. The crude product was purified by RP-HPLC to give 4-(4-(4-(5-Chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)-1-morpholinobutan-1-one as a white powder; ESMS m/z 571.3.3 (M+H+).
EXAMPLE 50
N2— (4-(14(2,2-difluorocyclopropyl)methyl)piperidin-4-yl)-2-fluoro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-5-(trifluoromethyl)pyrimidine-2,4-diamine (251)




A mixture of N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-5-(trifluoromethyl)pyrimidine-2,4-diamine (100 mg, 0.22 mmol), 2-(bromomethyl)-1,1-difluorocyclopropane (76.4 mg, 0.45 mmol) and triethylamine (60.6 μL, 0.42 mmol) in 1 mL of DMF was heated at 60° C. in a microwave reactor for 2 h. The crude product was purified by RP-HPLC to afford N2-(4-(1-(2,2-difluorocyclopropyl)methyl)piperidin-4-yl)-2-fluoro-5-methylphenyl)-N4— (5-methyl-1H-pyrazol-3-yl)-5-(trifluoromethyl)pyrimidine-2,4-diamine; ESMS m/z 540.2 (M+H+).
EXAMPLE 51
N2-(2,5-dimethyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-5-(trifluoromethyl)pyrimidine-2,4-diamine (257)




A mixture of 2-chloro-N-(5-methyl-1H-pyrazol-3-yl)-5-(trifluoromethyl)pyrimidin-4-amine (513.0 mg, 0.9 mmol), tert-butyl-4-(4-amino-2,5-dimethylphenyl)piperidine-1-carboxylate (282.7 mg, 0.9 mmol), and concentrated aqueous HCl (10 drops) in i-PrOH (12 mL) was heated at 150° C. in a microwave reactor for 30 min. The crude product was purified by RP-HPLC to afford N2-(2,5-dimethyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-5-(trifluoromethyl)pyrimidine-2,4-diamine; ESMS m/z 446.2 (M+H+).
EXAMPLE 52
5-Chloro-N2-(2-fluoro-4-(1-((3-isopropyl-1,2,4-oxadiazol-5-yl)methyl)piperidin-4-yl)-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (259)




A mixture of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (42 mg, 0.1 mmol), 5-(chloromethyl)-3-isopropyl-1,2,4-oxadiazole (17 mg, 0.10 mmol) and DIEA (86 μL, 0.5 mmol) in DMF (1 mL) was stirred at rt overnight. The reaction was diluted with EtOAc (50 mL) and washed with water (2×5 mL). The EtOAc layer was dried over Na2SO4 and concentrated in vacuo. The crude product was purified by silica chromatography (50-100% EtOAc in hexanes gradient) to give 5-Chloro-N2-(2-fluoro-4-(1-((3-isopropyl-1,2,4-oxadiazol-5-yl)methyl)piperidin-4-yl)-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine as a white solid; ESMS m/z 540.2 (M+H+).
EXAMPLE 53
(4-(4-(5-Chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)(3-isopropyl-1,2,4-oxadiazol-5-yl)methanone (265)




Step 1:
A solution of isobutyronitrile (4.49 mL, 50 mmol) and hydroxylamine (12.3 mL, 200 mmol) in anhydrous ethanol (20 mL) was stirred at 60° C. for two days. The solvent was evaporated. The residue was coevaporated repeatedly with toluene to give (E)-N′-hydroxyisobutyrimidamide as a light yellow liquid; 1H NMR (400 MHz, CDCl3) δ 7.50 (br s, 1H), 4.52 (br s, 2H), 2.43 (septet, J=6.8 Hz, 1H), 1.15 (d, J=6.8 Hz, 6H).
Step 2:
A solution of (E)-N′-hydroxyisobutyrimidamide (0.51 g, 5 mmol) and trichloroacetic anhydride (2.31 g, 7.5 mmol) in toluene (20 mL) was stirred at 80° C. After 4 h, the reaction was diluted with EtOAc (50 mL), washed with saturated aqueous NaHCO3 (2×10 mL), dried over Na2SO4 and evaporated to give 3-Isopropyl-5-(trichloromethyl)-1,2,4-oxadiazole as a clear liquid which was used without further purification; 1H NMR (400 MHz, CDCl3) δ 3.16 (septet, J=7.2 Hz, 1H), 1.39 (d, J=6.8 Hz, 6H).
Step 3:
A mixture of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (42 mg, 0.1 mmol), 3-isopropyl-5-(trichloromethyl)-1,2,4-oxadiazole (46 mg, 0.2 mmol) and DIEA (40 μL, 0.23 mmol) in MeOH (1 mL) was stirred at 70° C. overnight. The crude reaction mixture was purified by RP-HPLC to give (4-(4-(5-Chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)(3-isopropyl-1,2,4-oxadiazol-5-yl)methanone as a white solid; 1H NMR (400 MHz, CDCl3) δ 9.67 (br s, 2H), 8.50 (s, 1H), 8.07 (s, 1H), 7.57 (d, J=8.4 Hz, 1H), 7.05 (d, J=12.4 Hz, 1H), 6.16 (s, 1H), 5.53 (s, 1H), 3.98 (d, J=13.2 Hz, 1H), 3.34 (dt, J=2.0, 2.8 Hz, 1H), 3.15 (m, 1H), 2.82 (m, 2H), 2.62 (t, J=4.8 Hz, 2H), 2.34 (s, 3H), 2.25 9s, 3H), 1.90 (m, 2H), 1.76 (2H); ESMS m/z 554.2 (M+H+).
EXAMPLE 54
5-Chloro N2 (4 (1 (2 (3-isopropyl-1,2,4-oxadiazol-5-yl)ethyl)piperidin-4-yl)-2,5-dimethylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (269)




Step 1:
A mixture of (E)-N′-hydroxyisobutyrimidamide (510 mg, 5 mmol), 3-chloropropanoic acid (542 mg, 5 mmol) and dicyclohexylcarbodiimide (1.24 g, 6 mmol) in anhydrous dioxane (20 mL) was stirred at 0° C. for 1 h and then at room temperature for an additional 1 h. The reaction was then heated at 80° C. for an additional 18 h. The reaction was filtered and the filtrate was evaporated. The resulting residue was purified by silica chromatography (0-100% EtOAc in hexanes gradient) to give 5-(2-chloroethyl)-3-isopropyl-1,2,4-oxadiazole; 1H NMR (400 MHz, CDCl3) δ 3.85 (t, J=7.2 Hz, 2H), 3.27 (t, J=7.2 Hz, 2H), 3.03 (septet, J=7.2 Hz, 1H), 1.13 (d, J=7.2 Hz, 6H); ESMS m/z 175.1 (M+H+).
Step 2:
A mixture of 5-chloro-N2-(2,5-dimethyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (14 mg, 0.033 mmol), 542-chloroethyl)-3-isopropyl-1,2,4-oxadiazole (9 mg, 0.053 mmol) and DIEA (29 uL, 0.17 mmol) in NMP (1 mL) was stirred at 50° C. for 3 days. The crude reaction mixture was purified by RP-HPLC to give 5-Chloro-N2-(4-(1-(2-(3-isopropyl-1,2,4-oxadiazol-5-yl)ethyl)piperidin-4-yl)-2,5-dimethylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine as a white solid; ESMS m/z 550.3 (M+H+).
EXAMPLE 55
5-Chloro-N2-(2-fluoro-5-methyl-4-(1-(6-methylpyridazin-3-yl)piperidin-4-yl)phenyl)-N4—(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (277)




A suspension of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (20 mg, 0.05 mmol), 3-chloro-6-methylpyridazine (13 mg, 0.1 mmol) and Cs2CO3 (33 mg, 0.1 mmol) in dioxane (1 mL) was stirred at 150° C. in a sealed vial. After 15 h, additional 3-chloro-6-methylpyridazine (26 mg) and Cs2CO3 (66 mg) were added. The reaction was continued for an additional 3 h. The crude reaction mixture was purified by RP-HPLC to give 5-Chloro-N2-(2-fluoro-5-methyl-4-(1-(6-methylpyridazin-3-yl)piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine as a white solid; ESMS m/z 508.2 (M+H+).
EXAMPLES 56 AND 57
5-chloro-N2-(2-fluoro-5-methyl-4-((trans)-2-methylpiperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (279)




5-chloro-N2-(2-fluoro-5-methyl-4-((cis)-2-methylpiperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (280)




Step 1:
A solution of tert-butyl-2-methyl-4-oxopiperidine-1-carboxylate (1 g, 4.69 mmol) in THF (20 mL) was added dropwise into a cooled (−78° C.), vigorously stirring solution of LDA (3.75 mL of 1.5 M solution in cyclohexanes, 5.63 mmol) in THF (20 mL), under N2. The reaction mixture was stirred at −78° C. for 30 min before adding a solution of phenyl trifluorosulfonimide (1.84 g, 5.16 mmol) in THF (20 mL). Following this addition, the reaction mixture was warmed to room temperature and stirred for 3 h. The reaction was cooled to 0° C. and quenched with 100 mL of saturated aqueous NH4Cl, followed by filtration through Celite. The filtrate was added to 100 mL of EtOAc and the layers were separated. The organic layer was washed with water, dried over MgSO4 and concentrated. The crude product was purified by silica chromatography (0-30% EtOAc in hexanes gradient and checked by TLC stained with 2% of KMnO4 in EtOH) to afford tert-butyl 2-methyl-4-(trifluoromethylsulfonyloxy)-5,6-dihydropyridine-1(2H)-carboxylate as a yellow solid.
Step 2:
To a mixture of 2-fluoro-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (587 mg, 2.33 mmol), tert-butyl 2-methyl-4-(trifluoromethylsulfonyloxy)-5,6-dihydropyridine-1(2H)-carboxylate (968 mg, 2.80 mmol) and sodium carbonate (1.73 g, 16.35 mmol) in DMF/H2O (20/5 mL) was added tetrakis(triphenylphosphine) palladium (0) (135 mg, 5% mmol). The reaction tube was sealed, the mixture was purged with N2 for 3 min and then heated at 100° C. under N2 for 8 h. The reaction was cooled to room temperature and poured into saturated aqueous ammonia chloride solution. The crude reaction mixture was extracted with ethyl acetate (3×15 mL). The organic extracts were combined, washed with brine and concentrated. The crude product was purified with silica chromatography (50% ethyl acetate in hexanes) to afford tert-butyl 4-(4-amino-5-fluoro-2-methylphenyl)-6-methyl-5,6-dihydropyridine-1(2H)-carboxylate as a yellow oil. The obtained oil was dissolved in methanol (20 mL). To the solution was added Pd/C (10%). The reaction mixture was degassed and purged with H2 for several times and stirred vigorously under 1 atm. H2 overnight. The mixture was filtered and the filtrate concentrated to afford tert-butyl 4-(4-amino-5-fluoro-2-methylphenyl)-2-methylpiperidine-1-carboxylate as a white solid. ESMS m/z 267 (M−56+H+).
Step 3:
A mixture of 2,5-dichloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine (346 mg, 1.42 mmol) and tert-butyl 4-(4-amino-5-fluoro-2-methylphenyl)-2-methylpiperidine-1-carboxylate (352 mg, 1.09 mmol) in 2-propanol (10 mL) was treated with conc. HCl (12N, 0.43 mL). The mixture was sealed and heated in a microwave at 130° C. for 45 min. The mixture was concentrated. The residue was purified by RP-HPLC to afford 5-Chloro-N2-(2-fluoro-5-methyl-4-(2-methylpiperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine as a white solid. ESMS m/z 430.1 (M+H+).
Step 4:
5-Chloro-N2-(2-fluoro-5-methyl-4-(2-methylpiperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (20 mg, 0.046 mmol) was dissolved in a solvent mixture of DCM and methanol (0.5 mL, 10/1 v/v+0.175N NH3). The mixture was applied to preparative TLC in order to separate the cis and trans stereoisomers (eluent: 6% MeOH in DCM with 0.1N NH3) of 5-Chloro-N2-(2-fluoro-5-methyl-4-(2-methylpiperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine as white solids. The trans isomer was the preparative TLC top band and the cis isomer was the preparative TLC bottom band; ESMS m/z 430.1 (M+H+); cis stereoisomer 1H NMR (400 MHz, MeOD-d4): δ 8.03 (s, 1H), 7.84 (d, 1H), 7.02 (d, 1H), 6.24 (d, 1H), 3.90-3.85 (m, 1H), 2.32 (s, 3H), 2.27 (s, 3H), 2.03-1.84 (m, 2H), 1.65-1.54 (m, 1H), 1.55 (d, 3H), 1.38-1.19 (m, 4H).
EXAMPLE 58
3-(4-(4-(5-Chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)cyclopent-2-en-one (282)




A mixture of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (43 mg, 0.1 mmol), cyclopentane-1,3-dione (89 mg, 9.1 mmol), sodium cyanoborohydride (19 mg, 0.3 mmol) and DIEA (0.2 mL, 11 mmol) in MeOH (1 mL) was stirred in a sealed vial at 60° C. After 2.5 h, additional sodium cyanoborohydride (19 mg, 0.3 mmol) was added and the reaction continued to stir at 60° C. overnight. The mixture was purified by RP-HPLC to give 3-(4-(4-(5-Chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)piperidin-1-yl)cyclopent-2-en-one as an off white solid; 1H NMR (400 MHz, DMSO-d6) δ 9.97 (br s, 1H), 9.83 (br s, 1H), 8.90 (s, 1H), 8.32 (d, J=6.8 Hz, 1H), 7.88 (d, J=12.8 Hz, 1H), 6.97 (s, 1H), 6.04 (s, 1H), 5.30 (br s, 1H), 4.71 (d, J=12.0 Hz, 2H), 4.04 (t, J=12.4 Hz, 2H), 3.84 (m, 1H), 3.53 (m, 2H), 3.13 (m, 2H), 3.08 (s, 3H), 2.96 (s, 3H), 2.59-2.40 (m, 4H); ESMS m/z 496.2 (M+H+).
EXAMPLE 59
4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)-1-ethylpiperidine-1-oxide (289)




To a solution of 5-chloro-N2-(4-(1-ethylpiperidin-4-yl)-2-fluoro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (22.2 mg, 0.05 mmol) in DCM (10 mL) and MeOH (1 mL) was added MCPBA (11.2 mg, 0.07 mmol). The reaction was stirred at room temperature overnight. The reaction mixture was partitioned between DCM and saturated aqueous NaHCO3, the combined organic extracts were dried (Na2SO4), and concentrated in vacuo. The crude product was purified by RP-HPLC to afford 4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-5-fluoro-2-methylphenyl)-1-ethylpiperidine-1-oxide; 1HNMR (MeOD-d4) δ7.91 (s, 1H), 7.69 (d, 1H), 7.00 (d, 1H), 6.15 (s, 1H), 3.28 (m, 4H), 2.91 (m, 1H), 2.32 (m, 2H), 2.20 (s, 3H), 2.16 (s, 3H), 1.83 (s, 2H), 1.64 (d, 2H), 1.31 (t, 3H); ESMS m/z 460.2 (M+H+).
EXAMPLE 60
5-Chloro-N2-(2-fluoro-5-methyl-4-(1-(pyrimidin-5-ylmethyl)piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (314)




To a solution of 5-chloro-N2-(2-fluoro-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (45 mg, 0.1 mmol) and pyrimidine-5-carbaldehyde (32 mg, 0.3 mmol) in DCM (1.5 mL) was added NaBH(OAc)3 (64 mg, 0.3 mmol), followed by addition of AcOH (12 uL). After stirring at room temperature in a sealed vial for 16 h, the reaction was quenched with EtOAc (50 mL). The reaction mixture was sequentially washed with water (10 mL), brine (5 mL), dried over Na2SO4 and concentrated in vacuo. The resulting residue was purified by silica chromatography (0-10% MeOH in EtOAc gradient with 1% NH3 in MeOH additive) to give 5-Chloro-N2-(2-fluoro-5-methyl-4-(1-(pyrimidin-5-ylmethyl)piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine as an off white solid; 1H NMR (400 MHz, CD3OD) δ 9.09 (s, 1H), 8.81 (s, 2H), 8.00 (s, 1H), 7.73 (d, J=8.4 Hz, 1H), 6.99 (d, J=13.2 Hz, 1H), 6.23 (br s, 1H), 3.65 (s, 2H), 3.03 (m, 2H), 2.76 (m, 1H), 2.27 (s, 3H), 2.25 (s, 3H), 2.25 (m, 2H), 1.80-1.68 (m, 4H); ESMS m/z 508.2 (M+H+).
The following compounds in Table 1 are obtained by repeating the procedures described in examples above and using appropriate starting materials.










TABLE 1








IGF-1R





Ba/F3



STRUCTURE
NMR or ESMS
IC50 (uM)


















1




1H NMR (400 MHz, DMSO-d6) δ 10.33 (br, 1H), 9.90 (br, 1H0, 9.60 (br, 1H), 8.22 (s, 1H), 7.56 (d, 1H), 7.00 (d, 1H), 6.20 (s, 1H), 3.53- 3.50 (m, 2H), 3.16-3.10 (m, 2H), 2.97-2.92 (m, 1H), 2.81 (d, 3H), 2.26 (s, 3H), 2.16 (s, 3H), 1.94-1.91 (m, 2H), 1.83- 1.73 (m, 2H); ESMS m/z 430.1 (M + H+).
0.011


 


2




ESMS m/z 416.1 (M + H+).
0.050


 


3




ESMS m/z 470.2 (M + H+).
0.104


 


4




ESMS m/z 450.2 (M + H+).
0.150


 


5




ESMS m/z 450.3 (M + H+).
0.805


 


6




ESMS m/z 426.2 (M + H+).
0.015


 


7




ESMS m/z 446.1 (M + H+).
0.015


 


8




ESMS m/z 461.2 (M + H+).
1.93


 


9




ESMS m/z 461.2 (M + H+).
0.087


 


10




ESMS m/z 461.2 (M + H+).
0.869


 


11




ESMS m/z 461.2 (M + H+).
0.065


 


12




ESMS m/z 454.2 (M + H+).
0.010


 


13




ESMS m/z 458.2 (M + H+).



 


14




ESMS m/z 412.2 (M + H+).
0.016


 


15




ESMS m/z 412.2 (M + H+).
0.050


 


16




ESMS m/z 426.2 (M + H+).
0.019


 


17




ESMS m/z 442.2 (M + H+).
0.160


 


18




ESMS m/z 438.2 (M + H+).
0.095


 


19




1H NMR (400 MHz, MeOD-d4) 8.12 (s, 1H), 7.75 (d, 1H), 7.03 (s, 1H), 6.27 (s, 1H), 4.25 (s, 2H), 3.69-3.67 (m, 2H), 3.27-3.20 (m, 3H), 2.54 (s, 3H), 2.37 (s, 3H), 2.34 (s, 3H), 2.30 (s, 3H), 2.10-1.95 (m, 4H); ESMS m/z 525.1 (M + H+).
0.056


 


20




ESMS m/z 521.2 (M + H+).
0.011


 


21




ESMS m/z 504.2 (M + H+)
0.002


 


22




ESMS m/z 460.2 (M + H+).
0.059


 


23




ESMS m/z 456.21 (M + H+).
0.006


 


24




ESMS m/z 512.2 (M + H+).
0.085


 


25




ESMS m/z 508.2 (M + H+).
0.031


 


26




ESMS m/z 498.2 (M + H+).
0.142


 


27




ESMS m/z 528.2 (M + H+).
0.044


 


28




ESMS m/z 512.2 (M + H+).
5.46


 


29




ESMS m/z 524.2 (M + H+).
0.023


 


30




ESMS m/z 528.2 (M + H+).
0.071


 


31




ESMS m/z 528.2 (M + H+).
6.47


 


32




ESMS m/z 513.2 (M + H+).
0.042


 


33




ESMS m/z 509.2 (M + H+).
0.006


 


34




ESMS m/z 499.2 (M + H+).
0.049


 


35




ESMS m/z 495.2 (M + H+).
0.011


 


36




ESMS m/z 527.2 (M + H+).
0.019


 


37




ESMS m/z 469.2 (M + H+).
0.013


 


38




ESMS m/z 483.2 (M + H+).
0.010


 


39




1H NMR (400 MHz, MeOD-d4) δ 8.11 (s, 1H), 7.76 (d 1H), 7.09 (d, 1H), 6.27 (s, 1H), 4.0 (s, 2H), 3.75-3.73 (m, 2H), 3.22- 3.13 (m, 3H), 2.34 (s, 3H), 2.30 (s, 3H), 2.04- 2.00 (m, 4H); ESMS m/z 473.2 (M + H+).
0.019


 


40




ESMS m/z 469.2 (M + H+).



 


41




ESMS m/z 469.2 (M + H+).
0.026


 


42




ESMS m/z 487.2 (M + H+).
0.019


 


43




ESMS m/z 483.2 (M + H+).



 


44




ESMS m/z 483.2 (M + H+).
0.015


 


45




ESMS m/z 503.2 (M + H+).
0.018


 


46




ESMS m/z 499.2 (M + H+).
0.013


 


47




ESMS m/z 523.2 (M + H+).
0.022


 


48




ESMS m/z 487.2 (M + H+).
3.68


 


49




ESMS m/z 487.2 (M + H+).
0.015


 


50




ESMS m/z 501.2 (M + H+).
0.022


 


51




ESMS m/z 483.2 (M + H+).
0.009


 


52




ESMS m/z 497.2 (M + H+).
0.006


 


53




ESMS m/z 521.2 (M + H+).
0.078


 


54




ESMS m/z 488.2 (M + H+).
1.53


 


55




ESMS m/z 522.1 (M + H+).
0.024


 


56




ESMS m/z 518.2 (M + H+).
0.006


 


57




ESMS m/z 536.2 (M + H+).
0.021


 


58




ESMS m/z 551.2 (M + H+).
0.036


 


59




ESMS m/z 523.2 (M + H+).
0.038


 


60




ESMS m/z 579.2 (M + H+).
0.011


 


61




ESMS m/z 563.2 (M + H+).
0.056


 


62




ESMS m/z 494.2 (M + H+).
0.005


 


63




ESMS m/z 490.2 (M + H+).
0.002


 


64




ESMS m/z 520.2 (M + H+).
0.059


 


65




ESMS m/z 557.2 (M + H+).
0.076


 


66




1H NMR (400 MHz, MeOD-d4) δ 8.13 (s, 1H), 7.54 (d, 1H), 7.10 (d, 1H), 6.28 (s, 1H), 4.30-4.26 (m, 2H), 4.14 (q, 2H), 2.99- 2.96 (m, 3H), 2.33 (s, 3H), 2.29 (s, 3H), 1.8-1.77 (m, 2H), 1.64-1.55 (m, 2H), 1.28 (t, 3H); ESMS m/z 488.2 (M + H+).
0.064


 


67




ESMS m/z 504.2 (M + H+).
0.182


 


68




ESMS m/z 502.2 (M + H+).
0.080


 


69




ESMS m/z 487.2 (M + H+).
0.011


 


70




ESMS m/z 483.2 (M + H+).
0.006


 


71




ESMS m/z 483.2 (M + H+).
0.002


 


72




ESMS m/z 455.2 (M + H+).
0.006


 


73




1H NMR (400 MHz, MeOD-d4) δ 8.08 (s, 1H), 7.71 (d, 1H), 7.03 (d, 1H), 6.26 (s, 1H), 4.71-4.67 (m, 2H), 3.81-3.77 (m, 2H), 3.14-3.12 (m, 2H), 2.98 (s, 3H), 2.96 (s, 3H), 2.90- 2.83 (m, 1H), 2.34 (s, 3H), 2.28 (s, 3H), 1.87 (d, 2H), 1.76-1.55 (m, 2H); ESMS m/z 501.2 (M + H+).
0.019


 


74




ESMS m/z 517.2 (M + H+).
0.007


 


75




ESMS m/z 497.2 (M + H+).
0.011


 


76




ESMS m/z 513.2 (M + H+).
0.009


 


77




ESMS m/z 537.1 (M + H+).
0.007


 


78




ESMS m/z 515.2 (M + H+).
0.138


 


79




ESMS m/z 473.2 (M + H+).
0.075


 


80




ESMS m/z 487.2 (M + H+).
0.103


 


81




ESMS m/z 529.3 (M + H+).
0.030


 


82




ESMS m/z 487.2 (M + H+).



 


83




ESMS m/z 497.2 (M + H+).
0.013


 


84




ESMS m/z 529.3 (M + H+).



 


85




ESMS m/z 501.2 (M + H+).
0.042


 


86




ESMS m/z 487.2 (M + H+).
0.141


 


87




ESMS m/z 515.2 (M + H+).
0.017


 


88




ESMS m/z 531.2 (M + H+).
0.007


 


89




ESMS m/z 497.2 (M + H+).
0.023


 


90




ESMS m/z 509.2 (M + H+).
0.005


 


91




ESMS m/z 509.2 (M + H+).
0.052


 


92




ESMS m/z 537.3 (M + H+).
0.015


 


93




ESMS m/z 499.2 (M + H+).
0.033


 


94




ESMS m/z 527.2 (M + H+).
0.013


 


95




ESMS m/z 559.2 (M + H+).
0.006


 


96




ESMS m/z 529.2 (M + H+).
0.024


 


97




ESMS m/z 543.2 (M + H+).
0.020


 


98




ESMS m/z 513.2 (M + H+).
0.064


 


99




ESMS m/z 527.2 (M + H+).
0.038


 


100




ESMS m/z 523.2 (M + H+).
0.025


 


101




ESMS m/z 537.3 (M + H+).
0.007


 


102




ESMS m/z 539.3 (M + H+).
0.009


 


103




ESMS m/z 565.3 (M + H+).
0.009


 


104




ESMS m/z 593.3 (M + H+).
0.018


 


105




ESMS m/z 556.3 (M + H+).
0.051


 


106




ESMS m/z 484.2 (M + H+).
0.002


 


107




ESMS m/z 515.2 (M + H+).
0.057


 


108




ESMS m/z 531.2 (M + H+).
0.053


 


109




ESMS m/z 530.2 (M + H+).
0.060


 


110




ESMS m/z 454.2 (M + H+).
0.013


 


111




ESMS m/z 529.2 (M + H+).
0.008


 


112




ESMS m/z 542.2 (M + H+).
0.021


 


113




ESMS m/z 524.2 (M + H+).
0.013


 


114




ESMS m/z 569.2 (M + H+).
0.048


 


115




ESMS m/z 527.2 (M + H+).
1.57


 


116




ESMS m/z 513.2 (M + H+).
0.137


 


117




ESMS m/z 513.2 (M + H+).
0.099


 


118




ESMS m/z 541.2 (M + H+).
0.081


 


119




ESMS m/z 513.2 (M + H+).
2.99


 


120




ESMS m/z 509.2 (M + H+).
0.025


 


121




ESMS m/z 523.2 (M + H+).
0.017


 


122




ESMS m/z 537.2 (M + H+).



 


123




ESMS m/z 539.3 (M + H+).
0.048


 


124




ESMS m/z 509.2 (M + H+).
0.145


 


125




ESMS m/z 569.3 (M + H+).
0.012


 


126




ESMS m/z 571.3 (M + H+).
0.029


 


127




ESMS m/z 539.2 (M + H+).
0.027


 


128




ESMS m/z 543.2 (M + H+).
0.175


 


129




ESMS m/z 552.2 (M + H+).
0.025


 


130




ESMS m/z 592.2 (M + H+).
0.061


 


131




1H NMR (400 MHz, MeOD-d4) δ 8.08 (s, 1H), 7.68 (d, 2H), 7.04 (d, 2H), 6.26 (s, 1H), 4.74-4.68 (m, 2H), 4.39- 4.35 (m, 1H), 4.29-4.24 (m, 2H), 4.11-4.07 (m, 1H), 3.74-3.71 (m, 1H), 3.25-3.24 (m, 1H), 3.07- 3.04 (m, 1H), 2.87-2.80 (m, 1H), 2.33 (s, 3H), 2.28 (s, 3H), 1.87-1.84 (m, 2H), 1.66-1.56 (m, 2H); ESMS m/z 499.2 (M + H+).
1.25


 


132




ESMS m/z 499.2 (M + H+).
0.161


 


133




ESMS m/z 523.3 (M + H+).
0.013


 


134




ESMS m/z 527.2 (M + H+).
0.021


 


135




ESMS m/z 555.3 (M + H+).
0.048


 


136




ESMS m/z 525.2 (M + H+).
0.035


 


137




ESMS m/z 539.2 (M + H+).
0.018


 


138




ESMS m/z 527.2 (M + H+).
0.091


 


139




ESMS m/z 543.2 (M + H+).
0.175


 


140




ESMS m/z 512.2 (M + H+).
0.139


 


141




ESMS m/z 593.2 (M + H+).
0.069


 


142




ESMS m/z 541.2 (M + H+).
0.282


 


143




ESMS m/z 529.2 (M + H+).
0.071


 


144




ESMS m/z 550.1 (M + H+).
0.007


 


145




ESMS m/z 534.2 (M + H+).
0.018


 


146




ESMS m/z 544.2 (M + H+).
0.258


 


147




ESMS m/z 536.1 (M + H+).
0.016


 


148




ESMS m/z 520.2 (M + H+). 1H NMR (400 MHz, DMSO-d6 + 1 drop D2O) δ 8.02 (s, 1H), 7.37 (s, 1H), 7.02 (s, 1H), 6.23 (s, 1H), 4.28-4.22 (m, 2H), 4.12-4.07 (m, 2H), 3.22- 3.18 (m, 1H), 2.95-2.92 (m, 2H), 2.68-2.62 (m, 1H), 2.22 (s, 3H), 2.13 (s, 3H), 2.07-2.01 (m, 2H), 1.71-1.55 (m, 4H).
0.018


 


149




ESMS m/z 522.2 (M + H+).
0.955


 


150




ESMS m/z 414.1 (M + H+).
0.025


 


151




ESMS m/z 426.2 (M + H+).
0.009


 


152




ESMS m/z 427.2 (M + H+).
0.155


 


153




ESMS m/z 472.1 (M + H+).
0.091


 


154




ESMS m/z 447.1 (M + H+).
0.012


 


155




ESMS m/z 427.2 (M + H+).
1.65


 


156




ESMS m/z 481.2 (M + H+)
0.040


 


157




ESMS m/z 485.2 (M + H+).
0.075


 


158




ESMS m/z 425.2 (M + H+).
0.062


 


159




ESMS m/z 431.2 (M + H+).
0.073


 


160




ESMS m/z 425.2 (M + H+).



 


161




ESMS m/z 456.2 (M + H+).
0.332


 


162




ESMS m/z 438.9 (M + H+).
0.013


 


163




ESMS m/z 487.2 (M + H+)
0.056


 


164




ESMS m/z 501.2 (M + H+); 1HNMR (MeOD-d4) δ 8.25 (s, 1H), 7.56 (m, 1H), 7.20 (d, 1H), 6.46 (s, 1H), 3.97 (m, 1H), 3.79 (m, 1H), 3.62 (m, 1H), 3.25 (m, 3H), 2.84 (s, 3H), 2.40 (d, 6H), 2.08 (m, 4H), 1.62 (m, 3H).
0.033


 


165




ESMS m/z 487.2 (M + H+); 1HNMR (MeOD-d4) δ 8.22 (s, 1H), 7.61 (t, 1H), 7.18 (d, 1H), 6.40 (s, 1H), 3.79 (m, 1H), 3.65 (m, 1H), 3.54 (m, 1H), 3.22 (m, 3H), 2.39 (d, 6H), 2.08 (m, 4H), 1.66 (d, 3H)
0.038


 


166




ESMS m/z 483.2 (M + H+)
0.007


 


167




ESMS m/z 483.2 (M + H+)
0.006


 


168




ESMS m/z 497.2 (M + H+)
0.01


 


169




ESMS m/z 527.2 (M + H+); 1HNMR (MeOD-d4) δ 8.24 (s, 1H), 7.49 (d, 1H), 7.23 (d, 1H), 6.47 (s, 1H), 4.52 (d, 2H), 3.26 (q, 2H), 3.18 (m, 3H), 2.40 (s, 6H), 1.91 (d, 2H), 1.71 (m, 2H), 1.49 (m, 3H), 1.39 (t, 3H).
0.004


 


170




ESMS m/z 523.3 (M + H+)
0.003


 


171




ESMS m/z 470.1 (M + H+)
0.067


 


172




ESMS m/z 541.2 (M + H+)
0.069


 


173




ESMS m/z 527.2 (M + H+)
0.049


 


174




ESMS m/z 512.2 (M + H+)
0.008


 


175




ESMS m/z 525.3 (M + H+)
0.005


 


176




ESMS m/z 541.3 (M + H+)
0.084


 


177




ESMS m/z 527.2 (M + H+)
0.08


 


178




ESMS m/z 392.2 (M + H+)
3.229


 


179




ESMS m/z 504.3 (M + H+)
0.12


 


180




ESMS m/z 497.2 (M + H+)
0.025


 


181




ESMS m/z 469.2 (M + H+)
0.024


 


182




ESMS m/z 483.2 (M + H+)
0.019


 


183




ESMS m/z 426.2 (M + H+)



 


184




ESMS m/z 426.2 (M + H+)



 


185




ESMS m/z 497.2 (M + H+)
0.009


 


186




ESMS m/z 523.3 (M + H+)
0.012


 


187




ESMS m/z 495.2 (M + H+)
0.095


 


188




ESMS m/z 521.2 (M + H+)
0.019


 


189




ESMS m/z 511.3 (M + H+)
0.007


 


190




ESMS m/z 525.3 (M + H+)
0.007


 


191




ESMS m/z 521.2 (M + H+)
0.113


 


192




ESMS m/z 500.2 (M + H+)
0.021


 


193




ESMS m/z 496.2 (M + H+)
0.076


 


194




ESMS m/z 603.3 (M + H+)
0.013


 


195




ESMS m/z 573.2 (M + H+)
0.027


 


196




ESMS m/z 619.3 (M + H+)
0.37


 


197




ESMS m/z 524.2 (M + H+)
0.21


 


198




ESMS m/z 491.2 (M + H+)
0.022


 


199




ESMS m/z 455.2 (M + H+)
0.077


 


200




ESMS m/z 469.2 (M + H+)
0.036


 


201




ESMS m/z 524.2 (M + H+)
0.046


 


202




ESMS m/z 503.2 (M + H+); 1HNMR (MeOD-d4) δ 8.23 (s, 1H), 7.26 (s, 1H), 7.20 (s, 1H), 6.20 (s, 1H), 4.00 (s, 2H), 3.75 (d, 2H), 3.55 (m, 2H), 3.14 (m, 1H), 2.36 (s, 3H), 2.26 (s, 3H), 2.24 (s, 3H), 2.08 (m, 4H).
0.02


 


203




ESMS m/z 517.3 (M + H+)
0.015


 


204




ESMS m/z 482.2 (M + H+)
0.016


 


205




ESMS m/z 466.2 (M + H+)
0.019


 


206




ESMS m/z 444.2 (M + H+)
0.03


 


207




ESMS m/z 483.2 (M + H+)
0.026


 


208




ESMS m/z 483.2 (M + H+)
0.01


 


209




ESMS m/z 500.2 (M + H+); 1H NMR (DMSO- d6, 400 MHz) δ 12.08 (br, 1H), 9.58 (br, 1H), 8.65 (d, J = 28.4 Hz, 1H), 8.02 (s, 1H), 7.36 (d, J = 8.4 Hz, 1H), 7.03 (d, J = 12.4 Hz, 1H), 6.08 (br, 1H), 3.89 (dd, J = 10.8, 3.6 Hz, 2H), 3.28 (t, J = 10.4 Hz, 2H), 2.99 (d, J = 10.8 Hz, 2H), 2.64-2.43 (m, 2H), 2.24-2.15 (m, 8H), 1.71-1.40 (m, 8H)
0.027


 


210




ESMS m/z 456.2 (M + H+)
0.032


 


211




ESMS m/z 440.2 (M + H+)
0.009


 


212




ESMS m/z 470.2 (M + H+)
0.013


 


213




ESMS m/z 540.2 (M + H+)
0.012


 


214




ESMS m/z 573.2 (M + H+)
0.04


 


215




ESMS m/z 466.2 (M + H+)
0.047


 


216




ESMS m/z 484.2 (M + H+)
0.047


 


217




ESMS m/z 523.2 (M + H+)
0.034


 


218




ESMS m/z 480.2 (M + H+)
0.026


 


219




ESMS m/z 442.2 (M + H+)
0.009


 


220




ESMS m/z 537.2 (M + H+)
0.037


 


221




ESMS m/z 474.3 (M + H+)
0.034


 


222




ESMS m/z 490.2 (M + H+)
0.038


 


223




ESMS m/z 551.2 (M + H+)
0.036


 


224




ESMS m/z 567.3 (M + H+)
0.02


 


225




ESMS m/z 553.3 (M + H+)
0.017


 


226




ESMS m/z 537.3 (M + H+)
0.061


 


227




ESMS m/z 551.3 (M + H+)
0.123


 


228




ESMS m/z 540.2 (M + H+)
0.023


 


229




ESMS m/z 524.2 (M + H+)
0.211


 


230




ESMS m/z 414.1 (M + H+)
0.04


 


231




ESMS m/z 414.1 (M + H+)
0.05


 


232




ESMS m/z 444.2 (M + H+); 1HNMR (DMSO-d6) δ 8.01 (s, 1H), 7.35 (m, 1H), 7.02 (d, 1H), 6.22 (s, 1H), 2.97 (d, 2H), 2.62 (m, 1H), 2.34 (q, 2H), 2.21 (s, 3H), 2.13 (s, 3H), 1.98 (t, 2H), 1.64 (m, 4H), 1.01 (t, 3H).
0.020


 


233




ESMS m/z 587.3 (M + H+)
0.054


 


234




ESMS m/z 603.3 (M + H+)
0.073


 


235




ESMS m/z 506.2 (M + H+)
0.063


 


236




ESMS m/z 483.2 (M + H+)
0.059


 


237




ESMS m/z 384.2 (M + H+)
0.41


 


238




ESMS m/z 537.3 (M + H+)
0.039


 


239




ESMS m/z 511.3 (M + H+)
0.073


 


240




ESMS m/z 498.2 (M + H+)
0.102


 


241




ESMS m/z 494.2 (M + H+)
0.068


 


242




ESMS m/z 541.3 (M + H+)
0.06


 


243




ESMS m/z 577.2 (M + H+)
0.076


 


244




ESMS m/z 591.2 (M + H+)
0.084


 


245




ESMS m/z 607.2 (M + H+)
0.077


 


246




ESMS m/z 571.3 (M + H+)
0.058


 


247




ESMS m/z 527.2 (M + H+)
0.062


 


248




ESMS m/z 487.2 (M + H+)
0.14


 


249




ESMS m/z 502.2 (M + H+)
0.032


 


250




ESMS m/z 452.2 (M + H+)
0.025


 


251




ESMS m/z 540.2 (M + H+)
0.052


 


252




ESMS m/z 496.3 (M + H+)
0.014


 


253




ESMS m/z 470.1 (M + H+)
0.075


 


254




ESMS m/z 466.2 (M + H+)
0.07


 


255




ESMS m/z 482.2 (M + H+)
0.228


 


256




ESMS m/z 412.2 (M + H+)
0.044


 


257




ESMS m/z 446.2 (M + H+)
0.064


 


258




ESMS m/z 478.2 (M + H+)
0.026


 


259




ESMS m/z 540.2 (M + H+)
0.064


 


260




ESMS m/z 536.3 (M + H+)
0.018


 


261




ESMS m/z 483.2 (M + H+)
0.027


 


262




ESMS m/z 485.2 (M + H+)
0.019


 


263




ESMS m/z 487.2 (M + H+)
0.033


 


264




ESMS m/z 534.2 (M + H+)
0.021


 


265




ESMS m/z 554.2 (M + H+); 1H NMR (400 MHz, CDCl3) δ 9.67 (br s, 2H), 8.50 (s, 1H), 8.07 (s, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.05 (d, J = 12.4 Hz, 1H), 6.16 (s, 1H), 5.53 (s, 1H), 3.98 (d, J = 13.2 Hz, 1H), 3.34 (dt, J = 2.0, 2.8 Hz, 1H), 3.15 (m, 1H), 2.82 (m, 2H), 2.62 (t, J = 4.8 Hz, 2H), 2.34 (s, 3H), 2.25 9s, 3H), 1.90 (m, 2H), 1.76 (2H)
0.091


 


266




ESMS m/z 550.3 (M + H+)
0.025


 


267




ESMS m/z 554.3 (M + H+)
0.077


 


268




ESMS m/z 458.2 (M + H+)
0.022


 


269




ESMS m/z 550.3 (M + H+)
0.039


 


270




ESMS m/z 550.2 (M + H+)
0.018


 


271




ESMS m/z 444.2 (M + H+)
0.013


 


272




ESMS m/z 470.2 (M + H+)
0.050


 


273




ESMS m/z 430.2 (M + H+)
0.018


 


274




ESMS m/z 487.2 (M + H+)
0.006


 


275




ESMS m/z 444.2 (M + H+)
0.009


 


276




ESMS m/z 499.2 (M + H+)
0.437


 


277




ESMS m/z 508.2 (M + H+)
0.097


 


278




ESMS m/z 577.2 (M + H+)
0.009


 


279




ESMS m/z 430.2 (M + H+)
0.064


 


280




ESMS m/z 430.2 (M + H+)
0.163


 


281




ESMS m/z 507.2 (M + H+)
0.087


 


282




ESMS m/z 496.2 (M + H+); 1H NMR (400 MHz, DMSO-d6) δ 9.97 (br s, 1H), 9.83 (br s, 1H), 8.90 (s, 1H), 8.32 (d, J = 6.8 Hz, 1H), 7.88 (d, J = 12.8 Hz, 1H), 6.97 (s, 1H), 6.04 (s, 1H), 5.30 (br s, 1H), 4.71 (d, J = 12.0 Hz, 2H), 4.04 (t, J = 12.4 Hz, 2H), 3.84 (m, 1H), 3.53 (m, 2H), 3.13 (m, 2H), 3.08 (s, 3H), 2.96 (s, 3H), 2.59-2.40 (m, 4H)
0.048


 


283




ESMS m/z 556.3 (M + H+)
0.016


 


284




ESMS m/z 526.2 (M + H+)
0.033


 


285




ESMS m/z 540.2 (M + H+)
0.068


 


286




ESMS m/z 437.2 (M + H+)
0.037


 


287




ESMS m/z 470.2 (M + H+)
0.027


 


288




ESMS m/z 507.2 (M + H+)
0.093


 


289




ESMS m/z 460.2 (M + H+); 1HNMR (MeOD-d4) δ 7.91 (s, 1H), 7.69 (d, 1H), 7.00 (d, 1H), 6.15 (s, 1H), 3.28 (m, 4H), 2.91 (m, 1H), 2.32 (m, 2H), 2.20 (s, 3H), 2.16 (s, 3H), 1.83 (s, 2H), 1.64 (d, 2H), 1.31 (t, 3H).
0.37


 


290




ESMS m/z 512.2 (M + H+)
0.023


 


291




ESMS m/z 585.3 (M + H+)
0.067


 


292




ESMS m/z 512.2 (M + H+)
0.023


 


293




ESMS m/z 512.2 (M + H+)
0.026


 


294




ESMS m/z 516.2 (M + H+)
0.064


 


295




ESMS m/z 536.2 (M + H+)
0.039


 


296




ESMS m/z 471.2 (M + H+)
0.101


 


297




ESMS m/z 507.2 (M + H+)
0.079


 


298




ESMS m/z 514.2 (M + H+)
0.026


 


299




ESMS m/z 485.2 (M + H+)
0.101


 


300




ESMS m/z 549.2 (M + H+)
0.032


 


301




ESMS m/z 563.2 (M + H+)
0.038


 


302




ESMS m/z 508.2 (M + H+)
0.006


 


303




ESMS m/z 522.2 (M + H+)
0.006


 


304




ESMS m/z 508.2 (M + H+)
0.005


 


305




ESMS m/z 536.3 (M + H+)
0.025


 


306




ESMS m/z 472.2 (M + H+)
0.015


 


307




ESMS m/z 503.2 (M + H+)
0.007


 


308




ESMS m/z 503.2 (M + H+)
0.006


 


309




ESMS m/z 503.2 (M + H+)
0.008


 


310




ESMS m/z 514.2 (M + H+)
0.027


 


311




ESMS m/z 514.2 (M + H+)
0.021


 


312




ESMS m/z 563.2 (M + H+)
0.025


 


313




ESMS m/z 563.2 (M + H+)
0.030


 


314




ESMS m/z 508.2 (M + H+); 1H NMR (400 MHz, CD3OD) δ 9.09 (s, 1H), 8.81 (s, 2H), 8.00 (s, 1H), 7.73 (d, J = 8.4 Hz, 1H), 6.99 (d, J = 13.2 Hz, 1H), 6.23 (br s, 1H), 3.65 (s, 2H), 3.03 (m, 2H), 2.76 (m, 1H), 2.27 (s, 3H), 2.25 (s, 3H), 2.25 (m, 2H), 1.80-1.68 (m, 4H)
0.037


 


315




ESMS m/z 508.2 (M + H+)
0.036


 


316




ESMS m/z 508.2 (M + H+)
0.027


 


317




ESMS m/z 504.2 (M + H+)
0.004


 


318




ESMS m/z 504.2 (M + H+)
0.010









Assays
The IC50 of a drug may be determined constructing a dose-response curve and examining the effect of different concentrations of antagonist on reversing agonist activity. IC50 values may be calculated for a given antagonist by determining the concentration needed to inhibit half of the maximum biological response of the agonist. To calculate IC50 values, a series of dose-response data (e.g., drug concentrations x1, x2, . . . , xn and growth inhibition y1, y2, . . . , yn, the values of y are in the range of 0-1) is generated. IC50 values may be determined by a computer-aided system using the formula:

y=D+((A−D)/(1+10(x-log(IC50)B)

where A is the ratio of growth inhibition between lowest drug concentration and control; B is the slope of sigmoidal curvel; and D is the ratio of growth inhibition between highest drug concentration and control.
The IC50 value is given as that concentration of the test compound that results in growth inhibition that is 50% lower than that obtained using the control without inhibitor. The compounds of the invention in free form or in pharmaceutically acceptable salt form may exhibit valuable pharmacological properties, for example, as indicated by the in vitro tests described in this application. In general, compounds of the invention have IC50 values from 1 nM to 10 μM. In some examples, compounds of the invention have IC50 values from 0.01 μM to 5 μM. In other examples, compounds of the invention have IC50 values from 0.01 μM to 1 μM, or more particularly from 1 nM to 1 μM. In yet other examples, compounds of the invention have IC50 values of less than 1 nM or more than 10 μM. The compounds of the invention may exhibit a percentage inhibition of greater than 50%, or in other embodiments, may exhibit a percentage inhibition greater than about 70%, against IGF-1R at 10 μM.
Ba/F3 Cell Line Panel and Reagents
Ba/F3 is a murine IL-3-dependent pro-B lymphoma cell line. Parental Ba/F3 cells are used to generate a panel of sublines whose proliferation and survival is rendered IL-3-independent by stable transduction with individual tyrosine kinases activated by fusion with the amino-terminal portion of TEL (amino acid 1-375) or BCR. In order to generate Ba/F3 cell lines transformed by Tel-Tyrosine Kinase (TK) fusions, parental Ba/F3 cells are infected with a retrovirus harboring each TEL-fusion kinase and subjected to puromycin selection and IL-3 withdrawal to obtain IL-3-independent, transformed Ba/F3 cells.
Each transformed Ba/F3 cells are cultured in RPMI-1640 media (Gibco Cat #11875093, Carlsbad, Calif.) supplemented with 10% FBS (Hyclone Cat #SV30014.03, Logan, Utah), 4.5 g/L glucose (Sigma #G5400, St. Louis, Mo.), 1.5 g/L sodium bicarbonate (Biowhittaker #17-613E, Walkersville, Md.) and Pen/Strep (Gibco #10378-016, Carlsbad, Calif.). Cells are splitted twice weekly.
Ba/F3 Cell Viability Inhibition Assay
The potency of test compounds against various Tel-TK transformed Ba/F3 lines is determined as follows. Exponentially growing BaF3 Tel-TK cells are diluted in fresh medium to 75,000 cells/mL and seeded into 384-well plates (3750 cells/well) at 50 μL/well using a gill liquid dispenser (BioTek, Winooski, Vt., USA). Duplicate plates are run for each cell line. Test and control compounds are serially diluted with DMSO and arrayed in a polypropylene 384-well plate. 50 mL of compound is transferred into the assay plates using a pin-transfer device, and the plates are incubated at 37° C. (5% CO2) for 48 hours. 25 μL Britelite (Perkin Elmer) is added and luminescence is quantified using Analyst GT (Molecular Devices). Custom curve-fitting software is used to produce a logistic fit of percent cell viability as a function of the logarithm of inhibitor concentration. The IC50 is interpolated as the concentration of compound needed to reduce cell viability to 50% of a DMSO control. Parental Ba/F3 cells that are maintained and cultured in presence of IL-3 (1 ng/ml in final) are diluted in fresh medium containing IL-3 (1 ng/ml in final) to 75,000 cells/mL following the same procedure as described above.
Enzymatic HTRF Assay
IGF-1R and INSR (insulin receptor) are purchased from Upstate. Following reagents are prepared in-house; 10× kinase buffer (KB) (200 mM Tris (pH 7.0), 100 mM MgCl2, 30 mM MnCl2, 50 nM NaVO4), 10 mM ATP, 100 mg/ml BSA, 0.5 M EDTA, 4 M KF. Proxiplate-384 from Perkin-Elmer is used for set up assay. All the HTRF reagents including substrate (Biotin-poly-GT (61GT0BLB), Mab PT66-K, (61T66KLB), Streptavidin-XLent (611SAXLB)) are purchased from CIS-US, Inc.
The substrate/ATP mix is prepared by adding ATP (final concentration, 3 μM) and biotinylated poly-GT (final concentration, 10 ng/μl) into 1×KB, and dispensed into Proxiplate-384 at 5 μl/well using gill (Bio-TEK). Serially diluted compounds (in DMSO) are transferred into plate using 50 mL pinhead. 5 μL of prepared Enzyme mix (enzyme (final concentration, 5 ng/μl), mixed with BSA and DTT in 1×KB) is added to initiate kinase reaction using gill (Bio-TEK). Assay plate is incubated at room temperature for 2 hours. Detection mix is prepared by adding both Mab PT66-K and Streptavidin-XLent into 0.5×KB solution containing KF (final concentration, 125 mM), EDTA (final concentration, 50 mM) and BSA (final concentration, 100 μg/ml) in. At the end of reaction, 10 μL of detection mix is added and incubated for 30 minutes at room temperature before measurement. HTRF signal is detected using Analyst-GT (molecular Devices).
Cancer Cell Proliferation Inhibition Assay
For luciferizing cancer cell line, each cell line is transduced by ampholytic retrovirus carrying both luciferase gene and puromycin-resistant gene whose expression is driven by LTR. Briefly, the retroviral vector pMSCV-Puro-Luc is transfected into Phoenix cell line using Fugene6 (Roche) according to manufacturer's instruction. Two days after transfection, supernatant containing virus is harvested and filtered with 0.2 μm filter. Harvested virus is used immediately or stored at −80′C. For infection, cultured cancer cells are harvested and plated (5×105 cells/well in 1 ml medium) on 6-well tissue culture plate. For each well, 3 ml virus supernatant is added together with 400 μl FBS, 40 μl 1 M HEPES (pH8.0) and 4 μl of polybrene (10 μg/ml, Specialty media). The plate is centrifuged down for 90 minutes at 2500 rpm for spin-infection and is transferred into an incubator for overnight infection. Next day, infected cell line is transferred into T-75 flask containing fresh medium and incubated for one day. Two days after infection, puromycin is added at the final concentration of 1 μg/ml to begin selection. Within 1-2 weeks, puromycin-resistant cell line is established after at least two subsequent splits and is preserved as luciferized stock.
Each cell line is harvested while in log phase growth by trypsinization and diluted in respective media to appropriate density prior to plating. Cells are dispensed using μFill (BioTeK) at 50 μl/well into white walled clear bottom plates (Greiner—custom for GNF). Cells are then placed in 37° C. incubator supplying 5% CO2 overnight. Compounds are transferred using 50mL/well Pintool technology via Platemate (Matrix). Assay plates are then placed back into the incubator for 3 days. On the third day following compound transfer, BRITELITE® (Perkin Elmer, diluted according to manufacturer's suggestion) is added to assay plates and read on Analyst GT (Molecular Devices) or Envision (Perkin Elmer). Raw data is generated in RLU.
Tumor Activity of Exemplary Compounds
Three to 4×106 human neuroblastoma SK-N-MC cells resuspended in HBSS and mixed in 50% matrigel were injected subcutaneously (0.05 ml/mouse) into female nude (HsdNpa:athymic/nu) mice 10-12 weeks of age. Treatments were initiated when the mean tumor volumes were approximately 150-200 mm3. Body weights and tumor volumes were recorded three times a week. Tumor volumes were measured with calipers and determined according to the formula length×diameter2×π/6. In addition to presenting fractional changes of tumor volumes over the course of treatments, antitumor activity is expressed as T/C % (mean change of tumor volume of treated animals/mean change of tumor volume of control animals)×100. Efficacy of test compounds was determined by initiating oral dosing on day 19 post-cell injection following randomization of the mice so that each group has similar mean tumor size. Dosing with an appropriate schedule continued for 7 days based on the general health condition of the animals. All test compounds were formulated in NMP/PEG300 (10:90) and applied daily by gavage. Vehicle consisted of NMP/PEG300 (10:90). All application volumes were 5 ml/kg. The activity of exemplary compounds of the invention on tumor growth is shown in Tables 2-4.









TABLE 2









Tumor response














Δ tumor
Mean fold



T/C
Regr.
volume (mean
change in tumor


Treatment
(%)
(%)
mm3 ± SEM)
growth














NMP/PEG300 (10/90)
100
0
334 ± 59 
3.1 ± 0.3


5 ml/kg po q8/16 h


Test Compound 1
53
—
231 ± 145
2.1 ± 0.4


20 mg/kg, q8/16 h, po


Test Compound 1
35
—
107 ± 48*
 1.7 ± 0.2*


40 mg/kg, q8/16 h, po


















TABLE 3









Tumor response














Δ tumor
Mean fold



T/C
Regr.
volume (mean
change in tumor


Treatment
(%)
(%)
mm3 ± SEM)
growth














NMP/PEG300 (10/90)
100
0
334 ± 59 
3.1 ± 0.3


5 ml/kg po q8/16 h


Test Compound 2
69
—
232 ± 103
2.5 ± 0.4


12.5 mg/kg, q8/16 h,


po


Test Compound 2
22
—
 42 ± 10*
 1.5 ± 0.2*


25 mg/kg, q8/16 h, po


















TABLE 4









Tumor response














Δ tumor
Mean fold



T/C
Regr.
volume (mean
change in tumor


Treatment
(%)
(%)
mm3 ± SEM)
growth














NMP/PEG300 (10/90)
100
0
334 ± 59
3.1 ± 0.3


5 ml/kg po q8/16 h


Test Compound 3
58
—
220 ± 67
2.2 ± 0.3


12.5 mg/kg, q8/16 h,


po


Test Compound 3
26
—
 102 ± 40*
 1.6 ± 0.3*


25 mg/kg, q8/16 h, po





*p < 0.05 vs. Vehicle controls - ANOVA on ranks and post hoc Dunnett's test.






It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference for all purposes.

## Claims

1. A compound of Formula (3):



a pharmaceutically acceptable salt thereof, or a tautomer thereof;
wherein ring E may optionally contain a double bond;
Z1 and Z2 are CH2;
Z3 is NR6 or N(R6)+—O−;
R1 is halo or an optionally halogenated C1-6 alkyl;
R3 and R4 are each H;
R5b is H; and R5a and R5c are independently halo, C1-6 alkyl, C1-6 alkoxy, halo-substituted C1-6 alkyl, cyano or C(O)O0-1R8;
R6 is a radical selected from formula (a), (b), (c) or (d):




L is (CR2)1-4 or a bond; wherein R is independently H or C1-6 alkyl;
R10 is O, S, NR17 wherein R17 is H, C1-6 alkyl, SO2R8a or CO2R8a and R8a is C1-6 alkyl;
R11, R12, R13, R14, R15 and R16 are independently selected from H; C1-6 alkoxy; C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, each of which may be optionally substituted with halo, amino or hydroxyl groups; or R11 and R12, R12 and R15, R15 and R16, R13 and R14, or R13 and R15 together with the atoms to which they are attached may form a 3-7 membered saturated, unsaturated or partially unsaturated ring containing 1-3 heteroatoms selected from N, O and S, and optionally substituted with oxo and 1-3 R5 groups;
wherein R5 is halo, hydroxyl, C1-6 alkyl, C1-6 alkoxy, halo-substituted C1-6 alkyl, halo-substituted C1-6 alkoxy, cyano or C(O)O0-1R8; and
R8 is C1-6 alkyl.

2. The compound of claim 1, wherein R5a is halo and R5c is C1-6 alkyl.

3. The compound of claim 1, wherein R6 is a radical of formula (a) or (c); and R10 is O.

4. The compound of claim 1, wherein R1 is halo.

5. A compound selected from the group
























































































or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.

7. The compound of claim 1, wherein said compound is 5-chloro-N2-(2-fluoro-5-methyl-4-(1-(1,1-dioxido-3-thietanyl)piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine, or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1, wherein said compound is 5-chloro-N2-(2-fluoro-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine, or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 5 or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.

10. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 7 or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.

11. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 8 or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.